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ABSTRACT 
 
Coronary artery disease (CAD) continues to be the leading cause of death worldwide. 
CAD is thought to originate from the imbalance of lipids. Besides cholesterol, 
glycerophospholipids and sphingolipids are also emerging as important players in the 
pathogenesis of CAD. Among these, sphingosine-1-phosphate (S1P) is of particular interest, 
due to its role in the anti-inflammatory and cytoprotective functions of high-density 
lipoproteins (HDL). 
The first part of this work included the development and validation of two analytical 
methods based on a liquid chromatography-mass spectrometry technique. These methods 
enabled us to carry out the quantification of individual molecular species of 
glycerophospholipids and sphingolipids, as well as S1P. Subsequently, these methods were 
applied in the following studies.  
In a case-control study, we investigated whether plasma concentrations of 
glycerophospholipids and sphingolipids, as well as S1P and the sphingoid bases of 
sphingolipids, differ between healthy subjects and CAD or acute coronary syndrome (ACS) 
patients. In addition, we analysed the glycerophospholipid and sphingolipid distribution 
among the plasma lipoproteins of healthy individuals. We found that plasma concentrations of 
PC33:1, PC33:2, PC33:3 and PC35:3, that very likely represent PC plasmalogens, were the 
most significantly altered in CAD or ACS patients. Similar to the even-chain PC species, 
PC33:1, PC33:2, PC33:3 and PC35:3 were mostly associated with HDL, but also present in 
low-density lipoproteins (LDL). As the consequence, they exhibited a strong positive 
correlation with HDL-cholesterol levels. Besides 18:1-S1P, commonly known as S1P, we also 
identified other S1P species, which vary in the length and unsaturation degree of the 
sphingoid base. The most abundant S1P is 18:1-S1P. Compared to healthy subjects, it was 
reduced in plasma of ACS patients, while 16:1-S1P was found to be lower in plasma of both 
CAD and ACS patients. 
Research over the last decade has revealed that HDL display anti-atherogenic effects 
on the cardiovascular system, which are attenuated in CAD patients. We therefore 
investigated the triangular relationship between HDL-associated phospholipids, the anti-
apoptotic activity of HDL and the presence of CAD or ACS. The anti-apoptotic activity of 
HDL was tested by measuring the apoptosis of endothelial cells (ECs) in the presence of 
HDL. Among the 52 phospholipid species identified in HDL, PC33:3, PC35:2 and PC34:2 
showed the most consistent relationships with CAD and ACS, as well as with the anti-
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apoptotic activity of HDL. In addition, the HDL content of 18:1-S1P and 18:2-S1P 
significantly correlated with the anti-apoptotic activity of HDL, but did not associate with 
CAD or ACS. 
In the circulatory system, HDL particles carry more than half of the plasma 18:1-S1P, 
termed S1P hereafter. This is explained by the presence of a specific binding protein, called 
apolipoprotein M (apoM). Experimental studies based on mouse models showed a limiting 
effect of apoM on plasma concentrations and HDL content of S1P. We investigated the effect 
of apoM on two potential pathways of S1P metabolism, namely HDL-mediated S1P efflux 
from erythrocytes and the urinary excretion of S1P. We showed that S1P efflux was enhanced 
in the presence of HDL from Apom
tg
 mice, but not diminished in the presence of HDL from 
Apom
-/-
 mice when compared to HDL from wild type mice. This indicates that HDL facilitate 
S1P efflux from erythrocytes by both apoM-dependent and apoM-independent mechanisms. 
Analysis of S1P and apoM in plasma and urine samples from Apom
-/-
 mice and from mice 
with defective tubular endocytosis showed that apoM facilitates the tubular reabsorption of 
S1P from urine, but has no impact on the plasma content of S1P. 
Age-related macular degeneration (AMD) is a complex disease that can potentially 
lead to irreversible blindness in the elderly population. Genetic polymorphisms of 
paraoxonase1 (PON1), an enzyme which mediates some of the atheroprotective functions of 
HDL, was found to be associated with AMD. Since PON1 is thought to prevent lipid 
peroxidation, we used Pon1
-/-
 mice to investigate the impact of PON1 on the phospholipid 
composition of the retina/eyecup tissue. The eyes of the Pon1
-/-
 mice did not show an AMD-
like phenotype. The retina/eyecup samples of young Pon1
-/-
 mice contained less total 
lysophosphatidylcholines (LPCs) and LPC22:6 compared to wild type mice, reflecting a 
decreased activity of phospholipase A2 in these mice. Furthermore, one year old wild type 
mice displayed a decrease in the content of total LPCs and LPC22:6 by 63% and 75%, 
respectively, which could be a result of an age-related decrease in the expression of Pon1 
gene in the eyes. 
In summary, we showed that reduced plasma and HDL levels of odd-chain PCs, 
probably corresponding to PC plasmalogens, are most consistently associated with CAD and 
ACS. We also showed that HDL-associated P33:3, PC35:2 and PC34:2 correlate significantly 
with the anti-apoptotic activity of HDL. We demonstrated that apoM has an effect on S1P 
metabolism: first, HDL induce S1P efflux from erythrocytes by apoM-dependent and apoM-
independent mechanisms; second, apoM facilitates the reabsorption of S1P in the proximal 
renal tubules. Finally, we showed that retina/eyecup of Pon1
-/- 
mice have a diminished content 
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of total LPCs and LPC22:6, which may reflect a decreased phospholipase A2-like activity in 
the eyes.  
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ZUSAMMENFASSUNG 
 
Die Koronare Herzkrankheit (KHK) ist weiterhin weltweit die häufigste Todesursache. 
Es wird angenommen, dass KHK durch ein Ungleichgewicht der Lipide entsteht. Neben 
Cholesterin zeichnen sich auch Glycerophospholipide und Sphingolipide als wichtige Akteure 
bei der Pathogenese der KHK ab. Unter diesen ist das Sphingosin-1-Phosphat (S1P) wegen 
seiner Rolle bei den entzündungshemmenden und zellschützenden Funktionen der 
Lipoproteine mit hoher Dichte (HDL) von besonderem Interesse. 
Der erste Teil dieser Arbeit umfasste die Entwicklung und Validation von zwei 
Analysemethoden, welche auf einer gekoppelten Flüssigkeitschromatographie-
Massenspektrometrie Technik basieren. Diese Methoden ermöglichten uns eine 
Quantifizierung individueller Moleküle von Glycerophospholipiden und Sphingolipiden, wie 
auch S1P. Anschließend wurden diese Methoden in den folgenden Studien verwendet.  
In einer Fall-Kontroll-Studie untersuchten wir, ob die Plasmaspiegel von 
Glycerophospholipiden und Sphingolipiden sowie S1P sich zwischen gesunden Probanden 
und KHK-Patienten oder Patienten mit akutem Koronarsyndrom (AKS) unterscheiden. 
Zusätzlich analysierten wir die Glycerophospholipid- und Sphingolipid-Verteilung unter den 
Plasma-Lipoproteinen von gesunden Personen. Wir fanden, dass die Plasmakonzentrationen 
von PC33:1, PC33:2, PC33:3 und PC35:3, die sehr wahrscheinlich PC-Plasmalogene 
darstellen, am stärksten bei Patienten mit KHK oder AKS veränderten sind. Ähnlich wie die 
meisten geradkettigen PC-Arten  wurden PC33:1, PC33:2, PC33:3 und PC35:3 vor allem in 
HDL aber auch in Lipoproteinen geringer Dichte (LDL) gefunden. Als Folge hiervon 
korrelierten sie stark mit den HDL-Cholesterinspiegeln. Neben 18:1-S1P, allgemein bekannt 
als S1P, haben wir auch andere S1P-Arten identifiziert, die in der Länge und dem Grad der 
Nichtsättigung der Sphingoidbasis variieren. Das häufigste S1P ist 18:1-S1P. Im Vergleich zu 
gesunden Probanden war dessen Konzentration im Plasma von KHK-Patienten vermindert, 
während 16:1-S1P im Plasma sowohl der KHK als auch der AKS-Patienten in erniedrigter 
Konzentration gefunden wurde. 
Die Forschung im letzten Jahrzehnt hat gezeigt, dass HDL anti-atherogene 
Auswirkungen auf das Herz-Kreislauf-System haben, die bei KHK-Patienten abgeschwächt 
sind. Wir untersuchten deswegen die Dreiecks-Beziehung zwischen HDL-assoziierten 
Phospholipiden, der anti-apoptotischen Aktivität von HDL und dem Vorhandensein von KHK 
oder AKS. Die anti-apoptotische Aktivität von HDL wurde durch Messung der Apoptose von 
Endothelzellen (ECs) in der Gegenwart von HDL getestet. Unter den 52 identifizierten 
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Phospholipid-Arten von HDL zeigten PC33:3, PC35:2 und PC34:2 die beständigsten 
Beziehungen zu KHK und AKS, so wie auch mit der anti-apoptotischen Aktivität von HDL. 
Darüber hinaus korrelierten die HDL-Spiegel von 18:1-S1P und 18:2-S1P signifikant mit der 
anti-apoptotischen Aktivität von HDL, waren aber nicht mit KHK oder AKS assoziiert. 
Im Kreislaufsystem transportieren die HDL-Partikel mehr als die Hälfte des Plasma 
18: 1-S1P, im Folgenden als S1P bezeichnet. Dies wird durch das Vorhandensein eines 
spezifischen Bindungsproteins namens Apolipoprotein M (apoM) erklärt. Experimentelle 
Studien in genetisch veränderten Mäusen zeigten eine einschränkende Wirkung von apoM auf 
Plasmakonzentrationen und den HDL-Gehalt von S1P. Wir untersuchten die Wirkung von 
apoM auf zwei mögliche Pfade des S1P-Metabolismus, nämlich den HDL-vermittelten S1P-
Efflux auf Erythrozyten und die Urinausscheidung von S1P. Wir zeigten, dass der S1P-Efflux 
bei Anwesenheit von HDL von Apom
tg
 Mäusen, im Vergleich zu HDL von Wildtyp-Mäusen 
erhöht ist, und dass der S1P-Efflux bei Anwesenheit von HDL von Apom
-/-
 Mäusen, im 
Vergleich zu HDL von Wildtyp Mäusen nicht verringert ist. Dies zeigt, dass HDL den S1P-
Efflux aus Erythrozyten sowohl durch apoM-abhängige wie auch durch apoM-unabhängige 
Mechanismen erleichtert. Die Analyse von S1P und apoM in Plasma- und Urinproben von 
Apom
-/-
 Mäusen und von Mäusen mit defekter Tubular-Endozytose zeigte, dass ApoM die 
tubuläre Reabsorption von S1P aus Urin erleichtert, aber keinen Einfluss auf den 
Plasmagehalt von S1P hat. 
Die altersbedingte Makuladegeneration (AMD) ist eine komplexe Erkrankung, die 
möglicherweise zu einer irreversiblen Erblindung in der älteren Bevölkerung führen kann. 
Einige genetische Polymorphismen von Paraoxonase1 (PON1), einem Enzym, das einige der 
atheroprotektiven Funktionen von HDL vermittelt, sind mit AMD assoziiert. Da PON1 die 
Lipidperoxidation verhindert, haben wir Pon1
-/-
 Mäuse, bezüglich der Phospholipid-
Zusammensetzung der Retina und des Augenhintergrunds-Gewebes, untersucht. Die Augen 
der Pon1
-/-
 Mäuse zeigten keinen AMD-ähnlichen Phänotyp. Die 
Netzhaut/Augenhintergrunds-Proben von jungen Pon1
-/-
 Mäusen enthielt weniger 
Lysophosphatidylcholine (LPC) und LPC22:6 im Vergleich zu Wildtyp-Mäusen, was eine 
verminderte Aktivität der Phospholipase A2 bei diesen Mäusen widerspiegeln kann. 
Weiterhin zeigten ein Jahr alte Wildtyp-Mäuse eine Abnahme des Gehalts an LPCs und 
LPC22:6 um 63% und 75%, wobei dies ein Ergebnis einer altersbedingten Abnahme der 
Expression von Pon1 Genen in den Augen sein könnte. 
Zusammenfassend haben wir gezeigt, dass Plasma- und HDL-Spiegel ungeradkettiger 
PCs, wahrscheinlich PC-Plasmalogene, robust mit KHK und AKS assoziiert sind. Wir zeigten 
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auch, dass HDL-assoziierte P33:3, PC35:2 und PC34:2 signifikant mit der anti-apoptotischen 
Aktivität von HDL korrelieren. Wir zeigten, dass HDL den S1P-Efflux von Erythrozyten 
durch apoM-abhängige und apoM-unabhängige Mechanismen verstärkt und dass apoM die 
Resorption von S1P in den Nieren-Tubuli erleichtert. Schließlich zeigten wir, dass die 
Netzhaut/Augenhintergrunds-Gewebe der Pon1
-/- 
Mäuse einen verringerten Gehalt an LPC 
und LPC22:6 haben, was eine verringerte Phospholipase A2-ähnliche Aktivität 
wiederspiegeln kann.  
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1. INTRODUCTION 
 
1.1. Lipids 
1.1.1. Lipidomics: Definition and application 
Biological systems comprise thousands of chemically distinct lipids. The structural 
diversity of lipids explains the broad spectrum of lipid functionality. For most lipids, their 
functions depend on molecular structure and can be very different for the different lipid 
categories, classes as well as for different lipid species within the same lipid class 
1
. 
Lipidomics is a relatively young field of science 
2
, which aims to identify and quantify all 
individual lipid species and their functions within a biological system. In the past decade, 
progress in the lipidomics research has been driven by the development of electrospray 
ionization (ESI) mass spectrometry technologies 
3
. This advance in mass spectrometry 
enables the structural characterisation and quantification of individual lipid species within 
different lipid classes.  
Lipidomics studies are often aimed at the identification of lipid biomarkers which can 
be used for the diagnostics of onset, progression or severity of disease. Lipidomics can also 
provide information on biochemical mechanisms and pathways leading to disease. Thereby, 
lipidomics can be used in the discovery and clinical validation of novel biomarkers 
4, 5
. 
Furthermore, Laurila and colleagues showed that integration of lipidomics into genomic and 
transcriptomic studies can provide a new layer of information on biological pathways 
6
. 
 
1.1.2. Classification and structure of lipids 
Lipids are a diverse group of hydrophobic or amphipathic small molecules that 
originate entirely or in part by carbanion-based condensations of ketoacyl subunits (fatty 
acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids and polyketides) 
and/or by carbocation-based condensations of isoprene subunits (sterol and prenol lipids) 
7, 8
. 
According to a classification proposed by the members of the LIPID MAPS consortium 
7, 8
, 
all lipids are divided into eight primary categories based on their chemical structure and 
biochemical characteristics. These categories are fatty acids, glycerolipids, 
glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids and 
polyketides (Fig. 1) 
7, 8
. Each of these categories is subsequently subdivided into distinct 
classes and subclasses. The structural diversity of all identified lipids is addressed by several 
websites, for example LIPID MAPS (http://www.lipidmaps.org/).  
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Lipids exert a wide range of functions essential for living systems. Their primary 
functions include the formation of lipid bilayer barriers in cells and organelles, and the service 
as an energy source by β-oxidation. Lipids also play important roles in cell biology as 
signalling or regulatory molecules. 
 
 
Figure 1. Representative structures for each lipid category.  
 
1.1.2.1. Glycerophospholipids 
Glycerophospholipids are amphipathic lipids that derive from glycerol-3-phosphate 
esterified at the sn-1 and sn-2 positions of the glycerol backbone with two long-chain fatty 
acids. Glycerophospholipids esterified with one fatty acid at either position are called 
lysoglycerophospholipids. Simple glycerophospholipids contain a free phosphoryl group and 
are known as phosphatidic acids (PAs). Complex glycerophospholipids are formed when a 
phosphoryl group is attached to another hydrophilic molecule like choline, ethanolamine, 
serine, inositol or glycerol 
9
. The structure of the head group defines the class of 
glycerophospholipids, while variation in the numbers of carbons and double bonds in acyl 
chains defines lipid species (Fig. 2). Glycerophospholipids with vinyl ether double bond (-
CH2-O-CH=CH-) at the sn-1 position and an ester bond at the sn-2 position of the glycerol 
backbone represent plasmalogens. The plasmalogens mainly occur as species of 
14 
 
phosphatidylethanolamines (PEs) or phosphatidylcholines (PCs) and, to a lesser extent, as 
species of phosphatidylserines (PSs) 
10
. 
PAs are the metabolic precursors of almost all glycerophospholipids. In eukaryotic 
cells, PAs can be metabolised in two ways: either PAs are hydrolysed to diacylglycerols or 
transformed into cytidine diphosphate diacylglycerols. In the first case, phosphate groups can 
be attached to diacylglycerols and form PCs or PEs. In the second case, the phosphate group 
of cytidine diphosphate diacylglycerols can be replaced, giving rise to phosphatidylinositols 
(PIs), phosphatidylglycerols (PGs) or diphosphatidylglycerols (also known as cardiolipins). 
 
 
Figure 2. Structures of glycerophospholipids and head group variation. The complete 
molecular structure shown is phosphatidylcholine PC(16:0/16:0) (1,2-distearoyl-sn-glycerol-
3-phosphocholine). Substitution of choline with the head groups listed below results in the 
other glycerophospholipid structures 
9
. 
 
1.1.2.2. Sphingolipids 
Sphingolipids are amphipathic lipids that share a common structural feature, a 
sphingoid backbone, which is also called sphingosine. In humans, the most common 
sphingoid backbone is an 18-carbon-atom-long amino alcohol with one double bond. It is 
synthesised de novo from the condensation of serine and palmitoyl (C16:0)-CoA, catalysed by 
enzyme serine:palmitoyltransferase (SPT) 
11
. However, besides C16:0-CoA, human SPT can 
metabolise other acyl-CoAs, resulting in the formation of quantitatively minor sphingoid 
bases with different numbers of carbon atoms in the alkyl chain 
12
. The sphingoid base can be 
linked with a fatty acid through an amide bond and/or with a head group at the primary 
hydroxyl position. The head group ranges from a simple hydrogen of free sphingosine or 
ceramides (Cers) to a more complex head group, such as phosphocholine of sphingomyelins 
15 
 
(SMs), a one-sugar residue of neutral glycosphingolipids, or several charged sugar residues of 
gangliosides 
13
. According to a classification of the LIPID MAPS consortium, sphingolipids 
can be subdivided into several major classes: the sphingoid bases with their simple 
derivatives, Cers, and more complex sphingolipids, such as phosphosphingolipids 
7
. The 
variation in the number of carbon atoms and double bounds in the sphingoid backbone and, if 
present, in N-linked fatty acid, determines the structural diversity of sphingolipid species. 
 
1.1.2.3. Nomenclature of glycerophospholipids and sphingolipids 
Lipids are named according to a nomenclature recommended by the LIPID MAPS 
consortium 
7, 8
, which is largely based on the nomenclature defined by the International Union 
of Pure and Applied Chemists and the International Union of Biochemistry and Molecular 
Biology (IUPAC-IUBMB) Commission on Biochemical Nomenclature 
(http://www.chem.qmul.ac.uk/iupac/). Glycerophospholipid species are annotated by using 
“head group(sn1/sn2)” format (e.g. PC(16:0/18:1)). The head group is annotated by using 
two-letter abbreviations (PC/PE/PA/PG/PS, etc.), which is by default assumed to be at the sn-
3 position of the glycerol backbone. The structure of the side chains is indicated within 
parentheses; the number before the colon denotes the number of carbon atoms and the number 
after the colon denotes the number of double bonds in the fatty acid moieties of the given lipid 
molecule. The lysoglycerophospholipid species with only one fatty acid residue are specified 
with a letter “L” in the abbreviation. For example, PC(16:0/18:2) refers to 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine, while LPC(16:0/0:0) refers to 1-palmitoyl-2-hydroxy-
sn-glycero-3-phosphocholine 
8
. 
In the sphingolipid classification, the sphingoid base sphingosine is abbreviated as 
d18:1 by using a shorthand form with d for the two hydroxyl groups of sphingosine, followed 
by the chain length (typically 18 carbons) and number of double bonds (0, 1 or 2). The 
shorthand notation for complex sphingolipids is presented in order of sphingoid base and N-
acylated fatty acid. For example, SM(d18:1/24:1) refers to N-nervonoyl-D-erythro-
sphingosylphosphorylcholine 
7, 13
. 
Lipids can be annotated by the “molecular composition” that describes the structure of 
the attached fatty acid moieties (e.g. PC(16:0/18:2), LPC(16:0/0:0) and SM(d18:1/24:1)) or 
by the “sum composition” that indicates total numbers of carbons and double bonds for all 
acyl and/or alkyl chains (e.g. PC34:2, LPC16:0 and SM42:2). The abbreviation of the 
glycerophospholipids and sphingolipids depends on the analytical capabilities of mass 
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spectrometry methods applied, as described elsewhere 
14
. As glycerophospholipids and SMs 
contain a phosphate group, they are often summarized as phospholipids. 
 
1.1.3. Functions of glycerophospholipids and sphingolipids 
Glycerophospholipids and sphingolipids function as structural components of cell 
membranes and lipoproteins. A biological cell membrane is a lipid bilayer that provides a 
barrier between the interior of the cell and surroundings. The formation of lipid bilayers can 
be explained by the self-association of amphipathic lipids, containing hydrophobic and 
hydrophilic domains, in an aqueous environment. The driving force for the formation of a 
lipid bilayer is the minimised interaction between hydrophobic domains and water, resulting 
in an entropy-driven relaxation of water. Hydrophilic domains of glycerophospholipids and 
sphingolipids interact with water through hydrogen bonding or ionic interaction and, 
therefore, are stable 
9
. Biological membranes are not static; they are characterised by fluidity 
which is determined by the proportions of saturated and unsaturated fatty acid residues in 
glycerophospholipids and by the proportions of SMs and free cholesterol within the 
membrane. Furthermore, SMs tend to associate with each other as well as with cholesterol 
and form lipid rafts within the membrane 
13
. Lipid rafts are relatively small subdomains of 
biomembranes that provide platforms for proteins needed for cell function 
13
.  
In addition to being a component of cell membranes, some of glycerophospholipids 
and sphingolipids, like LPAs, LPCs, Cers and sphingosine-1-phosphate (S1P), are widely 
recognised as important intracellular and extracellular signalling molecules and mediators of 
cell-to-cell recognition and interaction 
13, 15
. These lipids have rather simple molecular 
structures and possess significant water solubility that enables them to move from the site of 
synthesis to targets inside or outside the cell. 
 
1.1.4. Glycerophospholipids and sphingolipids in human plasma 
The plasma lipidome consist of more than 500 lipid species distributed among six 
distinct categories of lipids, including fatty acids, glycerolipids, glycerophospholipids, 
sphingolipids, sterol lipids and prenol lipids 
16
. The number of identified species is largely 
limited by the sensitivity of available mass spectrometry technologies and probably will grow 
in the near future. Glycerophospholipids represent the second major component of the plasma 
lipidome, amounting to about one third of plasma lipids (Fig. 3A). Plasma 
glycerophospholipids comprise 160 individual molecular species with the PCs and PEs being 
17 
 
the most predominant lipids (Fig. 3B). In addition, plasma contains considerable amounts of 
LPCs, LPEs and PIs as well as minor amounts of PC-derived and PE-derived plasmalogens 
16
. 
Plasma sphingolipids comprise more than 200 molecular species and account for ~4% 
of total lipids in the plasma (Fig. 3A). SMs are the major sphingolipids, representing ~95% of 
total sphingolipids, followed by Cers (~3.5%) and monohexosyl ceramides (<1%) (Fig. 3C) 
16, 
17
. 
 
 
Figure 3. Distribution of plasma lipids (Figure 3A), glycerophospholipids (Figure 3B) 
and sphingolipids (Figure 3C). The figure is reproduced from the data reported by 
Quehenberger and colleagues 
16
. Cer stands for ceramide; MHCer, monohexosyl ceramide; 
LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; PA, phosphatidic acid; 
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, 
phosphatidylinositol; PS, phosphatidylserine; SB, sphingoid base; SM, sphingomyelin. 
 
Plasma glycerophospholipids and sphingolipids are associated with lipoproteins. They 
form the surface lipid monolayer around the hydrophobic core made of cholesteryl esters and 
triacylglycerols 
18-20
. Glycerophospholipids and sphingolipids are unequally distributed across 
plasma lipoproteins. Specifically, high-density lipoproteins (HDL) are major carriers of PC, 
PE and PE-based plasmalogens 
18, 20
. Conversely, low-density lipoproteins (LDL) represent 
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major carriers of SMs, Cers and monohexosyl ceramides 
18, 19
. S1P is a minor biologically 
active lysosphingolipid. Differently to other sphingolipids, ~60% of plasma S1P is associated 
with HDL, ~30% of S1P is present in albumin, while the other 10% of S1P is distributed 
among very-low-density lipoprotein (VLDL) and LDL particles 
21-23
. 
 
1.2. The pathophysiology of coronary artery disease and lipoprotein metabolism 
According to the World Health Organisation statistics for 2012, ischemic heart 
disease, which is mainly caused by coronary artery disease (CAD), is the leading cause of 
death worldwide 
24
. CAD most often results from atherosclerosis in the coronary arteries. 
Atherosclerosis is a chronic inflammatory disease which leads to narrowing of the arteries and 
decreasing blood flow and oxygen supply. Generally, atherosclerosis is an asymptomatic 
process, making the artery narrow and less flexible. Clinical manifestations of CAD 
commonly result from the disruption or erosion of an atherosclerotic plaque and a subsequent 
thrombus of one of the coronary arteries. This causes acute coronary syndromes (ACS) which 
encompass myocardial infarction (defined by the finding of biomarkers of myocardial 
necrosis in the plasma) and unstable angina (defined by chest pain without biomarkers of 
myocardial necrosis in the plasma). The major risk factors that significantly increase the 
chance of developing CAD are advanced age, male gender, smoking, physical inactivity, 
hypertension, dyslipidemias, obesity and diabetes 
25, 26
. 
Several clinical studies showed a strong association between an altered plasma lipid 
profile, specifically elevated total cholesterol and LDL-cholesterol (LDL-C) levels, and the 
risk of CAD 
27
. A number of epidemiological studies and studies on individuals with familial 
hypercholesterolemia have shown a direct correlation of high total cholesterol and LDL-C 
levels with the risk of incidence of CAD 
27
. Furthermore, clinical trials of LDL-C lowering 
drugs have shown reduction in CAD events 
28
, indicating the central role of cholesterol 
metabolism in the pathogenesis of CAD.  
In the circulatory system, cholesterol is transported by lipoproteins, mostly in the form 
of water-insoluble cholesteryl esters. The widely accepted concept of atherosclerosis suggests 
that accumulation of LDL-derived cholesterol within the artery wall is central in the formation 
of the atherosclerotic plaques. This process is initiated when the endothelial cell monolayer 
lining the lumen of the arteries undergoes inflammatory activation and excretes various 
chemokines. This directs monocytes into the intima layer of the artery where they transform 
into macrophages. In parallel, LDL enter the endothelial cell monolayer and are retained in 
the artery wall. After enzymatic and oxidative modification of the trapped LDL particles, they 
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are taken up by macrophages through receptors that are not regulated by the cholesterol 
content of the cells. The result is a massive intracellular accumulation of cholesterol, which 
transforms macrophages into lipid-loaded foam cells. This promotes the development of 
atherosclerotic lesions by stimulating inflammatory response, smooth muscle cell 
proliferation and migration, as well as synthesis of matrix macromolecules 
29, 30
. 
In addition to LDL, HDL also play an important role in cholesterol metabolism, as 
HDL transport cholesterol from peripheral tissue, notably cholesterol-loaded macrophages, to 
the liver 
30
. Moreover, low levels of HDL-cholesterol (HDL-C) correlate inversely with risk 
of CAD events 
31
. In recent years, several vascular effects of HDL have been identified. In 
vitro and in vivo studies have shown that HDL particles from healthy subjects exert anti-
inflammatory, anti-apoptotic and anti-thrombotic effects and stimulate endothelial NO 
production and endothelial repair. However, potentially atheroprotective effects of HDL were 
found to be markedly attenuated in HDL from CAD patients when compared to HDL from 
healthy subjects 
32, 33
. The loss of atheroprotective functions of HDL was largely attributed to 
the alterations in protein composition and oxidative modification of the protein components of 
HDL particles 
34-36
. This indicates that not only the quantity, reflected by HDL-C levels, but 
also the quality of HDL, reflected by molecular composition, plays an important role in the 
pathogenesis of CAD. 
 
1.2.1. Glycerophospholipids and sphingolipids in pathogenesis of coronary artery disease 
Glycerophospholipids and sphingolipids are abundant components of the vascular 
plaques and plasma lipoproteins. Today it is becoming clear that not only cholesterol, but 
other lipids, like glycerophospholipids and sphingolipids, are involved in the formation of the 
atherosclerotic plaques and development of CAD. Several studies have been carried out on 
the total plasma lipidome in relation to CAD 
37, 38
, as well as obesity 
39
 and hypertension 
40
. 
Glycerophospholipids and SMs were identified in significant amounts in 
atherosclerotic plaques at different stages of lesion development 
41
. Comparative analysis of 
stable and unstable regions within the same atherosclerotic lesion found major differences in 
the composition of PCs, LPCs and SMs 
42
. Differences in the plasma lipidome were identified 
between stable CAD and unstable CAD as well as between stable CAD and healthy subjects. 
Specifically, reduced plasma levels of specific PCs, LPCs, PC plasmalogens and PE 
plasmalogens as well as increased plasma levels of PIs with 20:4 fatty acid moiety were 
associated with stable CAD, relative to healthy controls. In addition, diminished plasma 
content of specific LPCs, PE-plasmalogens and most of PIs, as well as elevated plasma 
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content of PEs and LPEs displayed significant association with unstable CAD when compared 
to stable CAD patients 
37
. The large population-based Bruneck study with 10 years of follow-
up identified significant associations between increased plasma concentrations of 
triacylglycerols (TAGs), cholesteryl esters (CEs), PEs, PCs and SMs and the incidence of 
cardiovascular disease. In this study, TAG54:2, CE16:1 and PE 36:5 were identified as the 
strongest predictive risk factors for cardiovascular disease 
38
. Analyses of SMs in plasma of 
CAD patients yielded inconsistent results. Although few studies showed that plasma SM 
levels were elevated in CAD patients 
43, 44
, another more recent study showed no association 
of SM lipids with increased risk of CAD 
45
. Reduced serum levels of PC-based and PE-based 
plasmalogens, which are known to possess anti-oxidant properties, as well as elevated serum 
levels of LPCs were shown to be associated with acquired obesity 
39
. Furthermore, total PC 
plasmalogens and PE plasmalogens, as well as plasmalogens containing C20:4 and C22:5 
fatty acid moieties were found at reduced plasma levels in hypertensive individuals 
40
. 
Furthermore, the severity of CAD has been closely linked to low plasma levels of 
HDL-associated phospholipids 
46, 47
. A NMR-based study showed lower contents of SM and 
PC lipids in HDL of CAD patients than in HDL of healthy controls 
48
. In addition, Pruzanski 
and colleagues reported that acute-phase HDL are depleted of PEs, PE-based plasmalogens, 
polyunsaturated PCs, and SMs, specifically SM 33:1 and SM 38:1 species, and enriched with 
LPCs and saturated PCs 
49
. HDL of patients with low HDL-C contain less PC- and/or PE-
plasmalogens than HDL of patients with high HDL-C levels 
6, 50
. 
 
1.2.2. Functional relevance of the lipoprotein lipidome 
The composition of glycerophospholipids and sphingolipids can influence functions of 
plasma lipoproteins, such as LDL and HDL. A high ratio of SMs to PCs makes LDL particles 
more susceptible to lipolysis by SMase (secretory sphingomyelinase) 
51
. As a consequence, 
elevated levels of Cers lead to the aggregation of LDL in the arterial walls and facilitate 
atherosclerosis 
52
. The glycerophospholipids and sphingolipids in HDL, particularly PC and 
SM lipids, can influence the structure and dynamic properties of the surface monolayer of 
HDL. Changes in the fluidity of the lipid monolayer can have a subsequent effect on SR-B1 
mediated cholesterol efflux and on over all reverse cholesterol transport 
53
. It has been shown 
that variations in the acyl chains of PC lipids in reconstituted HDL (rHDL) influence the 
conformation of apoA1 
53
 as well as the ability to activate lecithin:cholesterol acyltransferase 
(LCAT) 
54
, to suppress the synthesis of endothelial cell adhesion molecules 
55
, and to accept 
phospholipid hydro-peroxides from LDL 
56
. Experimental studies with rHDL showed that 
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SMs inhibit cholesterol esterification by LCAT, which is important for the maturation of HDL 
particles 
57
. Moreover, mice with deficient SPTLC2 (serine:palmitoyltransferase long chain 
base subunit 2) or SM synthase present with elevated activity of LCAT, which is caused by 
reduced levels of plasma SMs 
58
. These facts suggest that plasma glycerophospholipids and 
sphingolipids are involved in lipoprotein metabolism and may be related to the pathogenesis 
of CAD. 
 
1.2.3. Sphingosine-1-phosphate 
S1P is a minor bioactive lysosphingolipid that plays important roles in immunity, 
inflammation and vascular function. S1P acts as the ligand for at least five different G 
protein-coupled S1P receptors (GPCRs) present on endothelial and smooth muscle cells. 
Through interaction with the GPCRs, S1P, for example, can regulate cell apoptosis, motility, 
proliferation, wound healing and immune response 
59-61
. S1P is synthesised via 
phosphorylation of sphingosine, catalysed by sphingosine kinases 1 and 2. S1P can be 
irreversibly degraded by S1P-lyase to PE and fatty acid aldehyde. Because of absent S1P-
lyase, erythrocytes and platelets represent the primary sources of S1P in the plasma 
61
, 
62
. 
Most of S1P in the circulatory system is transported by HDL (~60%) 
21-23
. Several in vitro and 
animal studies indicate that HDL-bound S1P mediates potentially atheroprotective functions 
of HDL, including promotion of endothelial cell growth and survival, tube formation, 
vasodilation as well as inhibition of the migration of vascular smooth muscle cells and 
apoptosis 
60, 63
. Importantly, plasma and HDL levels of S1P were found to be lower in patients 
with stable CAD 
64
. Moreover, the content of S1P and dihydro-S1P in the HDL-containing 
but apoB depleted serum was inversely correlated with the occurrence of ischemic heart 
disease 
65
. In addition, the content of S1P was lower in both total plasma and the HDL-
containing fraction of plasma of patients with HDL-C lowering monogenic disorders, 
involving mutations in APOA1, LCAT or ABCA1 genes, when compared to unaffected family 
members 
21
. Considering these facts, S1P appears to be associated with the atheroprotective 
effects of HDL and the pathogenesis of CAD. 
Enrichment of HDL particles with S1P is explained by the presence of a specific S1P-
binding protein, called apolipoprotein M (apoM). Christoffersen and colleagues 
22
 provided 
convincing evidence on the important role of apoM in binding and function of S1P in HDL. 
Furthermore, it has been shown that S1P is reduced in plasma and lacking in HDL of Apom
-/- 
mice 
21, 22
. In contrast, S1P was elevated in plasma and HDL of Apom
tg
 mice 
21, 22
. This 
indicates that apoM is involved in the regulation of S1P levels in both plasma and HDL. 
22 
 
However, a clinical study of humans with monogenic disorders of HDL metabolism did not 
show any significant correlation between S1P and apoM levels, neither in plasma nor in HDL-
containing fractions 
21
. These facts indicate complex and yet unknown interactions between 
HDL, apoM and S1P. 
 
1.2.4. Paraoxonase 1 and age-related macular degeneration 
Paraoxonase 1 (PON1) is a Ca
2+
 dependent, HDL-associated anti-oxidant enzyme. 
PON1 is a glycoprotein of 354 amino acids and approximate molecular mass of 43 kDa 
66
. An 
X-ray crystallography study has indicated the structure of PON1 to be a six-bladed beta-
propeller with two Ca
2+
 ions in the inner channel of the protein 
67
. PON1 is the first 
discovered member of the PON multi-gene family which comprises three members, PON1, 
PON2 and PON3, the genes for which are located next to each other on the long arm of 
chromosome 7 
68
. Together with PON2 and PON3, PON1 forms a family of lactonases with 
anti-oxidant properties, which differ in the sites of synthesis and mechanisms of actions 
69
. In 
the circulatory system, PON1 is almost exclusively present in HDL where it is anchored to 
lipids via its hydrophobic N-terminal region 
67
. PON1 is considered to be a major factor in the 
anti-oxidant function of HDL particles 
70
. In vitro experiments showed that PON1 inhibits 
lipid oxidation of LDL 
71
 and attenuates the oxidation of HDL and cell membranes 
72, 73
. The 
mechanism by which PON1 inhibits LDL oxidation is unproven, but it probably involves 
hydrolysis of oxidised phospholipids 
70
. Additionally, PON1 reduces macrophage oxidative 
stress and the ability of macrophages to oxidise LDL, inhibits cholesterol synthesis, and 
promotes cholesterol efflux 
74, 75
. Consequently, PON1 plays a protective role in the early 
stages of atherosclerosis. This is supported by a recent study showing a reduction in 
atherosclerotic lesion size in mice overexpressing human PON1 
76
. Furthermore, several 
studies have shown prospectively that low PON1 activity is a risk factor for development of 
CAD 
75, 77, 78
. Diminished serum arylesterase and paraoxonase activities were found to be 
associated with increased risk for major adverse cardiac events 
79
. However, the findings are 
not unequivocal 
80
. 
PON1 serum concentration and activity are highly variable in human populations 
70
. 
This variability is largely determined by the genetic polymorphisms in the PON1 gene. Two 
coding region polymorphisms - PON1 Q192R and PON1 L55M - affect substrate specificity, 
enzyme activity as well as the ability of HDL to protect LDL from oxidative modifications 
81-
83
. In addition, several polymorphisms in the promoter region of the PON1 gene are 
associated with different serum concentrations of the protein 
84
.  
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Numerous studies have investigated several PON1 polymorphisms as risk factors for 
CAD with positive associations being identified in some, but not all studies. Two meta-
analyses have shown the association of the PON1 Q192R variant with a small increase in the 
relative risk for CAD 
85, 86
. Large genome-wide association study revealed that PON1 
polymorphisms, which are highly significantly associated with serum paraoxonase or 
arylesterase activity, are not associated with risk of incident cardiac event or prevalent CAD 
79
. 
Several genetic studies have found significant associations of polymorphisms within 
coding and upstream regulatory regions of the PON1 gene and age-related macular 
degeneration (AMD) 
87, 88
. Furthermore, a clinical study has reported reduced serum 
paraoxonase activity of PON1 in patients with AMD 
89
. These data suggests that PON1 may 
be an important factor in the aetiology of AMD.  
AMD is a complex disease that leads to the degeneration of the retina and retinal 
pigment epithelium (RPE) in individuals older than 60 years of age. If not treated, AMD 
causes gradual deterioration and loss of central vision in the elderly 
90
. AMD and CAD share 
similar risk factors, such as advanced age, oxidative stress, smoking and inflammatory 
components
 91, 25
. Furthermore, the severity of CAD is significantly associated with 
appearance of early clinical signs of AMD 
92
. One of the earliest clinical hallmarks of AMD 
are drusen, which are formed between the retinal pigment epithelium (RPE) and Bruch`s 
membrane 
93
. That formation of the drusen has a negative effect on functions of RPE and 
photoreceptors 
94
. Similar to atherosclerotic plaques, the major constituents of drusen include 
aggregates of lipoproteins and cholesterol 
91, 94
. Taken together, the data suggest a role of 
PON1 in the development of AMD. However, neither the functions of PON1 in the retina, in 
general, nor its specific role in the pathogenesis have been directly studied yet. 
 
1.3. Mass spectrometry analysis of lipids 
1.3.1. Overview of targeted lipidomics 
Today, most lipidomics approaches are based on mass spectrometry (MS), which can 
be combined with direct-sample infusion systems or high-performance liquid chromatography 
(HPLC). Due to the diverse structure and chemical properties of lipids, the complete 
characterisation of the lipidome requires not one but several analytical methods specific to 
certain categories of lipids 
95
. 
The targeted approach aims for the identification and quantification of specific lipids, 
or numerous individual lipids species within a lipid class. Typically it is achieved by 
24 
 
employing MS monitoring methods such as precursor ion scanning, neutral loss scanning or 
multiple reaction monitoring (MRM). Most lipids display characteristic fragmentation 
patterns. Precursor ion and neutral loss MS methods allow lipid-class-specific scans due to the 
structural similarities of the lipids within a lipid class. For example, after fragmentation, all 
PC and SM lipids in positive mode give rise to the phosphocholine fragment at m/z 184.1. 
Thus, only PC and SM species can be detected by precursor ion scanning at m/z 184.1, even 
though present in a complex lipid extract. This methodology was widely applied for MS-
based analysis of different glycerophospholipid classes 
96
. In addition, MS analysis with 
MRM enables the detection of specific lipid species, such as S1P, based on their unique 
parent/fragment ion transitions. This MS method provides highly selective and very sensitive 
determination of individual lipid species in the complex lipid mixture, however it requires 
prior knowledge about the fragmentation patterns of lipids analysed. 
Targeted lipidomics is commonly used in combination with a shotgun approach or 
with HPLC. Targeted shotgun lipidomics refers to intra-source separation and ionization of 
lipids injected directly into the MS without on-line separation. Intra-source separation is 
usually achieved by varying the conditions of ion formation, aiming to enhance the ionization 
of analysed lipids and inhibit the ionization of all the matrix components. Shotgun lipidomics 
has been applied to the analysis of lipid species of different glycerophospholipid classes 
97, 98
. 
However, the high ion density in the ion source reduces the ionization efficacy of the low-
abundance lipids and leads to signal suppression. Moreover, a potential isotopic overlap of 
lipids with close molecular weight or isobaric lipids presents other important limitations of the 
shotgun methodology. Targeted liquid chromatography-mass spectrometry lipidomics is a 
reasonable solution for these problems. HPLC, combined with the MS technique, allows the 
separation of lipid classes or species prior to MS analysis and reduces, but does not eliminate, 
the isotopic overlap and co-elution of isobaric lipids. Furthermore, the HPLC system can be 
adjusted for the optimal retention of the lipids, while the sample matrix will be removed, 
ensuring maximal ionization in the ion source. Normal-phase HPLC (based on the retention of 
the polar head group in the column) is usually applied for the separation of lipid classes, while 
reversed-phase HPLC (based on the retention of the carbon chain in the column) is commonly 
used for the separation of individual lipid species 
96
. The targeted liquid chromatography-
mass spectrometry approach has been widely employed for quantitative analysis of different 
glycerophospholipids and sphingolipids 
96, 99, 100
. 
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1.3.2. Data processing and interpretation in lipidomics research 
Data processing is an important part of the workflow where recorded MS data are 
transformed into the knowledge about biological processes being studied 
95
. Briefly, 
processing of spectral data consists of several steps including peak detection, lipid 
identification, isotope correction and data normalization. Today, all MS instruments are 
supplied with built-in software that facilitates the processing of multidimensional spectral 
data. In addition, important steps in data processing, like lipid identification and isotope 
correction, can be done by lipid focused software, such as open-source software LIMSA
 101
 or 
LipidXplorer
 102
. Data normalization is usually achieved by comparisons of endogenous lipids 
with internal standards and results in quantitative information on identified lipids. Internal 
standards are often added to the samples before lipid extraction to compensate for losses 
during extraction and ionization efficiency, and to perform semi-quantitative analysis of 
identified lipid species. Stable-isotope labelled lipids present ideal internal standards, as they 
are chemically identical to non-labelled analogues. However, since not all lipids have 
commercially available stable-isotope labelled standards, a suitable alternative is the use of 
non-natural lipids belonging to the same lipid class. In addition, when lipidomics analysis 
includes screening of a large number of lipids, it is difficult to match every lipid species with 
internal standards, therefore only one or two internal standards from the same lipid class are 
used 
5
. 
The interpretation of quantitative lipidomics data largely depends on the experimental 
design and study objectives. Univariate and multivariate statistical analyses are routinely used 
for comparative analysis of study groups to extract relevant information from lipidomics data. 
Univariate analyses identify the lipid species with a significant difference between average 
content, analysing one lipid species at a time. Depending on the sample population, 
parametric (Student t-test) or nonparametric (Mann-Whitney U) statistical tests are used 
95
. 
Since univariate analyses of lipidomics data include testing for large numbers of different 
lipids, it may increase the probability of false positive results. Thus, p values should be 
corrected to account for multiple comparisons by using Bonferroni or Benjamini and 
Hochberg procedures 
103
. In contrast to the Bonferroni procedure, which strictly controls for 
even single false positive result, the Benjamini and Hochberg method tolerates a certain 
number of tests being incorrectly discovered, keeping the false discovery rate at 5% of all 
discoveries. Less conservative Benjamini and Hochberg procedure is commonly used in 
metabolomics and lipidomics studies. 
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Multivariate statistical analysis takes into account all lipid variables and their 
interrelationships simultaneously. Principal component analysis (PCA) is a key method in 
unsupervised analysis of multiple data. In practice, PCA reduces dimensionality of the data to 
the few uncorrelated variables (principal components) that explain the largest proportion of 
the variance within the data set. A score plot of the resulting model represents the distribution 
of individual samples, while a variable importance of the projection (VIP) coefficient plot 
provides a measure of the contribution of each lipid variable to the model. Supervised analysis 
of multivariate data can be performed by an orthogonal partial least square-discriminant 
analysis (OPLS-DA). This method is based on the concept of PCA, but also includes the 
information on the class membership. The acquired OPLS-DA model summarises data into 
predictive and orthogonal components that describe the between-group and the within-group 
variations, respectively 
95, 104, 105
. Previously, our group applied the OPLS-DA to evaluate 
association of deoxysphingolipids with diabetes and the metabolic syndrome 
105
. 
 
1.4. Aim of the study  
We applied lipidomics to address the following research questions: 
1. Do plasma concentrations of glycerophospholipids, sphingolipids and S1P differ between 
healthy controls and patients with either stable or acute CAD, and what is the distribution 
of glycerophospholipids and sphingolipids among plasma lipoproteins? 
2. Are stable CAD or ACS associated with differences in the composition of 
glycerophospholipids, sphingolipids and S1P in HDL, and do differences in the lipidome 
affect the functionality of HDL? 
3. Does apoM affect the ability of HDL to elicit S1P efflux from erythrocytes and the renal 
excretion of S1P? 
4. Does the presence of PON1 affect the composition of glycerophospholipids and 
sphingolipids in the mouse retina, and thereby modulate the pathogenesis of AMD? 
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Abstract 
Background: Coronary artery disease (CAD) is a chronic disease resulting from the 
formation of atherosclerotic lesions within the arterial wall. Glycerophospholipids and 
sphingolipids play an important role in lipoprotein metabolism, plaque formation and 
therefore in the development of atherosclerosis. 
Objectives and Methods: Here, we show the association of plasma levels of 
glycerophospholipids and sphingolipids as well as sphingosine-1-phosphate (S1P) species and 
sphingoid bases of sphingolipids with CAD and acute coronary syndrome (ACS). In this 
study, we included comparison of statin-treated and untreated CAD patients. Furthermore, we 
described the distribution of phosphatidylcholines (PCs) and sphingomyelins (SMs) among 
plasma lipoproteins. Plasma lipids were measured using three different liquid 
chromatography-mass spectrometry methods. 
Results: The glycerophospholipid and sphingolipid profile was altered in plasma of CAD and 
ACS patients. Specifically, 45 out of 65 quantified glycerophospholipid and sphingolipid 
species, 16:1-S1P as well as four sphingoid bases were lower in plasma of CAD patients as 
compared to healthy controls. Similarly, plasma levels of 42 glycerophospholipids and 
sphingolipids, 16:1-S1P, 18:1-S1P as well as six sphingoid bases were lower in ACS patients, 
relative to healthy subjects. The statin therapy did not have any significant effect on the 
plasma concentrations of glycerophospholipids and sphingolipids. The odd-chain PCs, 
PC33:1, PC33:2, PC33:3 and PC35:3, which are PC plasmalogens, were the most 
significantly and consistently altered species in plasma of both CAD and ACS patients. The 
PC and SM species were abundant exclusively in lipoprotein particles, whereas LPCs were 
mainly present in the lipoprotein-free fraction. 
Conclusion: Both CAD and ACS are associated with alterations in the plasma concentrations 
of glycerophospholipids and sphingolipids, among them four PC plasmalogens were the most 
significantly altered lipids. Since the vast majority of glycerophospholipids and sphingolipids 
are present in lipoproteins, our observations are likely to be related to the changes in 
composition, number and/or oxidative state of lipoproteins.  
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2.1. Introduction 
Coronary artery disease (CAD) remains the leading cause of death worldwide 
1
. The 
primary cause of CAD is atherosclerosis, which results from plaque formation within the 
arterial wall 
2
. CAD can take several years before it becomes symptomatic, for example, 
before manifestation of an acute coronary syndrome (ACS). Imbalanced lipid metabolism 
plays a central role in the pathogenesis of CAD. Indeed, elevated levels of total cholesterol 
and low-density lipoprotein cholesterol (LDL-C) as well as reduced levels of high-density 
lipoprotein cholesterol (HDL-C) have been widely recognised as independent risk factors for 
CAD 
3,4
. Today, it is becoming clear that beyond cholesterol other lipids, including 
glycerophospholipids and sphingolipids, contribute to the development of atherosclerosis 
5, 6
.  
In the circulatory system, plasma glycerophospholipids and sphingolipids are mainly 
associated with lipoprotein particles 
7, 8
. They form a lipid monolayer around the hydrophobic 
core made of triglycerides and cholesteryl esters. Hundreds of different glycerophospholipid 
and sphingolipid species were identified in plasma lipoproteins and vascular plaques 
9-11
. The 
lipid composition of lipoprotein particles was found to be altered in different pathologies 
related to CAD. Specifically, the acute-phase high-density lipoproteins (HDL) were found 
depleted of sphingomyelins (SMs), polyunsaturated phosphatidylcholines (PCs), 
phosphatidylethanolamines (PEs) and phosphatidylinositols (PIs), and enriched with 
lysophosphatidylcholines (LPCs) and saturated PCs when compared to normal HDL 
12
. The 
PCs associated with very-low-density lipoproteins (VLDL) and low-density lipoproteins 
(LDL) had increased levels of C16:1 and C20:3 fatty acid residues in patients with 
dyslipidaemic type 2 diabetes 
13
. Furthermore, alterations in the plasma or serum content of 
specific glycerophospholipids and sphingolipids have been described for hypertensive and 
obese individuals as well as for patients with stable and unstable CAD 
14-16
. The prospective 
population-based Bruneck study has identified triacylglycerol TAG54:2, cholesteryl ester 
CE16:1 and PE36:5 lipids as strong predictive risk factors of cardiovascular disease 
17
. A few 
studies in humans have shown that the plasma content of SMs is significantly elevated in 
CAD patients 
18, 19
, and that plasma SMs represent an independent predictor of myocardial 
infarction in ACS patients 
20
. However, a more recent clinical study did not find any 
significant association of high plasma SM levels with increased risk of CAD 
21
. In addition, 
sphingosine-1-phosphate (S1P), which exerts several atheroprotective effects of HDL 
22, 23
, 
was found at lower levels in the plasma and HDL of CAD patients 
24, 25
. Furthermore, S1P in 
the HDL-containing fraction of serum, has been inversely correlated with the occurrence of 
ischemic heart disease 
26
. Recently, in human plasma, Quehenberger and colleagues have 
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identified different S1P species which vary in length and disaturation degree of sphingoid 
base 
27
. However, until now the association of these S1P species with CAD has not been 
studied. In addition, our group previously showed altered profiles of sphingoid bases in 
plasma of patients with metabolic syndrome 
28
 or type 2 diabetes mellitus 
29
, which are major 
risk factors for cardiovascular disease 
30
. 
In this study, we used three different liquid chromatography - mass spectrometry (LC-
MS) methods to identify and quantify glycerophospholipids and sphingolipids, including 
phosphatidic acids (PAs), phosphatidylglycerols (PGs), PCs, PEs, SMs, 
ceramides/hexosylceramides (Cers/HexCers) as well as different S1P species and 11 
sphingoid bases of sphingolipids. First, we explored differences in the composition of 
glycerophospholipids and sphingolipids in plasma of CAD and ACS patients relative to 
healthy subjects. Then, we assessed the relationships between plasma lipidome and traditional 
risk factors for CAD. Finally, we characterised the distribution of glycerophospholipids and 
sphingolipids among the lipoprotein fractions of healthy subjects. 
 
2.2. Materials and methods 
2.2.1. Patients 
Patients with stable CAD (n=18) or ACS (n=17) were selected from the SPUM cohort 
(Special Program University Medicine) 
31
 and compared to healthy subjects (n=14). In 
addition, ten patients with CAD but not on statin treatment were selected to explore the 
influence of cholesterol-lowering therapy (statins) on glycerophospholipid and sphingolipid 
levels. The age of the patients ranged between 43 and 77 years. 
 
2.2.2. Clinical chemistry 
Plasma concentrations or activities of total cholesterol, triglycerides, LDL-C and 
HDL-C, glucose, creatine kinase, CK-MB, and troponin levels were determined by 
photometric tests or immunoassay by using the Cobas 8000 autoanalyser from Roche 
diagnostics (Rotkreuz, Switzerland).  
 
2.2.3. Isolation of lipoproteins 
Human lipoprotein fractions and the lipoprotein-free fraction (LFF) were isolated from 
2 ml of plasma of three healthy blood donors by stepwise ultracentrifugation, as described 
previously 
32
 using solid potassium bromide for density adjustment and a tube slicer for 
collection of the lipoprotein fractions. 
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2.2.4. Analysis of plasma glycerophospholipids and sphingolipids 
In the present study, we analysed six lipid classes of glycerophospholipids or 
sphingolipids. Lipids were compared to 200 ng of the internal standards PG(17:0/17:0), 
LPG(17:1/0:0), PA(14:0/14:0), LPA(17:0/0:0), PE(14:0/14:0), LPE(17:1/0:0), PC(14:0/14:0), 
PC(24:0/24:0), LPC(17:0/0:0), SM (d18:1/12:0) and Cer(d18:1/17:0) (Avanti Polar Lipids, 
Alabaster, AL, USA). A sample volume of 20 µl was extracted with 375 µl of 
methanol/chloroform (2:1 v/v). After vortexing, 100 μl water and 125 μl chloroform were 
added. The mixture was shaken for 15 minutes and centrifuged at 16,100×g for 5 minutes at 
25°C. The lower phase was collected and an additional 250 μl chloroform was added. The 
mixture was shaken for 15 minutes and centrifuged at 16,100×g for 5 minutes at 25°C. All 
lower phases were combined and evaporated to dryness under a stream of nitrogen. Dried 
material was reconstituted in 200 µl of a mixture of mobile phases A (80%) and B (20%). 
Then, 10 µl were injected into the LC-MS system. 
The total lipid extract was analysed by LC-MS which comprised a Rheos 2200 pump 
and a TSQ Quantum Access triple quadrupole mass analyser. The lipid extract was separated 
on a diol silica-based column (QS Uptisphere 6 OH, 150 x 2.1 mm, 5 µm). The mobile phase 
A was a mixture of hexane/isopropanol/water (70:30:2 v/v) containing 15 mM NH4COOH 
and mobile phase B was a mixture of isopropanol/water (50:2 v/v) containing 15 mM 
NH4COOH. The solvent gradient was 0-7 min A/B (%) 80/20; 8-10 min A/B (%) 60/40, 11-
23 min A/B (%) 40/60 and 25-30 min A/B (%) 80/20 at a flow rate of 0.35 ml/min. Molecular 
masses provided by a neutral loss and precursor scans were used to detect specific 
glycerophospholipids and sphingolipids. A neutral loss scan of m/z 115 and 189 from 
[M+NH4]
+
 
 
ions were used for the analysis of PA and PG lipids, respectively. A precursor ion 
scan of m/z 184, which is specific for phosphocholine-containing lipids, was used for PC, SM 
and LPC lipids. A neutral loss scan of m/z 141 was used for PEs and a precursor scanning of 
m/z 264 was applied for screening of Cers and HexCers with d18:1 sphingoid base. Data 
obtained were analyzed using Xcalibur software (version 2.0.6) from Thermo Scientific. 
Identification of molecular species was performed by lipid mass spectrum analysis software 
(LIMSA) 
33
. 
The assignment of glycerophospholipids includes total numbers of carbons and double 
bonds in two acyl chains. The SM assignment comprises total numbers of carbons and double 
bonds in the sphingoid base and N-linked fatty acid. Hexosylceramide species include 
isomeric glucosyl- and galactosylceramides. For identified Cers and HexCers, molecular 
structures are reported. Quantification was done in relation to the added internal standards.  
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2.2.5. Quantification of sphingosine-1-phosphate species 
Determination of the sphingosine-1-phosphates (S1Ps) in plasma samples was 
performed by LC-MS as described previously 
25
. Concentrations of S1P species were 
measured in 25 µl of plasma supplemented with 10 pmol internal standard 18:1-D7S1P 
(Avanti Polar Lipids, Alabaster, AL, USA). Samples were extracted with ethyl acetate/iso-
propanol (6:1 v/v). The lipid extracts obtained were evaporated to dryness under a stream of 
nitrogen, and derivatised by adding 50 µl of acetic anhydride and 100 µl of pyridine. 
Acetylated S1P species were separated on a C18 column (Nucleosil 125 x 2 mm, 100 Å, 5 m) 
and analysed on a TSQ Quantum Access triple quadrupole mass analyser. The lower level of 
quantification amounted to 1 pmol extracted S1P corresponding to 0.04 µM in plasma. 
Analysis of S1P species included the quantification of 16:1-S1P, 17:1-S1P, 18:1-S1P and 
18:0-S1P lipids. 
 
2.2.6. Quantification of sphingoid bases 
The LC-MS method was applied to quantify 11 sphingoid bases in 100 µl of human 
plasma supplemented with 200 pmol of the internal standards d7-sphingosine (D7SO) and d7-
sphinganine (D7SA) (Avanti Polar Lipids, Alabaster, AL, USA), as described earlier 
28
. After 
acid-base hydrolysis of the plasma samples, the sphingoid bases were separated on a C18 
column (Uptispere 120 Å, 5 µm, 125 × 2 mm) and analysed on a TSQ Quantum Ultra mass 
spectrometer.  
 
2.2.7. Statistical analysis 
Statistical analysis was performed using SPSS, version 19 (IBM Corporation, Somers 
NY, USA). Normality of the data was determined by using the Kolmogorov-Smirnov test. 
Because values of variables did not follow a Gaussian frequency distribution, the univariate 
statistics were performed by applying the Kruskal-Wallis and the Mann-Whitney U tests. 
Categorical variables were compared using the Chi-square test. Spearman rank tests were 
used to describe the correlations of plasma glycerophospholipids and sphingolipids with total 
cholesterol, LDL-C and HDL-C levels. To maintain the rate of false-positive results, p values 
were adjusted for multiple comparisons by applying the Benjamini-Hochberg procedure 
34
. 
The adjusted (adj.) p values of < 0.05 were considered as statistically significant.  
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2.3. Results 
2.3.1. Clinical characteristics of the CAD and ACS patients 
In the present study, we compared the plasma lipid profile of healthy subjects with the 
lipid profile of stable CAD or ACS patients. On average, healthy subjects (56.4 ± 7.5 years) 
and CAD patients (61.3 ± 8.3 years) were ten and five years younger than ACS patients (66.8 
± 10.0 years), respectively. In addition, the prevalence of smoking was significantly higher in 
the CAD and ACS patients than in healthy subjects. Average BMI was higher in the CAD 
patients when compared with healthy subjects. Furthermore, all CAD and ACS patients in the 
cohort were treated with statins, which resulted in significantly lower LDL-C and total 
cholesterol levels compared to healthy subjects. The ACS patients showed several features of 
acute myocardial infarction, including elevated plasma levels of NT-proBNP, creatine kinase, 
CK-MB and troponin (Table 1). 
 
2.3.2. CAD effect on plasma lipidome 
We compared plasma levels of 65 lipid species of glycerophospholipids and 
sphingolipids between healthy subjects, CAD and ACS patients. To exclude the possibility 
that the observed differences are caused by cholesterol lowering drugs, we also compared the 
lipid profiles of CAD patients with and without statin treatment. However, no differences 
were observed between CAD patients that were treated with statins and those who were not 
(Table 2). This agrees with earlier results from Meikle et al. 
16
 who showed that only few of 
plasma glycerophospholipids and sphingolipids associate with statin use. 
Univariate statistical analysis revealed significantly different lipid profiles of plasmas 
from CAD and ACS patients compared to healthy individuals (Table 3). The total content of 
PC, LPC, PE, SM and Cer/HexCer lipids was significantly lower in the CAD and ACS 
patients compared to healthy subjects (Table 3). However, only total Cer/HexCer was present 
at lower plasma concentration in ACS patients when compared with CAD subjects. 
Comparison of the individual lipid species in the plasmas of CAD patients with healthy 
controls revealed differences in concentrations of 45 molecular species including 19 PCs, 4 
LPCs, 5 PEs, 12 SMs and 5 Cers/HexCers. Furthermore, in patients with ACS, plasma levels 
of 42 lipid species, including 15 PCs, 2 LPCs, 9 PEs, 11 SMs and 5 Cers/HexCers, were 
decreased relative to healthy subjects (Table 3). 
Analysis of plasma samples revealed the presence of typical 18:1-S1P as well as other 
S1P species including: 16:1-S1P, 17:1-S1P and 18:0-S1P. Abbreviations of S1P species 
indicate total numbers of carbons and double bonds in sphingoid base. In plasma of healthy 
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subjects, 17:1-S1P was found at very low concentration below or close to lower level of 
quantification, which corresponds to 0.04 µmol per liter plasma. In plasma of CAD and ACS 
patients, 17:1-S1P was below the detection limit. Furthermore, the plasma content of 18:1-
S1P was lower in ACS patients than in healthy individuals (Table 3). The plasma levels of 
16:1-S1P were lower in both CAD and ACS patients when compared with healthy controls 
(Table 3). 
All plasma sphingolipid species share a common structural feature, a sphingoid base, 
which can be amide-linked with fatty acid and conjugated to different head groups giving rise 
to a number of different sphingolipids. To analyse the composition of the sphingoid bases, all 
sphingolipids extracted from plasma samples were hydrolysed to remove the N-acyl chains 
and head groups. Hence, sphingoid base concentrations reported here refer to the total content 
of sphingoid bases, present in different sphingolipid species. 
Plasma levels of C17SO, C18SO, C18SA and C18SAdiene were found to be lower in 
both CAD and ACS patients compared to healthy subjects but did not differ between CAD 
and ACS patients (Table 3). Moreover, the plasma content of C16SO and C16SA was 
significantly lower in ACS patients relative to healthy controls (Table 3). Plasma 
concentrations of doxSO and doxSA sphingoid bases were not significantly different between 
healthy individuals and CAD or ACS patients. 
Data representation with volcano plots helped to identify the most significantly 
changed parameters with the magnitude of change and significance of change displayed on 
the x and y axes, respectively. All data on plasma samples were divided into four groups: 
group of glycerophospholipids includes even-chain PCs, PEs, LPCs and PGs; group of odd-
chain PCs includes all PCs with odd number of carbons in two acyl chains; group of 
sphingolipids includes SMs, Cers/HexCers, S1P species and sphingoid bases; clinical 
measures include patient`s data and data on clinical chemistry. The volcano plots in Fig. 1 
compare the relative abundance of the analysed lipids and clinical measures of healthy 
subjects vs. CAD patients (Fig. 1A), healthy subjects vs. ACS patients (Fig. 1B), CAD vs. 
ACS patients (Fig. 1C). Four species of odd-chain PCs, including PC33:1, PC33:2, PC33:3 
and PC35:3, differed most significantly between CAD patients and healthy subjects (Fig. 1A). 
ACS patients differed from healthy subjects more prominently by troponin level, but also by 
PC33:1, PC33:2, PC33:3 and PC35:3 levels (Fig. 1B). The CAD and ACS patients differed 
most prominently by routine clinical measures, including troponin, creatine kinase and CK-
MB (Fig. 1C). 
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Table 1. Clinical characteristics of the study population. 
 
Values are expressed as means ± SD or percentages for scale or categorical variables, respectively. Statistical significance was determined by 
the Kruskal-Wallis test used for multiple group comparisons, and by the Mann-Whitney U test applied for two group comparisons. The p 
values for the categorical variables were calculated by using Chi-square test. The p values were adjusted for multiple testing by using the 
Benjamini-Hochberg procedure. Statistically significant results are indicated in bold font. Values marked by asterisk * were measured in the 
patient samples before hospital discharge. Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; CK-MB, creatine 
kinase MB; BMI, body mass index; H, healthy subjects; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; NT- proBNP, amino terminal prohormone B-type natriuretic peptide. 
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Table 2. Plasma glycerophospholipids and sphingolipids don`t differ between statin-
treated and untreated CAD patients. 
 
(Continued) 
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Values are expressed as medians with ranges. Statistical significance was determined by the 
Mann-Whitney U test. Statistically significant results are indicated in bold font. The p values 
were adjusted for multiple testing by using the Benjamini-Hochberg procedure. Total lipids 
are presented for phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), 
phosphatidylethanolamines (PEs), phosphatidylglycerols (PGs), sphingomyelins (SMs), 
ceramide/hexosylceramides (Cers/HexCers). Glycerophospholipids are named according to 
the summarized numbers of carbons and double bounds in two acyl chains. Names of SM 
species reflect summarized numbers of carbons and double bounds in sphingoid base and N-
linked fatty acid. An assignment of sphingosine-1-phosphate (S1P) species includes numbers 
of carbons and double bounds in sphingoid base. HexCer species include isomeric glucosyl- 
and galactosylceramides. For Cer/HexCer species molecular structures are reported. n.d. 
stands for not detected. 
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Table 3. Plasma glycerophospholipids and sphingolipids differ significantly between 
healthy subjects, CAD and ACS patients. 
 
(Continued)  
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Values are expressed as medians with ranges. Statistical significance was determined by the 
Kruskal-Wallis test used for multiple group comparisons, and by the Mann-Whitney U test 
applied for two group comparisons. Statistically significant results are indicated in bold font. 
The p values were adjusted for multiple testing by using the Benjamini-Hochberg procedure. 
ACS stands for acute coronary syndrome; CAD, coronary artery disease; n.d., not detected.
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Figure 1. Volcano plots illustrating differences in the clinical measures and plasma lipidome of healthy subjects, CAD and ACS patients. 
The x axis shows the magnitude of change (displayed as Log(fold-change)), while the y axis shows the significance of change (displayed as -Log 
10(adj. p value), p values were calculated by the Mann-Whitney U test). Volcano plots were used for the comparisons of healthy subjects (H) 
with CAD or ACS patients: H vs. CAD patients (Figure 1A), H vs. ACS (Figure 1B); as well as for the comparison of CAD vs. ACS patients 
(Figure 1C). Colour of each dot represents group of the data (blue, GPLs; green, SLs including SMs, Cers/HexCers, S1Ps and sphingoid bases of 
SLs; grey, clinical measures; crimson, odd-chain PCs). The dashed horizontal line denotes the cut-off thresholds (adj. p <0.05) to define the 
significantly altered parameters. The p values were adjusted for multiple comparisons according to the Benjamini-Hochberg procedure. The 
most significant parameters present those that are distributed much above the dash line. Abbreviations: ACS, acute coronary syndrome; CAD, 
coronary artery disease; PC, phosphatidylcholine; GPL, glycerophospholipids; SL, sphingolipid. 
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 Figure 1. (Continued) 
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2.3.3. Structural analysis of odd-chain phosphatidylcholines 
Odd-chain PC species – PC33:1, PC33:2, PC33:3 and PC35:3 – which showed the 
greatest difference between the healthy individuals and CAD patients, can be either PCs with 
an odd number of carbon atoms in one of the acyl chains, or PC plasmalogens with a vinyl-
ether bond at the sn-1 position of the glycerol backbone. Structural analysis of PC35:3 using 
collision-induced dissociation of [M-CH3]
-
 showed a fragmentation pattern like a 
commercially-available plasmalogen PC(P-18:0/18:1), indicating that this species represents 
plasmalogen PC(P-18:0/18:2) (Fig. 2A and 2B). In contrast to fragmentation pattern of even-
chain PCs, for example PC(16:0/18:1) (Fig. 2C), fragmentation of plasmalogens shows only 
one carboxylate ion that corresponds to the sn-2 substituent, whereas cleavage of the vinyl-
ether or the ether-linked substituent from the sn-1 position of the glycerol backbone is 
unfavourable. A similar fragmentation pattern for PC lipids and PC-based plasmalogens was 
previously described by Berdeaux et al. 
35
. After detailed structural analysis of PC33:1, 
PC33:2, PC33:3 and PC35:3, these species were identified as PC plasmalogens PC(P-
18:0/16:0), PC(P-16:0/18:1), PC(P-16:0/18:2) and PC(P-18:0/18:2), respectively. Even 
though the structural identity of some odd-chain PCs was established, the molecular structure 
of other odd-chain PC species remains unknown. Thus, in the volcano plots, odd-chain PCs 
and identified PC plasmalogens were grouped together and named “odd-chain PCs” (Fig. 1). 
 
2.3.4. Correlations of the plasma glycerophospholipids and sphingolipids with 
cholesterol levels 
Plasma concentrations of several glycerophospholipids and sphingolipids showed 
significant positive correlations with total cholesterol, HDL-C and LDL-C (Fig. 3). Among all 
glycerophospholipid and sphingolipid species, PC33:1, PC33:2, PC33:3 and PC35:3 exhibited 
the strongest positive correlation with HDL-C levels (Spearman correlation coefficient r = 
0.81, r = 0.71, r = 0.75 and r = 0.68, respectively). We also noted a similar correlation pattern 
for total cholesterol and LDL-C. Both total cholesterol and LDL-C correlated very strongly 
with sphingoid bases C18SO (r = 0.93 and r
 
= 0.86, respectively) and C17SO (r = 0.85 and r = 
0.81, respectively). Furthermore, total cholesterol as well as LDL-C correlated more strongly 
than HDL-C with saturated LPC species, i.e. LPC16:0 (r
 
= 0.81, r = 0.74 and r = 0.53, 
respectively) and LPC18:0 (r = 0.73, r = 0.71 and r = 0.32, respectively). 
 
52 
 
Figure 2. Product ion spectrum of negative ions of plasmalogen PC(P-18:0/18:1), plasma phosphatidylcholine PC35:3 and PC(16:0/18:1) 
(collision energy 35V). 
Product ion spectrum of the selected molecular ion [M-CH3]
-
 of PC(P-18:0/18:1) at m/z 756,4 shows the carboxylate anion at m/z 281.2 which 
correspond to the fatty acid C18:1 at the sn-2 position of the glycerol backbone (Figure 2A). Product ion spectrum of the selected molecular 
anion [M-CH3]
-
 of plasma PC35:3 at m/z 754,8 shows one prominent ion at m/z 278.99 which correspond to the fatty acid C18:2 at the sn-2 
position of the glycerol backbone indicating that PC35:3 is PC-derived plasmalogen, PC(P-18:0/18:2) (Figure 2B). Product ion spectrum of the 
selected molecular anion [M-CH3]
-
 of PC(16:0/18:1) at m/z 744,3 shows two carboxylate anions first at m/z 255,15 and second at m/z 280,77 
which correspond to the fatty acids C16:0 and C18:1 at the sn-1 and sn-2 position of the glycerol backbone, respectively (Figure 2C). 
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Figure 3. Spearman correlation matrix of glycerophospholipids and sphingolipids with 
cholesterol levels of the entire cohort (N=49), presented as a heat map.  
Red color indicates positive correlation, blue - negative. Intensive color indicates stronger 
correlations.  
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2.3.5. Glycerophospholipid and sphingolipid levels in the lipoprotein fractions 
Because of very strong correlations between cholesterol levels and the plasma content 
of glycerophospholipids and sphingolipids, we decided to characterise the distribution of 
these lipids across various lipoproteins. We analysed the lipoprotein fractions of the plasma 
samples isolated from three healthy volunteers. We calculated the lipid composition of the 
four major lipoprotein fractions: the chylomicron/very-low-density lipoprotein (CM/VLDL), 
the LDL, the HDL fractions and the lipoprotein-free fraction (LFF). Species of PC, SM and 
LPC were recovered in all plasma lipoprotein fractions. LC-MS analysis showed the presence 
of PE and Cer/HexCer species in the lipoprotein fractions, but at very low levels that could 
not be quantified by our LC-MS method. Furthermore, neither PG nor PA lipids were 
identified in the plasma lipoprotein and LFF fractions.  
Figures 4A, 4B and 4C show the percentage of total PC, SM and LPC lipids in the 
lipoprotein fractions of normal plasma. Figures 4D, 4E and 4F indicate the percentages of the 
individual PC, SM and LPC species relative to the total concentration of a given species in all 
lipoprotein fractions. In agreement with previous publications, the largest amount of total PCs 
were found in HDL (Fig. 4A) 
7
. Specifically, 55% of total PCs were found in the HDL, 
approximately 34% were found in the LDL, 9% were found in the LFF and 2% of PCs were 
found in the combined CM/VLDL fractions. The distribution of the odd-chain PC species was 
found to be similar to the distribution of even-chain PCs, with HDL being the major carrier of 
these lipids in the circulatory system (Fig. 4D). As shown in Fig. 4B, 56% of total circulating 
SMs were found in LDL, 36% were found in HDL, 5% were found in LFF and 2% were 
found in CM/VLDL. These findings agree with the literature that the largest part of 
sphingolipids in circulation is carried by LDL 
7
. Although not very pronounced, all SM 
species showed heterogeneous distribution across lipoprotein fractions (Fig. 4E). 80% of the 
total LPC molecular species were found in the LFF, indicating that a substantial amount of 
plasma LPCs is bonded by albumin (Fig. 4C). Furthermore, rather small amounts of total 
LPCs were found associated with LDL (11%) and HDL (7%). A remarkable difference in the 
lipoprotein distribution was noted for LPC18:0, when compared to other LPC species (Fig. 
4F). The proportion of LPC18:0 was decreased by 20% in the LFF and increased by 11% in 
the LDL fraction relative to the proportion of LPC16:0 in the same fractions.  
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Figure 4. Distribution of the total phosphatidylcholines, lysophosphatidylcholines and 
sphingomyelins (pie charts) and individual species (bar diagram) in different lipoprotein 
fractions isolated from plasma of healthy volunteers. 
Displayed are the percentages of total phosphatidylcholines (PCs), lysophosphatidylcholines 
(LPCs) and sphingomyelins (SMs) and their species relative to the summarized content of a 
representative lipid class or species found in all lipoprotein fractions, respectively. Values are 
expressed as mean for total lipids (Figures 4A, 4B and 4C) and as mean ± SD for molecular 
species (Figures 4D, 4E and 4F) of three healthy blood donors. Figures 4A and 4D display 
total PCs and PC species, respectively (upper row). Figures 4B and 4E display total SMs and 
SM species (middle row). Figures 4C and 4F display total LPCs and LPC species (lower row). 
Abbreviations: CM/VLDL, chylomicron/very-low-density lipoprotein, HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; LFF, lipoprotein-free fraction.  
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2.4. Discussion 
In the present study, we aimed to assess differences in the composition of 
glycerophospholipids and sphingolipids in the plasma of CAD and ACS patients relative to 
healthy subjects. Univariate statistical analysis revealed the association of chronic and acute 
CAD with distinct alterations in the plasma lipidome independent of statin therapy. Overall, in 
comparison with healthy individuals, 45 molecular species of glycerophospholipids and 
sphingolipids, 16:1-S1P as well as C17SO, C18SO, C18SA and C18Adiene sphingoid bases 
were significantly lowered in the plasma of CAD subjects. Moreover, 42 molecular species of 
glycerophospholipids and sphingolipids, 16:1-S1P, 18:1-S1P as well as C16SO, C16SA, 
C17SO, C18SO, C18SA and C18SAdiene sphingoid bases were found at significantly 
reduced plasma levels in patients with ACS when compared to healthy subjects. These 
associations are likely related to CAD rather than to ACS, as only a few lipids differed by 
plasma levels between CAD and ACS patients. Furthermore, our analysis of the lipid 
distribution among the plasma lipoprotein fractions indicated that the vast majority of PCs and 
SMs are associated with lipoprotein particles, whereas only LPCs are substantially recovered 
in the lipoprotein-free fraction (LFF). Similar results were previously reported by others 
suggesting that lipoprotein particles are the main carriers of major plasma 
glycerophospholipids and sphingolipids 
7, 8
. Thus, the alterations in plasma lipidome of CAD 
and ACS patients may be related to the variations in particle numbers and/or composition of 
these lipoproteins.  
Four odd-chain PC species – PC33:1, PC33:2, PC33:3 and PC35:3 – assumed to be PC 
plasmalogens, were significantly altered in plasma of both CAD and ACS patients. 
Diminished plasma levels of plasmalogens have previously been shown in hypertensive and 
obese patients 
14, 15
. Furthermore, these findings support previously described significant 
associations of reduced plasma levels of PC plasmalogens with stable CAD 
16
. In addition, 
decreased levels of HDL-associated PE plasmalogens have been found in patients with low 
HDL-C levels and in acute-phase HDL 
12, 36
. Our analysis of lipoprotein fractions showed that 
PC33:1, PC33:2, PC33:3 and PC35:3 (= PC plasmalogens) are largely associated with HDL. 
This is reflected in strong positive correlations of these lipids with HDL-C found both by our 
and other studies 
37
. 
Although the physiological functions of plasmalogens are very poorly understood, the 
decreased levels of PC plasmalogens noted in CAD and ACS patients indicate that they play a 
role in the pathogenesis of atherosclerotic CAD. It is known that plasmalogens possess 
antioxidant properties due to their ability to scavenge oxygen radicals 
38
. Evidence from in 
57 
 
vitro studies indicates that plasmalogens are capable of reducing the oxidation of cell 
membrane cholesterol, polyunsaturated fatty acids and LDL 
39-41
. Thus, low levels of PC 
plasmalogens observed in the plasmas of CAD and ACS patients may relate to increased 
oxidative stress causing oxidative degradation of plasmalogens in the lipoprotein particles. 
This can also explain why PC plasmalogens, but not polyunsaturated PCs, were significantly 
lower in CAD and ACS patients. Considering this and that oxidative modification of the lipid 
component of LDL is thought to promote the formation of vascular plaques, it is plausible that 
a deficiency of PC plasmalogens in LDL particles may contribute to the initial steps of CAD 
pathogenesis. It is also possible that diminished contents of PC plasmalogens in plasmas of 
CAD and ACS patients can be directly or indirectly linked to low plasma levels of HDL-C, 
which is an independent risk factor for CAD 
4
. 
The LC-MS analysis of plasma samples revealed the presence of various S1P species, 
including typical 18:1-S1P and atypical 16:1-S1P, 17:1-S1P and 18:0-S1P. Different S1P 
species have been previously identified in plasma samples of healthy subjects 
27
, however, 
17:1-S1P is reported for the first time in the present study. Variations in the structure of S1Ps 
result from the promiscuous substrate use by serine:palmitoyltransferase (SPT), the enzyme 
responsible for the first step in the de novo synthesis of sphingolipids. Besides the canonical 
substrates L-serine and C16:0-CoA, SPT can metabolize other acyl-CoAs in the range of C12 
to C18 which results in the number of sphingoid bases with variable carbon chain length 
42
. 
The 18:1-S1P represents the most abundant S1P species and was found to be lower in the 
plasma of ACS patients. In addition, 16:1-S1P was diminished in the plasma of CAD and 
ACS patients compared to healthy subjects. Other studies reported reduced S1P levels in the 
plasma and HDL samples of CAD patients 
24, 25
 and a significant inverse relationship between 
18:1-S1P and 18:0-S1P levels in the HDL-containing fraction of serum and the occurrence of 
ischemic heart disease 
26
. However, in contrary to Argraves and colleagues, we did not find 
any association between plasma levels of 18:0-S1P and CAD or ACS. 
Several lipids exhibit biological activity through interaction with various G protein-
coupled receptors. Among them 18:1-S1P is an important regulator of vascular function, 
immune and inflammation responses. HDL is the major carrier of 18:1-S1P in the circulatory 
system. 18:1-S1P in HDL mediates several atheroprotective properties of these lipoproteins 
26
, 
which are attenuated in HDL of CAD patients 
43
. Thus, differences in the plasma composition 
of S1Ps in CAD and ACS patients may contribute to the loss of atheroprotective functions of 
HDL. 
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Our analysis of the sphingoid bases of plasma sphingolipids revealed a reduced 
content of four and six out of eleven identified sphingoid bases in CAD and ACS patients, 
respectively, when compared to healthy subjects. This agrees with the significantly reduced 
plasma levels of SM species in CAD and ACS patients relative to healthy individuals, 
described above. Although sphingoid bases strongly correlate with the total cholesterol and 
LDL-C levels, statin therapy did not show any significant association with the composition of 
sphingoid bases. In agreement with previous studies 
7, 44
, we showed that LDL are the main 
carriers of plasma sphingolipids. This resulted in strong positive correlations between 
sphingoid bases and total cholesterol and LDL-C levels, observed in the present study. 
However, plasma levels of the sphingoid bases doxSA and doxSO, which were found elevated 
in patients with metabolic syndrome and in patients with type 2 diabetes mellitus 
28, 29
, did not 
differ between healthy controls and CAD or ACS patients. 
One limitation of the present study is the relatively small study size (n = 69). Another 
limitation is that the CAD and ACS patients were receiving statins, which may influence 
glycerophospholipid and sphingolipid composition and metabolism, although we did not see 
any statistically significant differences between statin-treated and untreated patients. The main 
strength of this study is the analysis of a wide range of the lipid species. However, larger 
studies are needed to confirm our findings. Prospective studies are needed to unravel any 
prognostic clinical relevance. 
In conclusion, we show that the levels of various glycerophospholipid and 
sphingolipid species are diminished in plasma of CAD and ACS patients relative to healthy 
controls. Among them, PC33:1, PC33:2, PC33:3 and PC35:3 – indirectly identified as PC 
plasmalogens – are the most significantly altered species in plasmas of CAD patients. 
Correlation analysis provides interesting insights into the relationship between odd-chain PCs 
and HDL-C levels. We also report that PC and SM lipids are preferentially localised in HDL 
and LDL particles, while LPCs are mostly present in the LFF. The results of this study should 
be further verified in larger case-control and prospective studies.  
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Abstract 
Objective: Low high-density lipoprotein (HDL) cholesterol and loss of atheroprotective 
functions of HDL are associated with coronary artery disease (CAD). Here, we investigated 
the associations of HDL phospholipids with acute and stable CAD as well as with the anti-
apoptotic activity of HDL. 
Methods: 49 species of phosphatidylcholines (PCs), lysophosphatidylcholines and 
sphingomyelins (SMs) as well as three species of sphingosine-1-phosphate (S1P) were 
quantified by liquid chromatography - mass spectrometry in HDL isolated from 22 healthy 
subjects as well as 23 and 22 patients with stable CAD and acute coronary syndrome (ACS), 
respectively. HDL was tested for its capacity to inhibit apoptosis of endothelial cells (ECs) 
induced by serum deprivation.  
Results: HDL of CAD or ACS patients differed from HDL of healthy controls by the content 
in nine of the 52 quantified phospholipid species as well as reduced anti-apoptotic activity. 
EC apoptosis in the presence of HDL exhibited significant inverse correlations with five of 
eleven odd-chain PC’s (= plasmalogens), two S1P’s, SM42:2, PC34:2, and PC32:0. An 
orthogonal partial least square - discriminant analysis revealed independent associations of 
stable CAD with HDL-associated PC34:2, PC33:3 and PC35:2 as well as anti-apoptotic 
activity of HDL and of ACS with HDL-associated PC33:3, PC35:2, SM42:1, PC34:2 and 
PC36:2.  
Conclusions: Two apriori undefined plasmalogens – PC33:3 and PC35:2 – as well as PC34:2 
– showed the most consistent relationships with the presence of both stable and acute CAD as 
well as the capacity of HDL to inhibit EC apoptosis. 
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3.1. Introduction 
High-density lipoprotein (HDL) particles are believed to play an important role in the 
pathogenesis of coronary artery disease (CAD). Indeed, a low plasma level of HDL 
cholesterol (HDL-C) represents a strong independent risk factor for CAD 
1
. Moreover, HDLs 
isolated from healthy blood donors exert multiple atheroprotective functions that are 
attenuated or lost in HDLs of CAD patients 
2, 3
. Recent proteomic studies related the loss of 
atheroprotective functions to alterations in the protein composition of HDL 
4, 5
 as well as  to 
structural modifications of HDL proteins 
6
. However, not only proteins but also lipids 
contribute to the structural and functional heterogeneity of HDL. 
The HDL lipidome is complex and contains more than 200 different molecular lipid 
species. Among them phospholipids comprise the major part of the HDL lipidome, followed 
by cholesteryl esters, triglycerides and free cholesterol 
7
. Phosphatidylcholines (PCs), 
sphingomyelins (SMs), and free cholesterol are key structural molecules of the surface 
monolayer of HDL particles 
7
. The length and desaturation degree of acyl chains of PC 
species as well as the content of SMs and free cholesterol define the fluidity of the lipid 
monolayer 
8, 9. Through modulation of the fluidity, the surface PCs directly affect HDL’s 
ability to accept cholesterol from peripheral tissues 
8
 as well as phospholipid hydroperoxides 
from low-density lipoproteins (LDLs) 
10
. Moreover, the fatty acid composition of PCs defines 
the capacity of artificially reconstituted HDL (rHDL) to inhibit the expression of 
inflammatory markers in activated endothelial cells (ECs) 
11
. HDL phospholipids also have 
impact on HDL-associated proteins and enzymes. Indeed, a reduced abundance of 
phospholipids on the surface of HDL facilitates CETP-mediated dissociation of lipid-free 
apoA-I from HDL particles 
12
. Furthermore, changes in the molecular composition of PCs in 
rHDL lead to conformational changes of apoA-I and changes in the activity of 
lecithin:cholesterol acyltransferase (LCAT) 
13
. In contrary, enrichment of HDL with SMs 
inhibits the unfolding of apoA-I and cholesterol esterification catalyzed by LCAT 
9, 14
. In 
previous studies, total content of PCs and SMs in HDL was found to correlate with the 
severity of coronary atherosclerosis 
15, 16
.  
In addition to PCs and SMs, of which 10 to 100 molecules are present on each HDL 
particle, HDLs contain low abundant lipids at concentrations which are below particle 
concentration 
2
. For example, plasmalogens constitute a subclass of PCs and 
phosphatidylethanolamines (PEs) 
17
 which scavenge oxygen radicals and thereby inhibit the 
oxidation of cholesterol and polyunsaturated fatty acids in plasma membranes and LDL 
18-20
. 
Other low abundant lipids exert biological activities through direct interaction with G-protein 
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coupled receptors. Among them sphingosine-1-phosphate (S1P) is the best characterised lipid 
agonist carried by HDL. HDL-associated S1P mediates several atheroprotective functions of 
HDL via interaction with at least five different S1P receptors 
21, 22
. Specifically, S1P 
modulates the capacity of HDL to stimulate nitric oxide production, promote EC growth and 
survival, inhibit EC apoptosis and migration of smooth muscle cells 
21-23
. However, S1P is not 
a distinct molecule but in contrast to the general notion differs by the length and desaturation 
degree of its sphingoid base 
24,25
. The heterogeneity in length results from the substrate 
promiscuity of serine:palmitoyltransferase 
26
, the rate limiting enzyme in sphingolipid 
biosynthesis. However, the functional importance of S1P’s structural heterogeneity is as yet 
unknown. 
In this cross-sectional study we used both hypothesis-free and hypothesis driven 
approaches to identify phospholipids which are associated with both CAD and correlate with 
the capacity of HDL to inhibit the apoptosis of ECs. 49 phospholipid species of unknown 
relevance were measured by liquid chromatography – tandem mass spectrometry (LC-
MS/MS). Three species of S1P which is a known mediator of HDL’s anti-apoptotic activity 
and has been previously associated with CAD were quantified by a targeted LC-MS/MS 
method. 
 
3.2. Materials and methods 
3.2.1. Subjects and blood samples 
Patients with coronary artery disease (CAD) or acute coronary syndrome (ACS; ST 
elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction 
(NSTEMI)) were recruited at the University Hospital of Zurich as described previously 
27
. 
The diagnosis of stable CAD or an ACS was made according to the guidelines of the 
American College of Cardiology/American Association task force 
28, 29
. Patients with ACS 
(STEMI or NSTEMI) were recruited into the study within the first 12 h after the onset of the 
symptoms. The following exclusion criteria were considered for both CAD and ACS patients: 
evidence for accompanying infectious, inflammatory or autoimmune disorders, diabetes, 
advanced kidney or liver failure, neoplastic disorders and a history about major surgery or 
trauma within the previous month. Advanced kidney failure was defined as < 60 ml/min of 
glomerular filtration rate (GFR). Age- and sex-matched healthy control individuals were 
enrolled by the Blood Donation Service Zurich and had no cardiovascular risk factors 
(according to history, clinical examination and laboratory tests) or accompanying disorders. 
All subjects gave written informed consent prior to inclusion in the study. This study was 
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approved by the local ethics committee (Kantonale Ethik – Kommission, Zurich, 
Switzerland).  
Venous blood was collected from the antecubital vein into sterile evacuated tubes (BD 
Vacutainer) in the absence of anticoagulants (to obtain serum) or in the presence of EDTA (to 
obtain EDTA-plasma). After blood collection, EDTA plasma was immediately separated by 
centrifugation at 4°C (20 min at 2000 rcf) and aliquoted by 1 ml into cryotubes and stored at -
20°C. Blood in the absence of anticoagulants was kept at room temperature for 30-60 min and 
then centrifuged at 4°C (20 min at 4000 rcf). Serum was then isolated, aliquoted (~1 ml in 
each cryotube) and stored at -20°C. 
 
3.2.2. Isolation of HDL 
HDL was isolated from EDTA-plasma by sequential ultracentrifugation (d=1,063-1,21 
kg/l) using solid potassium bromide (Merck KGaA, Germany) for density adjustment as 
described previously 
30
. For phospholipid analysis, HDL samples were supplemented with 
antioxidant butylhydroxytoluene (BHT) to the final concentration 50 µg/mg of HDL and 
stored at -80°C. HDL for functional studies were isolated from serum samples. These HDL 
samples were stored at 4°C. 
 
3.2.3. Clinical laboratory measurements 
Routine blood testing was performed at the clinical laboratories of the University 
Hospital Zurich. Plasma concentrations or activities of total cholesterol, triglycerides, and 
HDL- cholesterol, glucose, creatinine, creatinine kinase and troponin levels were determined 
by photometric tests or immunoassay by using the Cobas 8000 autoanalyser from Roche 
diagnostics (Rotkreuz, Switzerland). Automated differential blood counts were performed on 
the ADVIA 2120 Hematology System. Cholesterol concentrations in isolated HDL were 
measured by using the Amplex
®
Red Cholesterol Assay Kit (Roche, Switzerland) according to 
the manufacturer’s instructions.  
 
3.2.4. Endothelial cell culture 
Human aortic endothelial cells (ECs) were cultured as described previously 
4
. Briefly, 
ECs were obtained from (LONZA) and cultured in (EBM-2, Lonza) supplemented with 
endothelial growth medium–SingleQuots as indicated by the manufacturer (37°C, 95% air / 
5% CO2). SingleQuots contain human epidermal growth factor (hEGF), hydrocortisone, 
gentamicin and amphotericin-B, fetal bovine serum, vascular endothelial growth factor 
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(VEGF), human fibroblast growth factor-basic (hFGF-B), insulin-like growth factor (R3-IGF-
1), and ascorbic acid. ECs were grown to sub-confluency and rendered quiescent before 
experiments by incubation in medium containing 0.5% FCS. Serum and growth factor 
deprivation was induced by changing the medium to serum-free RPMI. ECs (7500 cells/well 
in 96 well plates) were exposed to serum and growth factor deprivation in the absence or 
presence of 100 µg/ml of HDL (10 µg HDL in 100 µl RPMI medium) for 24 h.  
 
3.2.5. Measurement of endothelial cell apoptosis 
ECs were lysed and apoptotic cell death was measured by the Cell Death Detection 
ELISA
PLUS
 (Roche, Switzerland) according to the supplier’s instructions. This quantitative 
sandwich-enzyme-immunoassay records the amount of mono- and oligonucleosomes 
generated by apoptotic cells. EC apoptosis is expressed as fold increase over the basal level of 
apoptosis without the cell death inducing treatment. 
 
3.2.6. Quantification of phospholipids and S1P  
Phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs) and sphingomyelins 
(SMs) in 12.5 µg of HDL (by protein mass) were quantified by LC-MS essentially as 
described previously 
31
. Briefly, HDL samples were fortified with the internal standards (ISs), 
including phosphatidylglycerol PG(17:0/17:0), lysophosphatidylglycerol LPG(17:1/0:0), 
phosphatidic acid PA(14:0/14:0), lysophosphatidic acid LPA(17:0/0:0), PE(14:0/14:0), 
lysophosphatidylethanolamine LPE(17:1/0:0), PC(14:0/14:0), PC(24:0/24:0), LPC(17:0/0:0), 
SM (d18:1/12:0) and ceramide Cer(d18:1/17:0) obtained from Avanti Polar Lipids (Alabaster, 
AL, USA), and extracted with chloroform/methanol/water (2:2:1, v/v) solvent system. After 
evaporation and reconstitution in 200 µl of mobile phase, samples were injected on the Rheos 
2200/TSQ Access LC-MS system and eluted from a diol silica, 150 x 2.1 mm, 5 µm particle 
size column with solvent system containing hexane/isopropanol/water (70:30:2, v/v) with 15 
mM NH4COOH and isopropanol/water (50:2, v/v) with 15 mM NH4COOH. Phospholipid 
species were detected by using precursor ion and neutral loss scans. A neutral loss scan of m/z 
115 (collision energy, 27 eV) and 189 (17 eV) were used for analysis of PA and PG lipids, 
respectively. A precursor ion scan of m/z 184 (30 eV) was used for screening of PC, SM and 
LPC lipids. A neutral loss scan of m/z 141 (25 eV) was used for PE and a precursor ion scan 
of m/z 264 (30 eV) was applied for screening of Cer and HexCer. The data were collected and 
processed using the Xcalibur and LIMSA software systems. 
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Quantitative analysis was based on calibration curves for seven lipid standards 
including PC(16:0/18:2), SM(d18:1/16:0), LPC(16:0), PE(18:0/18:0), Cer(d18:1/14:0), 
PG(16:0/16:0) and PA(14:0/14:0). The calibration curves were constructed by plotting the 
lipid standard/IS peak area ratios against the nominal concentrations of the standards. The 
concentrations for the identified lipid species were calculated from linear regressions of the 
calibration curves. To estimate the total serum content of HDL-associated lipids, the protein 
normalized amount of lipid species were divided by the protein-normalized amount of 
cholesterol measured in isolated HDL and multiplied with the HDL-C concentration measured 
in serum by the homogenous clinical assay. 
S1P species were quantified in 50 µg of HDL proteins supplemented with 10 pmol of 
18:1-D7S1P which was used as IS. Extracted and derivatized S1P lipids were subjected to 
LC-MS/MS analysis using a previously described method 
32
 with minor modifications. 
Beyond the canonical 18:1-S1P derived from the d18:1 sphingoid base formed by the 
condensation of serine with palmitoyl (C16:0)-CoA catalyzed by serine:palmitoyltransferase, 
we also measured the non-canonical 16:1-S1P and 18:2-S1P species derived from d16:1 and 
d18:2 sphingoid bases. Previously, in the human plasma, d18:2 and d16:1 sphingosines were 
identified as the second and third most abundant sphingoid bases next to the predominant 
d18:1 sphingosine 
24, 33, 34
. S1Ps were analysed on a Rheos 2200/TSQ Access LC-MS system, 
operating in a Selective Reaction Monitoring (SRM) positive ionization mode. The SRM 
transitions monitored were as follows: 18:1-S1P(Ac)2 m/z 446.2/264.2 (30 eV); 16:1-
S1P(Ac)2 m/z 418.2/236.2 (30 eV); 18:2-S1P(Ac)2 m/z 444.2/262.2 (30 eV) and 18:1-
D7S1P(Ac)2 (IS) m/z 453.2/271.2 (27 eV). The tube lens voltage for all SRM transitions was 
set to 130.1 V. Quantitative analysis of 18:1-S1P, 16:1-S1P and 18:2-S1P was based on the 
18:1-S1P calibration curve. This calibration curve was constructed by adding increasing 
amounts of 18:1-S1P to 10 pmol of IS, followed by extraction with ethyl acetate/2-propanol 
(6:1, v/v) and derivatization with acetic anhydride. Linearity of calibration curve and 
correlation coefficient were obtained by linear regression analysis. 
 
3.2.7. Statistical analysis 
Statistical analyses were performed using SPSS version 19 (IBM Corporation, Somers 
NY, USA), Graph-Pad Prism (GraphPad Software, San Diego, CA, USA) and SIMCA-P 
+12.0.1.0 (Umetrics, Ume, Sweden). Normality of the data was determined by using the 
Kolmogorov-Smirnov test. Because many variables did not follow a Gaussian frequency 
distribution, even after log-transformation, the univariate statistics were performed by 
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applying Kruskal-Wallis and Mann-Whitney U tests. Categorical variables were compared 
using the Chi-square test. Spearman rank tests were used to analyze and describe the 
correlation between HDL-associated phospholipids and EC apoptosis. To maintain the rate of 
false-positive results, p values were adjusted for multiple comparisons by applying the 
Benjamini-Hochberg procedure 
35
. The adjusted (adj.) p values of <0.05 were considered as 
statistically significant.  
A multiple regression analysis was used to identify independent variables capable of 
predicting the EC apoptosis. 
Multivariate analyses were performed by using an orthogonal partial least square-
discriminant analysis (OPLS-DA) to identify most discriminating parameters among two 
groups of samples. Data on HDL-associated phospholipids and EC apoptosis were exported to 
SIMCA-P +12.0.1.0. The three groups (Healthy, CAD, ACS) were assigned as classes. 
Models were used to compare only two groups at the time: Healthy vs CAD; Healthy vs ACS; 
CAD vs ACS. The OPLS-DA models were fitted to the classes in order to get the highest Q
2
Y 
(goodness of prediction) and R
2
Y (percent of the model fitting the data) values. The data set 
was normalized to unit variance (UV) and centered on the mean. Model evaluation was 
performed by cross-validation with seven groups as a default. The quality of the model was 
represented by cross-validated Q
2
Y and R
2
Y values. Furthermore, CV-ANOVA was 
calculated to identify significance of the predicted Y-variation. The Hotelling`s T
2
 and 
distance to model, DmodX, were used to identify outliers.  
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3.3. Results 
3.3.1. Characteristics of the study population 
HDL samples were isolated from 23 and 22 patients with stable coronary artery 
disease (CAD) and acute coronary syndrome (ACS), respectively, as well as from 22 healthy 
subjects. Their clinical and biochemical characteristics are shown in Table 1. All CAD 
patients but only 86% of the healthy controls and the ACS patients were male. Furthermore, 
91% of CAD patients but only 41% of ACS patients and no healthy subject received statin 
medication. Patients with CAD were older (adj. p = 0.049; adj. p = 0.019) and had higher 
systolic BP (adj. p = 0.008; adj. p = 0.004) than healthy subjects and ACS patients, 
respectively. Both CAD and ACS patients had higher glucose levels (adj. p =0.022 and adj. p 
= 0.017, respectively) than healthy subjects. The ACS patients had lower HDL-C (adj. p 
<0.001; adj. p = 0.027) than both healthy subjects and CAD patients. Probably as the 
consequence of more prevalent statin treatment, the ACS patients had lower levels of total 
cholesterol (adj. p = 0.022), while CAD patients had lower levels of both total cholesterol 
(adj. p = 0.002) and LDL-C (adj. p = 0.002) as compared to healthy subjects. As expected, 
troponin T levels (adj. p <0.001) and leukocyte counts (adj. p <0.001) were higher in blood 
samples of ACS patients as compared to healthy individuals or CAD patients. 
 
3.3.2. Characteristics of the HDL lipidome 
The LC-MS/MS analysis of HDL-associated phospholipids resulted in the 
quantification of 29 PC species, 4 LPC species and 16 SM species (Table 2). Several PE and 
Cer species were also recovered in HDL, however at levels below the limit of quantification. 
PG and PA lipids were below the level of detection. 
HDL-associated PC lipids comprise species with even or odd numbers of carbon 
atoms in the acyl chains. Structural analysis of the plasma odd-chain PC35:3 using collision-
induced dissociation of [M-CH3]
- 
ions showed similar fragmentation patterns as a 
commercially available plasmalogen standard PC(P-18:0/18:1) (= PC35:2). The structural 
analysis of plasma PC35:3 revealed that this odd-chain PC lipid represents PC-derived 
plasmalogen, PC(P-18:0/18:2). See Chapter 1 for more information on fragmentation pattern 
of PC-derived plasmalogens and even-chain PC species. Thus, HDL-associated odd-chain 
PCs most likely are PC plasmalogens. 
Our second LC-MS/MS method identified three S1P species in HDL which differ by 
length or desaturation of the sphingoid base: 18:1-S1P, corresponding to the canonical S1P, 
16:1-S1P and 18:2-S1P.  
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Table 1. Characteristics of the study population. 
 
Data are expressed as medians (with ranges) and percentages for scale and categorical variables, respectively. Statistical significance of the 
categorical variables was evaluated by Chi-square test. The p values marked by asterisk indicate that results of Chi-square test may be invalid, 
because more than 20% of the expected frequencies have a value less than 5. Since some of the continuous variables were not normally distributed, 
statistical significance was determined by the Kruskal-Wallis test applied for multiple group comparisons and by the Mann-Whitney U test applied 
for two group comparisons. The p values were adjusted for multiple testing by using the Benjamini-Hochberg procedure. Significant p values are 
marked in bold font. ACE-I indicates angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; BMI, body mass index; CAD, 
coronary artery disease; H, healthy subjects; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. 
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3.3.3. Associations of HDL phospholipids with CAD  
We compared the protein normalized content of phospholipid species in HDL isolated 
from healthy subjects with those in HDL isolated from CAD or ACS patients. The entire data 
set is shown in the Table 2. After adjustment for multiple testing, levels of HDL-associated 
PC34:2 (adj. p = 0.022), PC34:3 (adj. p = 0.033), PC33:3 (adj. p = 0.033) and PC35:2 (adj. p 
= 0.033) were found significantly lower in CAD patients as compared to healthy subjects. In 
contrary, PC38:4 (adj. p = 0.018) was more abundant in HDL of CAD patients than in HDL 
of healthy controls. The levels of HDL-associated PC33:3 (adj. p = 0.008), PC35:2 (adj. p = 
0.018), PC35:3 (adj. p = 0.04), PC35:5 (adj. p = 0.018) and SM42:1 (adj. p = 0.018) were 
significantly lower in ACS patients than in healthy individuals. However, their HDL content 
did not differ between CAD and ACS patients (Table 2). Cholesterol per protein levels were 
lower in HDL of ACS patient than in HDL of healthy subjects (adj. p = 0.033). We did not 
find any statistically significant differences in the HDL content of individual S1P species or 
total S1P although by trend, the 18:1-S1P and 16:1-S1P content in HDL of CAD and ACS 
patients was lower than in HDL of healthy controls (Table 2). 
To estimate the serum levels of HDL-associated lipids, the protein-normalized amount 
of lipid species were divided by the protein-normalized amount of cholesterol measured in 
isolated HDL and multiplied with the HDL-C concentration measured in serum by the 
homogenous clinical assay. Only serum levels of HDL-associated PC33:3 (adj. p = 0.013) 
were significantly lower in ACS patients compared to healthy controls (Table 3). 
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Table 2. Phospholipid composition of HDL from healthy subjects, CAD and ACS patients. 
(Continued) 
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Data are medians (and ranges). Of note, all PC lipids identified as odd-chain PC species probably represent PC plasmalogens. Statistical 
significance was determined by using the Kruskal-Wallis test for multiple group comparisons and the Mann-Whitney U test for two group 
comparisons. The p values were adjusted for multiple testing by using the Benjamini-Hochberg procedure. Significant p values are marked in bold 
font. PC and LPC species are named according to the summarized numbers of carbons and double bounds in acyl chains. Names of SM species 
reflect summarized numbers of carbons and double bounds in sphingoid base and N-linked fatty acid. ACS stands for acute coronary syndrome; 
CAD, coronary artery disease; Chol. in HDL, cholesterol in isolated HDL; H, healthy subjects; LPC, lysophosphatidylcholine; PC, 
phosphatidylcholine; SM, sphingomyelin; 16:1-S1P, sphingosine-1-phosphate with 16:1 sphingoid base; 18:1-S1P, sphingosine-1-phosphate with 
18:1 sphingoid base; 18:2-S1P, sphingosine-1-phosphate with 18:2 sphingoid base.  
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Table 3. Estimated serum concentrations of HDL-associated phospholipids in healthy subjects, CAD and ACS patients. 
(Continued) 
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Data represent medians (with ranges). To estimate the serum levels of HDL-associated lipids, the protein-normalized amount of lipid species were 
divided by the protein-normalized amount of cholesterol measured in isolated HDL and multiplied with the HDL-C concentration measured in 
serum by the homogenous clinical assay. Of note, all PC lipids identified as odd-chain PC species probably represent PC plasmalogens. Statistical 
significance was determined by using the Kruskal-Wallis test for multiple group comparisons and the Mann-Whitney U test for two group 
comparisons. The p values were adjusted for multiple testing by using the Benjamini-Hochberg procedure. Significant p values are marked in bold 
font. ACS stands for acute coronary syndrome; CAD, coronary artery disease; H, healthy subjects; LPC, lysophosphatidylcholine; PC, 
phosphatidylcholine; SM, sphingomyelin; 16:1-S1P, sphingosine-1-phosphate with 16:1 sphingoid base; 18:1-S1P, sphingosine-1-phosphate with 
18:1 sphingoid base; 18:2-S1P, sphingosine-1-phosphate with 18:2 sphingoid base. 
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3.3.4. Associations of anti-apoptotic activity of HDL with CAD and HDL lipids 
The anti-apoptotic activity of HDL was evaluated by measuring the apoptosis of ECs 
in the presence of HDL, while cell death was induced by serum and growth factor deprivation. 
Consistent with previous data 
4
, HDL from CAD patients was less effective in inhibiting EC 
apoptosis ( p = 0.0005) as compared to HDL from healthy subjects (Fig. 1). However, HDL 
from ACS patients and healthy individuals did not differ by their anti-apoptotic activities (Fig. 
1). 
We revealed negative correlations of EC apoptosis in the presence of HDL with 
several lipid components of HDL: SM42:2 (Spearman coefficient r = -0.49, adj. p = 0.019), 
PC33:3 (r = -0.45; adj. p = 0.029), 18:1-S1P (r = -0.43; adj. p = 0.035), and PC34:2 (r = -0.42; 
adj. p = 0.035), PC33:1 (r = -0.397; adj. p = 0.036), PC35:1 (r = -0.39; adj. p = 0.036), PC35:2 
(r = -0.39; adj. p = 0.036), PC37:6 (r = -0.39; adj. p = 0.036) as well as PC32:0 (r = -0.38; adj. 
p = 0.036) and 18:2-S1P (r = -0.38; adj. p = 0.036) (Table 4). Upon multiple regression 
analysis entering into the model seven lipids with the strongest association with EC apoptosis, 
i.e. SM42:2, PC33:3, 18:1-S1P, PC34:2, PC33:1, PC35:1 and PC35:2, none of them evolved 
as an independent determinant of HDL’s anti-apoptotic activity (adjusted R square = 0.22; F = 
2.97; p = 0.013). The contribution of each lipid species to the model is shown in the Table 5. 
 
Figure 1. Association of CAD status with endothelial cell apoptosis in the presence of 
HDL. 
Data show the impact of 100 µg/ml HDL from 16 healthy subjects, 16 CAD patients and 17 
ACS patients on endothelial cell (EC) apoptosis. EC apoptosis was induced by serum and 
growth factor deprivation and determined by measuring nucleosomes in the lysate of ECs. 
Presented are fold increases over the basal level of apoptosis without cell death induction. 
Solid lines indicate median values. Since data were not normally distributed, p values were 
calculated by using the Mann-Whitney U test. ACS indicates acute coronary syndrome; CAD, 
coronary artery disease.  
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Table 4. Spearman correlations of endothelial cell apoptosis in the presence of HDL with 
HDL-associated phospholipids. 
 
 
 
Adj. p values display Benjamini-Hochberg corrected p values. Bold font indicates p <0.05. 
16:1-S1P represents sphingosine-1-phosphate with 16:1 sphingoid base; 18:1-S1P, 
sphingosine-1-phosphate with 18:1 sphingoid base; 18:2-S1P, sphingosine-1-phosphate with 
18:2 sphingoid base, LPC, lysophosphatidylcholine; PC, phosphatidylcholine; SM, 
sphingomyelin. 
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Table 5. Multiple regression analysis of HDL-associated phospholipids and endothelial 
cell apoptosis in the presence of HDL.  
 
 
Determinant 
variables 
Dependent variable, 
EC apoptosis 
Standardized 
coefficients, Beta 
p values 
PC33:3 -0.223 0.291 
PC34:2 0.051 0.813 
SM42:2 -0.207 0.265 
PC33:1 -0.255 0.193 
PC35:1 -0.246 0.125 
PC35:2 0.175 0.395 
18:1-S1P -0.013 0.955 
 
Seven phospholipids showing the strongest correlation with EC apoptosis in the presence of 
HDL (see Table 4) were entered into the model. 
 
3.3.5. An orthogonal partial least square - discriminant analysis (OPLS-DA)  
Due to the highly correlative nature of lipid data, an orthogonal partial least square - 
discriminant analysis (OPLS-DA) was applied to identify parameters that associate with 
stable or acute CAD. The data matrix contained values of 53 individual lipid species of HDL 
including HDL cholesterol as well as EC apoptosis in the presence of HDL. Fig. 2 shows the 
results of the OPLS-DA. After reducing the dimensions of the data to the principle 
components, OPLS-DA models Healthy vs CAD and Healthy vs ACS showed good fit (R2Y) 
and predictive power (Q2Y) (Table 6). In contrary, the OPLS-DA analysis of the CAD vs 
ACS samples led to an insignificant model (Table 6). 
The score plot of the Healthy vs CAD model (Fig. 2A) showed complete separation of 
the healthy and CAD samples localized in the right and left part of the ellipse, respectively. 
The variable importance for the projection (VIP) plot shows the contribution of each variable 
to the model. Only variables with coefficient value VIP and confidence intervals not crossing 
1 are considered as significant contributors to the model. According to the VIP plot of the 
Healthy vs CAD model (Fig. 2B), EC apoptosis, PC34:2, PC33:3 and PC35:2 contribute 
significantly to the CAD state model. 
The score plot of the Healthy vs ACD model (Fig. 2C) revealed clustering into 
separate groups of the healthy and ACS samples with a minor overlap at the middle of ellipse. 
The VIP plot (Fig. 2E) showed that PC33:3, PC35:2, SM42:1, PC34:2 and PC36:2 made 
significant contributions to the ACS state model. 
In summary, the OPLS-DA analysis highlighted that some HDL phospholipid species 
as well as the anti-apoptotic activity of HDL associate with stable CAD and/or ACS 
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independently of other lipid parameters. PC33:3, PC34:2 and PC35:2 were the only variables 
which discriminated HDL of healthy subjects from both patients with stable CAD and patients 
with ACS. 
 
Figure 2. An orthogonal partial least square-discriminant analysis on HDL lipids and the 
anti-apoptotic capacity of HDL from healthy subjects, CAD and ACS patients.  
Figures 2A and 2C display score plots of Healthy vs CAD and Healthy vs ACS models, 
respectively. Individual observations are shown as: blue squares, healthy subjects; red dots, 
CAD or ACS patients. The data matrix contained values of 53 individual lipid species of HDL, 
total cholesterol in HDL and EC apoptosis in the presence of HDL. Variations on the x-axis 
reflect between-group separation, while variations on the y-axis reflect within-group variation. 
Figures 2B and 2D show variable importance of the projection (VIP) plots of Healthy vs CAD 
and Healthy vs ACS models, respectively. VIP plot indicates which variables are important in 
explaining both the X- and Y-data. Error bars show 95% confidence intervals (CIs) for the 
calculated VIP coefficients. Variables with VIP values exceeding 1.0 are important 
contributors to the model, whereas contribution of the variables with their 95% CI exceeding 
1.0 should be interpreted with caution. Variable cut off is shown as dash line in the VIP plot. 
Only first twenty variables are shown in the VIP plot. Important discriminative variables are 
depicted in red. ACS indicates acute coronary syndrome; CAD, coronary artery disease; S1P, 
sphingosine-1-phosphate; EC apoptosis, endothelial cell apoptosis in the presence of HDL; 
Chol. in HDL, cholesterol determined in isolated HDL; LPC, lysophosphatidylcholine; PC, 
phosphatidylcholine; SM, sphingomyelin. 
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Table 6. Evaluation of the orthogonal partial least square-discriminate analysis (OPLS-
DA) models. 
 
 
Model R2X R2Y Q2Y 
CV-
ANOVA 
F values 
CV-
ANOVA 
p values 
Healthy vs CAD 0.59 0.916 0.62 5.2 0.0001 
Healthy vs ACS 0.4 0.683 0.417 6.9 0.0002 
CAD vs ACS 0.45 0.653 0.178 1.29 0.2857 
 
OPLS-DA models were fitted for the classes to get the highest R
2
Y and Q
2
Y values. R
2
X, 
R
2
Y and Q
2
Y represent amount of explained X-variation, Y-variation and predicted Y-
variation. Cross validation is evaluated using CV-ANOVA p value, which represents 
significance of the predicted Y-variation for the given F value. ACS indicates acute coronary 
syndrome; CAD, coronary artery disease. 
 
3.4. Discussion 
Despite the inverse association of HDL-C levels and cardiovascular risk and despite 
many anti-atherogenic functions of HDL, it has been proven difficult to successfully reduce 
risk of CAD with drugs increasing HDL-C such as fibrates, niacin, or inhibitors of cholesteryl 
ester transfer protein. Because of these controversial data, the pathogenic role and, thus, 
suitability of HDL as a therapeutic target has been increasingly questioned. However, HDLs 
form a very heterogeneous class of lipoproteins which differ by protein and lipid composition 
and, hence, functionality which is not recovered by the measurement of the routine clinical 
parameter “HDL-cholesterol” (= HDL-C) 2. In fact, HDL isolated from plasmas of patients 
with CAD and other inflammatory diseases were found to have diminished atheroprotective 
properties in several bioassays. As yet, the search for the underlying disturbed structure-
function-relationships was focused on compositional and structural modifications of HDL-
associated proteins. The contribution of alterations in the lipidome of HDL to physiological 
function and pathological dysfunction of HDL as well as disease association has only started 
to be explored. In this cross-sectional case-control study we used a combination of a 
hypothesis-free lipidomics approach and a hypothesis-driven candidate approach to 
investigate the triangular relationship of HDL-associated phospholipids, anti-apoptotic 
capacity of HDL (i.e. EC apoptosis in the presence of HDL) and presence of acute or stable 
CAD. Two apriori undefined plasmalogens – PC33:3 and PC35:2 – as well as PC34:2 – 
showed the most consistent relationships with both CAD and the capacity of HDL to inhibit 
apoptosis of ECs. Furthermore, two SMs – SM42:1 and SM42:2 – showed significant 
associations with ACS and EC apoptosis, respectively. By contrast, S1P which was pre-
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defined as a candidate because of its well established anti-apoptotic activity, did not show any 
association with CAD phenotype although it correlated with the anti-apoptotic activity of 
HDL as much as the plasmalogens and SM42:2. 
PC33:3 and PC35:2 were equally decreased by 50% and 30%, respectively, in HDL of 
patients with either acute ACS or chronic CAD and remained significantly associated with 
ACS and CAD upon multivariate OPLS-DA analysis. The statistical significance and 
independence, the more strongly decreased concentrations of plasmalogens relative to total 
PC, and the lack of difference between HDL of acute and stable CAD patients indicate that 
the deprivation of HDL in plasmalogens is a specific feature of HDL from CAD patients. Our 
observation is in line with those of other researchers: two studies found that HDL of patients 
with low HDL-C contain significantly less PC- and/or PE-derived plasmalogens when 
compared to HDL of patients with high HDL-C 
37, 38
. The content of PE plasmalogens was 
also found to be lower in acute-phase HDL than in non-inflammatory HDL 
39
. Furthermore, 
different species of PE- or PC-plasmalogens were found at reduced serum or plasma 
concentrations in hypertensive 
40
, obese 
41
, stable and unstable CAD patients 
42
. 
Interestingly both PC33:3 and PC35:2 also showed significant positive correlations 
with the ability of HDL to prevent apoptosis of ECs.  As yet a direct anti-apoptotic effect of 
extracellular plasmalogens has only been demonstrated for the neuronal cell line Neuro-2A 
43
. 
Moreover, disturbed formation of plasmalogens in cells with peroxisomal dysfunction was 
found to be associated with increased apoptosis 
44
. Thus, the significant correlations between 
specific plasmalogens and the anti-apoptotic activity of HDL may point to a direct causal 
relationship. For example, plasmalogens are known to scavenge oxygen radicals with their 
vinyl-ether bound of alkenyl chain 
17
 and to reduce the oxidation of cholesterol by free 
radicals 
18
 and to delay the oxidative degradation of polyunsaturated fatty acids 
20
 and LDL 
19
. 
If exerted on plasma membranes, HDL-associated plasmalogens may exhibit direct 
cytoprotective effects. If happening within HDL, plasmalogens may prevent the formation of 
pro-apoptotic agonists or help to maintain the anti-apoptotic properties of other HDL-
associated anti-apoptotic agonists. The demonstration of any direct anti-apoptotic or other 
anti-atherogenic activities of plasmalogens will raise the question of whether also the inverse 
association between plasmalogen content of HDL and CAD reflects a causal relationship. 
However, low plasmalogen levels may also be the result of enhanced oxidative degradation 
caused by reactive oxygen species and increased oxidative stress in CAD and ACS patients. 
Of note myeloperoxidase which is present in plasma and atheroma of CAD patients at 
increased concentration and generates dysfunctional HDL by multiple protein modifications 
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45, 46
 was previously demonstrated to generate α-chlorofatty aldehydes from plasmalogens 47. 
Thus, the decreased concentration of plasmalogens in HDL of CAD patients may reflect 
enhanced plasmalogen degradation by myeloperoxidase or other oxidative processes. This 
process may generate pro-apoptotic derivatives of plasmalogens such as α-chlorofatty 
aldehydes or acids which counteract the anti-apoptotic activity of HDL. Alternatively the 
myeloperoxidase mediated modification of plasmalogens is only an innocent bystander and 
reporter of other causative protein and lipid modifications exerted by myeloperoxidase in 
HDL.  
Like two plasmalogens and unlike all other even-chain PC species or total PC, PC34:2 
showed significant and independent associations with both CAD and ACS. Furthermore, 
PC34:2 significantly correlated with the anti-apoptotic activity of HDL . With a proportion of 
about 25% PC34:2 constitutes the majority of HDL-associated PC’s as compared to only 1% 
constituted by PC33:3 and PC35:2. Also other studies found PC34:2 to be the quantitatively 
predominant PC species of lipoproteins including HDL
48
. Yetukuri and colleagues showed 
that HDL-associated PC34:2 comprises only one molecular species, namely PC(16:0/18:2) 
38
. 
Interestingly, PC(16:0/18:2) but not other PCs present in HDL was found to mimic the 
inhibitory effect of HDL on the Th1 function of mature dendritic cells 
49
. Artificially 
reconstituted HDL (rHDL) containing apoA-I and PC(16:0/18:2) were found more effective 
than rHDL containing saturated or mono-unsaturated PCs in inhibiting endothelial expression 
of VCAM1 or inhibiting NADPH oxidase activation in neutrophils 
11, 50, 51
. Moreover, in the 
presence of cholesteryl ester transfer protein (CETP), rHDL containing PC(16:0/18:2) but not 
rHDL containing PC(16:0/18:1) released prebeta1-HDL, an important stimulator of 
cholesterol efflux 
52
. A recent lipidomic analysis of HDL by NMR spectroscopy revealed low 
contents of total PC in HDL as independently associated with CAD in a case-control study 
53
. 
As discussed for plasmalogens before, the associations of PC34:2 with CAD as well as the 
correlation with EC apoptosis do not allow any conclusion on causality: the reduced HDL 
content in CAD patients in combination with the significant  correlation with the anti-
apoptotic activity of HDL may directly reflect anti-atherogenic effects of PC34:2. However, it 
may also be an indirect reporter of oxidative and enzymatic activities which affect the 
functionality of HDL beyond the modification of the specific PCs and may even exert pro-
atherogenic effects independently of HDL 
10, 54
.  
The SM42:1 showed a strong and independent association with ACS. Its average 
concentration in HDL was 35% lower in ACS patients than in healthy controls. Of note, 
neither total SM nor any other SM species showed any association with CAD. As yet only 
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data on associations of CAD with total SM levels in HDL have been reported. Two cross-
sectional studies quantified total SM in HDL by the use of either NMR spectroscopy or an 
enzymatic test found inverse associations between HDL content of SM and the presence and 
extent of CAD 
53, 55
. Since only the association of SM42:1 with ACS was statistically 
significant and independent and because SM42:1 did not show any significant correlation 
with the anti-apoptotic activity of HDL, the decreased SM42:1 levels may be the result rather 
than the cause of CAD. In fact, Pruzanski and colleagues previously reported that acute phase 
depletes HDL of some SM species, specifically SM33:1 and SM38:1 
39
. Although less 
prominent, also SM42:1 was present at reduced concentrations in acute-phase HDL 
39
. 
Several cytoprotective functions of HDL including inhibition of EC apoptosis have 
been assigned to S1P which signals to a variety of cells upon interaction with at least five 
different G-protein coupled S1P receptors 
21, 22
. At least one half of S1P in plasma is 
transported by HDL 
22, 56, 57
. We therefore complemented the general phospholipid profiling 
approach by targeted quantification of S1P to test whether the anti-apoptotic activity of HDL-
associated S1P is reflected by significant correlations and associations with the anti-apoptotic 
activity of HDL and the presence of CAD, respectively. Rather than total S1P we quantified 
S1P species which differ by the chain length and desaturation of the sphingoid bases 
24
. As yet 
little appreciated structural variety of the S1P chain length (and sphingolipids in general) 
results from the promiscuous substrate use of serine:palmitoyltransferase (SPT) 
26
. This 
enzyme catalyses the first step in sphingolipid synthesis and uses acyl-CoAs beyond its 
canonical substrate palmitoyl (C16:0)-CoA. In fact, in our hands only 70% of HDL associated 
S1P corresponds to 18:1-S1P, which is the canonical metabolite. About 20% and 10% of 
HDL-associated S1P are the non-canonical 16:1-S1P and 18:2-S1P, respectively. Whereas 
16:1-S1P is formed on a sphingoid base that results from the SPT-mediated condensation of 
serine with myristoyl (C14:0)-CoA
26
, 18:2-S1P is probably formed on a sphingadiene (d18:2) 
backbone with a second double bond at presumably delta position 
58, 59
. Interestingly, only 
18:1-S1P and 18:2-S1P but not 16:1-S1P correlated significantly with the anti-apoptotic 
activity of HDL indicating that the carbon chain length affects the biological activity of S1P 
species. By contrast to the plasmalogens, this correlation is not translated into significant 
association of S1P species with the presence of stable CAD or ACS. At first sight this lack of 
association is in contrast to the findings of two previous studies which reported that S1P 
levels of HDL are associated with the presence, extent, or incidence of CAD 
60-62
. However, 
Sattler and colleagues recovered S1P of plasma from healthy individuals almost completely in 
HDL 
61, 62 
which is in sharp contrast to the observations of several other labs which found 
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about 30% and 10% of plasma S1P associated with albumin and apoB containing 
lipoproteins, respectively 
22, 56, 57
. Furthermore, measurements of S1P in these studies were 
performed by HPLC coupled with fluorescence detection which does not discriminate the 
different S1P species. In addition, the nested case-control study of Argraves and colleagues 
measured S1P after precipitation of apoB containing lipoproteins and hence did not separate 
HDL- and albumin-associated S1P 
60
. These differences in magnitude of concentration and 
methodology interfere with any interpretation of reasons for the different findings in our and 
the other studies.  
In conclusion, our cross-sectional case-control study unravelled significant 
associations and correlations of specific phospholipid species with the presence of acute or 
stable CAD and the capacity of HDL to inhibit apoptosis. The plasmalogens PC33:3 and 
PC35:2 as well as PC34:2 showed consistent associations and correlations with clinical 
presentation of CAD as well as anti-apoptotic activity of HDL. This makes them interesting 
candidates for both clinical validation in larger studies and functional characterization in vitro, 
to assess their importance as biomarkers for CAD risk prediction and determinants of HDL 
functionality, respectively. 
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Abstract 
Sphingosine-1-phosphate (S1P) mediates several cytoprotective functions of HDL. 
ApoM acts as a specific S1P binding protein in HDL. Erythrocytes are the major source of 
S1P in plasma. After glomerular filtration, apoM is endocytosed in the proximal renal tubules. 
Human and murine HDL elicited time- and dose-dependent S1P efflux from erythrocytes. 
Compared with HDL of wild-type (wt) mice, S1P efflux was enhanced in the presence of 
HDL from apoM transgenic mice, but not diminished  in the presence of HDL from apoM 
knockout (Apom
-/-
) mice. Artificially reconstituted and apoM-free HDL also effectively 
induced S1P efflux from erythrocytes. S1P and apoM were not measurable in the urine of wt 
mice. Apom
-/-
 mice excreted significant amounts of S1P. ApoM was detected in the urine of 
mice with defective tubular endocytosis because of knockout of the LDL receptor-related 
protein, chloride-proton exchanger ClC-5 (Clcn5
-/-
), or the cystine transporter cystinosin. 
Urinary levels of S1P were significantly elevated in Clcn5
-/-
 mice. In contrast to Apom
-/-
 mice, 
these mice showed normal plasma concentrations for apoM and S1P. In conclusion, HDL 
facilitates S1P efflux from erythrocytes by both apoM-dependent and apoM-independent 
mechanisms. Moreover, apoM facilitates tubular reabsorption of S1P from the urine, however, 
with no impact on S1P plasma concentrations.  
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Abbreviations: 
Apom
-/-
 apoM knockout mice 
Apom
tg
 Mice transgenic for apoM 
IS Internal standard 
LRP2 LDL receptor-related protein 2 
rHDL Reconstituted HDL 
S1P Sphingosine-1-phosphate 
S1P(Ac)2 Acetylated S1P 
TBS-T TBS Tween 
wt Wild-type 
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4.1. Introduction 
Sphingosine-1-phosphate (S1P) acts both as an intracellular signaling molecule and an 
extracellular agonist of at least five different G protein-coupled receptors. By its dual 
functions, S1P regulates the survival, proliferation, and migration as well as the functionality 
of many cells, eventually in opposite directions 
1-4
. Therefore the absolute and relative 
abundance of S1P in intracellular and extracellular compartments appears to be important for 
its biological functionality
4
.  
Most cells form S1P by the phosphorylation of sphingosine, a degradation product of 
ceramides, through sphingosine kinase and degrade S1P to phosphoethanolamine and fatty 
aldehyde through S1P-lyase 
1-4
. By contrast, not only erythrocytes and platelets, but also other 
cells which have low or no lyase activity, release S1P 
4-6
, probably by an as yet unidentified 
ABC transporter 
4, 7, 8
. Within the plasma compartment, the majority of S1P is transported by 
HDLs in which it exerts many cytoprotective and anti-inflammatory effects, for example, on 
endothelial cells 
8-10
. The enrichment of S1P in HDL has been explained by the presence of a 
specific S1P binding protein, namely apoM 
10
. Purified and recombinant apoM binds S1P 
with an IC50 of 0.9 µmol/l, which is in the range of physiological S1P plasma concentrations 
11
. X-ray crystallography of apoM identified an S1P binding domain which was confirmed by 
the recombinant generation of non-S1P binding apoM mutants 
11
. In agreement with these 
physicochemical data, S1P was copurified with apoM containing HDL, but not apoM-free 
HDL, from both human and murine plasma. Moreover, S1P concentrations were dramatically 
decreased in HDL of the apoM knockout (Apom
-/-
), but increased in HDL of mice transgenic 
for apoM (Apom
tg
). As an in vitro indication of functional relevance, the stimulatory effects of 
S1P on nitric oxide production by endothelial cells were mimicked by apoM-containing HDL, 
but not by apoM-free HDL. Finally, the physiological relevance of S1P binding by apoM was 
indicated by the reduced basal endothelial barrier function in lungs of Apom
-/-
 mice 
12
. Despite 
this very strong in vitro and in vivo evidence for the limiting effect of apoM on the transport 
and function of S1P in plasma and HDL, concentrations of S1P and apoM in either plasma or 
HDL do not correlate with each other 
12, 13
. Moreover, stoichiometric calculations revealed 
that apoM is not saturated with S1P but present at an up to 8-f molar excess 
12, 13
. We 
therefore investigated the impact of apoM on two other potential pathways of S1P 
metabolism, namely efflux from erythrocytes and urinary excretion.  
Plasma concentrations of S1P were recently shown to correlate with red blood cell 
counts 
5, 6, 14
, probably because the lack of the S1P-degrading lyase makes erythrocytes the 
main source of S1P in plasma 
4, 5
. Because HDL was previously found to induce S1P efflux 
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from erythrocytes 
5
, we compared the S1P efflux capacity of HDL from wild-type (wt), Apom
-
/-
, and Apom
tg
 mice 
15
.  
After glomerular filtration, apoM is reabsorbed from the primary urine into proximal 
tubular epithelial cells by binding to the endocytic receptor megalin [LDL receptor-related 
protein 2 (LRP2)]. Accordingly, mice with a conditional renal knockout of megalin excrete 
apoM in urine 
16
. Megalin and its coreceptor cubilin also mediate the tubular reabsorption of 
several small plasma proteins which carry small molecules and are filtrated through the 
glomeruli 
17, 18
. Not only megalin  and cubilin, but also endosomal and lysosomal proteins 
such as chloride-proton exchanger ClC-5 (mutated in Dent’s disease) and the cystine 
transporter cystinosin (mutated in cystinosis), respectively, are key components of the 
machinery that rescues essential molecules such as vitamin B12 and vitamin D from 
inappropriate urinary loss 
17, 19, 20
. To test whether this is also of relevance for the metabolism 
of S1P, we compared the urinary excretion of S1P and apoM in wt and Apom
-/-
 mice 
15
 as well 
as mice with dysfunctional megalin (Lrp2
-/-
) 
21
, ClC-5 (Clcn5
-/-
) 
22
, or cystinosin (Ctns
-/-
) 
23
. 
 
4.2. Methods 
4.2.1. Plasma and urine collection from mice 
Mice with knockout of apoM (Apom
-/-
) 
34 
as well as mice with defective expression of 
megalin (Lrp2
-/-
) 
21
, ClC-5 (Clcn5
-/-
) 
22
, or cystinosin (Ctns
-/-
) 
23
 were previously described. 
Mice with transgenic overexpression of murine apoM (Apom
tg
) have not been published yet, 
but the generation of these animals is briefly described in Fig. 1. Blood samples were obtained 
by cardiac puncture immediately after euthanization. Plasma was prepared by 15 min of 
centrifugation of blood at 2,000 g. Urine samples were collected in metabolic cages for 8 h 
(Clcn5
-/- 
, Ctns
-/-
, and their littermate controls), 16 h (Lrp2
-/-
 and their littermate controls), or 
24 h (Apom
-/-
, Apom
tg
, and their littermate controls) according to standard protocols. Each 
drop of urine was immediately cooled down to -20°C in the collector of the metabolic cages. 
All plasma and urine samples were kept frozen at -80°C before further use or analysis. The 
age of the mice, at which samples were obtained, is reported in the Results section. All animal 
procedures were approved by the appropriate National Research Council Guide for the Care 
and Use of Laboratory Animals/Animal Ethics Committee. 
 
4.2.2. Generation of transgenic TTR-apoM mice 
The murine apoM cDNA was cloned downstream of the liver-specific transthyretin 
(TTR) promoter within a modified TTR expression plasmid described earlier 
35
 (Fig. 1). 
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Transgenic lines were generated following pronuclear microinjection in fertilized mouse eggs 
(C57B1/6). The genotype was determined by Southern blotting and PCR using the Southern 
probe and PCR primers indicated in Fig. 1. The Southern probe was amplified by PCR 
spanning exon 2 of TTR and the apoM cDNA (≈50bp each). PCR primers spanning exon 1 
and 2 of apoM were used to distinguish wt litter from apoM transgenic animals. 
 
Figure 1. Schematic overview of cloning strategy used to generate Apom
tg
 mice. 
Murine apoM cDNA was inserted into a modified transthyretin (TTR) expression plasmid 
described earlier 
35
 downstream of the TTR promoter. Position of the Southern probe and 
PCR primers used for genotyping transgenic animals are indicated. 
 
4.2.3. Isolation and reconstitution of HDL  
Human HDL was isolated from plasma of healthy blood donors (Kantosspital 
Schaffhausen, Switzerland) or mouse plasma by stepwise ultracentrifugation (d = 1.063-1.21 
kg/l) at 360,000 g for 15 h at 15°C, as described previously 
24
, using solid potassium bromide 
(Sigma Aldrich, Buchs, Switzerland) for density adjustment. ApoA-I was further purified 
from delipidated HDL as described previously 
24
. Discoidal reconstituted HDL (rHDL) 
particles were produced by the cholate dialysis method and contained apoA-I, POPC (Sigma), 
and sodium cholate (Sigma) in a molar ratio of 1/100/100 
24
. 
 
4.2.4. S1P efflux from erythrocytes  
Erythrocytes were isolated from the blood of healthy adult volunteers. The blood was 
anticoagulated with sodium citrate and then centrifuged at 2,000 g for 5 min at 4°C. After 
removing the plasma, the sedimented erythrocytes were washed three times with sterile PBS 
and resuspended 1:1 in PBS (v/v) containing either BSA, human or murine HDL, rHDL, or 
lipid-free apoA-I at the concentrations indicated in the Results section and incubated at 37°C. 
Aliquots were removed at different time points (as indicated in the Results section) and 
immediately centrifuged at 2,000 g for 3 min at 4°C to sediment erythrocytes. The 
supernatants were carefully transferred into new tubes avoiding any contamination with 
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erythrocytes. For S1P measurement, 25 µl aliquots of the supernatant were taken and 
processed as described below. 
 
4.2.5. Quantification of S1P in plasma, HDL, and urine 
S1P was quantified by LC-MS/MS after derivatization with acetic anhydride. The S1P 
concentrations in plasma or erythrocyte supernatants (25µl), HDL (50 µg), and urine (500µl) 
were analyzed after adding 10 pmol internal standard (D7S1P, Avanti Polar Lipids, Alabaster, 
AL, USA). For calibration, S1P (Avanti Polar Lipids) was dissolved in DMSO/concentrated-
HCl (100:2, v/v) at a concentration of 0.28 mmol/l stock solution. Each series of 
measurements was calibrated with 1, 2.5, 5, 10, 15, 20, and 25 pmol of S1P supplemented 
with 10 pmol of D7S1P as the internal standard (IS). Quality control samples with 7.5 and 
22.5 pmol S1P were evaluated at the beginning and at the end of each sample series. Double 
blank and blank samples for carry-over control were prepared by adding methanol and 
internal standard, respectively, to 25 l of water and processed as plasma samples. 
Lipids were extracted with 1 ml of an organic solution consisting of ethyl acetate/2-
propanol (6:1, v/v) and 50µl of concentrated formic acid added for phase separation 
25
. The 
upper organic phase was separated and evaporated to dryness under a stream of nitrogen. For 
the derivatisation of the primary amino and the secondary alcohol groups of S1P 
26
, the dried 
lipids were dissolved in 100µl of pyridine and 50µl of acetic anhydride and incubated at 40°C 
for 20 min. After evaporating the acetylation reagents, the reaction products were dissolved in 
100µl of methanol and transferred to glass vials prior to LC-MS/MS analysis.  
Acetylated S1P [S1P (Ac)2] was analyzed on an LC-MS system consisting of an HTC 
PAL autosampler (CTC Analytics, Zwingen, Switzerland), a Rheos 2200 HPLC pump (Flux 
Instruments, Reinach, Switzerland), and a TSQ Quantum Access mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA, USA). Chromatographic conditions for reverse-phase 
separation of S1P(Ac)2 were modified from Berdyshev et al. 
26
. Separation of S1P(Ac)2 was 
done on a Nucleosil C18 HD column (125 x 2 mm, 100 Å, 5 m) at 40C. Mobile phase A 
consisted of water/methanol/formic acid (20:80:0.5, v/v) and mobile phase B consisted of 
methanol/acetonitrile/formic acid (59:40:0.5, v/v), both containing 5mM ammonium formate. 
Elution started with 100% A for 1.0 min (0.25 ml/min) and increased to 100% B within 4.0 
min and was then kept constant for 4 min. Finally the column was reequilibrated with 100% 
mobile phase A for 5.5 min.  The injection volume was 10 L. The injection system and 
syringe were washed twice with methanol/acetone/2-propanol (1:1:1, v/v), containing 
HCOOH 0.1% and acetone/methanol/water (2:2:1, v/v) solutions after every injection. 
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S1P(Ac)2 and D7S1P(Ac)2 eluted at tr ~6.3 min. Double blank and blank samples were 
analysed before each set of calibrators and samples to exclude carry-over. 
For ionization, ESI was used and detection was performed in the positive mode, 
monitoring [M-H2O]
+
 ions using selective reaction monitoring (SRM) for the transitions of 
m/z 446.2  264.2 (30V) for S1P(Ac)2 and m/z 453.2  271.2 (27 V) for D7S1P(Ac)2 (spray 
voltage 5000 V, skimmer offset 10 V and ion transfer capillary temperature 300C). Further 
ionization and detection parameters were optimized by tuning the system with S1P(Ac)2 
standard. Data analysis was performed on XCalibur 2.0.6 (Thermo Scientific). 
The standard curve was constructed by plotting the S1P/D7S1P peak area ratios against 
the concentrations of the S1P standards. The S1P concentration in samples was determined by 
linear regression obtained from the standard curve. The lower level of quantification was 
defined as the 10% functional assay sensitivity and amounted to 1 pmol extracted S1P 
corresponding to 40 nmol/l plasma or 2 nmol/l urine. At amounts of 7.5 pmol and 22.5 pmol, 
the intra-day imprecision was 5.8% and 2.3%, respectively, and the inter-day imprecision was 
4.3% and 8.1%, respectively.  
 
4.2.6. Western blotting of apoM in plasma and urine  
Proteins were separated on 14% SDS polyacrylamide gels and transferred onto 
nitrocellulose membrane. The membranes were blocked with 5% milk in 0.1% TBS Tween 
(TBS-T) buffer for 1 h at room temperature. Thereafter, the membranes were incubated 
overnight at 4°C with a commercially available apoM antibody (LC-C51665; LifeSpam 
BioSciences). The 1:1,000 dilution of antibody was made in 5% milk TBS-T. The membranes 
were then washed three times with TBS-T and incubated with secondary antibody anti-rabbit 
coupled with HRP (1:10,000). After washing three times for 10 minutes, the membrane was 
developed with ECL Plus Western blotting detection reagent (Pierce) according to the 
manufacturer’s instructions.  
 
4.2.7. Statistical analyses 
Statistical analyses were performed by using Graph-Pad. Normality of the data was 
determined by using the Kolmogorov-Smirnov test. Normally distributed data were analyzed 
by the two-tailed unpaired Student`s t-test, and data that was not normally distributed were 
analysed by the Mann-Whitney U test. Differences in prevalences were analysed by chi-
square test. 
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4.3. Results 
4.3.1. HDL and apoM promote S1P efflux from erythrocytes  
To confirm previous data that HDL induces S1P efflux from erythrocytes 
5
, 1 ml of 
washed human erythrocytes were incubated with two different concentrations of human HDL 
for increasing time. Figures 2A and 2B show the time-dependent accumulation of S1P in 
human HDL without and with correction for the endogenous S1P content, respectively. 
Maximal efflux, which doubled the concentration of S1P preexisting in HDL, was reached 
after 4 h. Half-maximal efflux was reached after 1-2 h of incubation. Albumin (500 µg/ml), 
which is the second most important carrier of S1P in plasma 
4, 10
, elicited very little S1P efflux 
under the same conditions.  
Next we monitored the time-dependent S1P efflux from erythrocytes in the presence 
of 300 µg/ml HDLs which were isolated from plasma of wt, Apom
-/-
, or Apom
tg
 mice in 
comparison with 300 µg/ml albumin. As reported previously, HDLs of these three mouse 
strains differ by endogenous S1P content (see also baseline data in Fig. 2C). Therefore, we 
present S1P efflux before and after correction for the endogenous S1P content of HDLs (Fig. 
2C and 2D). During 8 h of incubation, S1P concentrations increased steadily in the HDL of all 
three mouse strains. S1P efflux capacity of HDL from wt mice resembled that of human HDL. 
The maximal net S1P efflux measured was significantly increased in the presence of HDL 
from Apom
tg
 mice, but not decreased in the presence of HDL from Apom
-/-
 mice (Fig. 2D). 
Also of note, S1P efflux in the presence of HDL from both wt and Apom
-/-
 mice reached 
saturation after 2-4 h, whereas S1P efflux in the presence of HDL from Apom
tg
 mice did not 
reach saturation within 8 h, the maximal time the experiment could be performed without 
hemolysis.  
To provide further evidence that HDL can elicit S1P efflux independently of apoM, 
we compared the capacity of native HDL, rHDL, lipid-free apoA-I, and albumin to induce 
S1P efflux. Whereas lipid-free apoA-I was not capable of inducing S1P efflux, reconstituted 
apoM-free HDLs were even more active in stimulating S1P efflux than native HDLs at 
concentration of 200 µg/ml (Fig. 3). 
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Figure 2. Time-dependent efflux of S1P from washed human erythrocytes in the presence of 500 µg/ml BSA (Figures 2A-2D), 
250 or 500 µg/ml human HDL (Figures 2A, 2B), or 300 µg/ml HDL from wt, Apom
-/-
, or Apom
tg
 mice (Figures 2C, 2D).  
Figures 2A, 2C: Absolute S1P amounts in 1 ml of supernatant after incubation of HDL or albumin with erythrocytes for the 
indicated time intervals and subsequent removal of erythrocytes by centrifugation. Figures 2B, 2D: Data on net S1P efflux which 
were obtained by subtracting the S1P concentrations of the various HDL preparations at baseline from the S1P concentrations at the 
indicated time points. Values are mean ± SD. Statistically significant differences between HDL of Apom
-/-
 and wt mice, as well as 
between HDL of Apom
tg
 and wt mice, are indicated by asterisks. (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; Student´s t-test). 
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Figure 3. Net S1P efflux from washed human erythrocytes in the presence of native and 
rHDL, lipid-free apoA-I, or BSA.  
Presented are net amounts of S1P released by erythrocytes in 1 ml of supernatant after 4 h 
incubation with 20 µg/ml or 200 µg/ml HDL isolated either from human plasma or 
artificially reconstituted by cholate dialysis of apoA-I and POPC (rHDL), 20 µg/ml lipid-free 
apoA-I, or 200 µg/ml BSA. Values are mean ± SD. 
 
4.3.2. Urinary excretion of S1P is increased in Apom
-/-
 mice, as well as in mice with 
dysfunctional tubular protein reabsorption  
As reported previously 
12, 13
 and as compared to their wt littermates, S1P levels in 
plasma and HDL were significantly decreased by 20 and 50%, respectively, in 12-14-week-
old Apom
-/-
 mice, and were significantly increased by factors three and five, respectively, in 
plasma and HDL of age-matched Apom
tg
 mice (Fig. 4A and 4B) . 
In 21 urine samples of wt mice, we measured S1P at very low concentration below or 
close to the lower level of quantification of our method (10% functional assay sensitivity: 1 
pmol S1P corresponding to 2 nmol S1P per liter urine). In fact, only 5 of 21 samples of wt 
mice, but 4 of 5 samples Apom
-/-
 mice, had S1P levels above this threshold (p = 0.018, chi-
square test). In the direct comparison, urine concentrations of S1P were significantly higher in 
6- and 16-week-old Apom
-/-
 mice than in 6- and 16-week-old wt controls (p < 0.05, Fig. 4C).  
Next, we investigated whether disturbances of tubular apoM reabsorption are 
associated with increased urinary S1P excretion. By Western blotting, we found apoM present 
in the urine samples of mice with nonfunctional megalin (Lrp2
-/-
), ClC-5 (Clcn5
-/-
), or 
cystinosin (Ctns
-/-
) (Fig. 5A). ApoM was not detectable in the urine of wt littermates.  
In the urine samples of 21 wt mice from three different laboratories, S1P was below or 
close to the level of quantification (2 nmol/l). By contrast, three of four urine samples from 
11-week-old Lrp2
-/-
 mice and six of seven samples from 12-16-week-old Clcn5
-/-
 mice 
contained clearly quantifiable concentrations of S1P (Fig. 6A and 6B). Upon direct 
comparison of mutant mice and littermate controls, S1P excretion was significantly increased 
 104 
in Clcn5
-/-
 mice (Fig. 6B), which are known to suffer from a severe dysfunction of the 
proximal tubule 
27
. At ages of 18 weeks, 20-24 weeks, or 30-38 weeks, neither male nor 
female Ctns
-/-
 mice showed increased S1P excretion. 
Western blotting did not provide any evidence for grossly altered concentrations of 
apoM in the plasma of Lrp2
-/-
, Clcn5
-/-
, or Ctns
-/-
 mice (Fig. 5B). These three mouse models 
with tubular apoM proteinuria also did not show any statistically significant or consistent 
differences in plasma concentrations of S1P (Fig. 6D-6F). 
 
 
Figure 4. ApoM determines S1P 
concentration in plasma (Figure 4A), HDL 
(Figure 4B), and urine (Figure 4C) of wt, 
Apom
-/-
, and Apom
tg
 mice.  
Figures 4A, 4B: S1P levels in plasma and HDL 
samples from 12-14-week-old wt, Apom
-/-
, and 
Apom
tg
 mice. Figure 4C: Urinary S1P excretion 
by 6- and 16-week-old Apom
-/-
 mice and their wt 
littermates. Each point identifies data from 
individual mice. Solid lines indicate median 
values. The dashed line indicates the lower level 
of quantification of S1P by LC-MS in urine 
samples. (* p ≤0.05, ** p ≤0.01, *** p ≤0.001; 
Mann-Whitney U test).  
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Figure 5. Western blotting of apoM in urine (Figure 5A) and plasma (Figure 5B) of 
Apom
-/-
, Apom
tg
 mice and mice with defective megalin (Lrp2
-/-
), ClC-5 (Clcn5
-/-
), and 
cystinosin (Ctns
-/-
) and their wt controls. 
Urine (20 µl) or 11.5 µl of 1/10 diluted plasma were separated by SDS-PAGE and 
immunoblotted as described in the Methods section. Note the absence of apoM from urine 
samples of wt mice, but the presence in urine samples of mice with defective tubular transport 
(Figure 5A). By contrast apoM plasma levels appear indistinguishable between wt mice and 
the different tubular proteinuria models (Figure 5B). 
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Figure 6. Concentrations of S1P in urine (Figures 6A-6C) or plasma (Figures 6D-6F) of 
mice with defective megalin (Lrp2
-/-
) (Figures 6A, 6D), ClC-5 (Clcn5
-/-
) (Figures 6B, 6E), 
or cystinosin (Ctns
-/-
) (Figures 6C, 6F) as compared with their wt controls. 
Each point represents data from an individual mouse sample. Figures 6A, 6D: Urine and 
plasma levels of S1P in 11-week-old Lrp2
-/-
 mice (open symbols). Figures 6B, 6E: Urine and 
plasma levels of S1P in 12-16-week-old Clcn5
-/-
 mice (open symbols). Figures 6C, 6F: Urine 
and plasma S1P levels in 18-week-old Ctns
-/-
 mice (open symbols), in 20-24-week-old Ctns
-/-
 
mice (closed symbols), and in 30-38-week-old Ctns
-/-
 mice (crossed symbols). Dashed lines 
indicate the lower level of quantification of S1P by LC-MS in urine samples. (** p ≤0.01; 
Mann-Whitney U test). Note the higher medians of S1P excretion in mice with defective 
tubular protein reabsorption as compared with wt controls. 
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4.4. Discussion 
Previous work by the laboratories of Dahlbäck and colleagues and Nielssen and 
colleagues 
11, 12
 identified apoM as a physiologically relevant binding protein of S1P in HDLs 
of plasma. Our lab previously confirmed the limiting effect of apoM on S1P levels in plasma, 
but also found indications for more complex relationships between HDL, apoM, and S1P 
13
. 
Most notably, concentrations of apoM and S1P in total or apoB-depleted plasma did not 
correlate with each other 
13
, possibly due to the molar excess of apoM compared to its ligand 
S1P, which varies inter-individually between factors 1.2 and 8 and/or in the presence of 
alternative ligands, which compete with S1P for binding to apoM 
10, 13
. However, we also 
observed statistically significant correlations of S1P concentrations with concentrations of 
HDL-cholesterol, apoA-I and other measures of HDLs 
13
. This raised the questions whether 
HDLs can handle S1P also independently of apoM and whether apoM may influence S1P 
plasma levels independently of its transport function in plasma.  
To answer the first question, we investigated the capacity of HDLs to induce S1P 
efflux from erythrocytes. HDLs of both humans and wt mice were found to induce time-
dependent and saturable S1P efflux leading to maximal doubling of the endogenous S1P 
concentration in normal human or murine HDLs (400 pmol/l/l S1P per mg HDL protein). 
Assuming that 80% of HDL protein mass corresponds to apoA-I, i.e. the predominant protein 
of HDLs which has a molecular mass of 28 kDa, the molar concentration of S1P per apoA-I 
amounts to 1/72. Assuming that the HDL particles contain an average of three molecules of 
apoA-I 
28, 29
, every 24th HDL particle in our experiments contained one molecule of S1P at 
baseline. The doubling of S1P content by efflux indicates the saturation of S1P efflux much 
below the HDL particle concentration. This can be explained by the presence of a specific 
S1P binding site in HDLs which is not saturated in HDLs isolated from plasma, such as apoM 
10-12
. At first sight and in agreement with this explanation, we found the net S1P efflux 
capacity of HDLs from Apom
tg
 mice significantly increased without reaching saturation. By 
contrast, HDLs from both wt and Apom
-/-
 mice elicited time-dependent and saturable S1P 
efflux from erythrocytes, which did not differ from each other and that was markedly greater 
than in the presence of albumin. Moreover, rHDL consisting only of apoA-I and POPC 
induced S1P efflux from erythrocytes. The apparent 2- to 3-fold higher efficacy of rHDL, as 
compared with native HDL, probably reflects the higher particle concentration at identical 
protein mass concentrations, because rHDL contains two molecules of apoA-I, whereas native 
HDL contains at least three molecules of apoA-I plus other proteins. Our finding of rHDL-
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induced S1P efflux does also explain the previous observation that, initially, S1P-free rHDLs 
exert cytoprotective effects on cardiomyocytes in a S1P receptor-dependent fashion.
30
  
Taken together, our findings indicate the presence of an additional apoM-independent 
mechanism by which HDLs can induce efflux and/or mediate the binding of S1P. Because of 
the saturation much below the concentration of HDL particles or phospholipids, it is unlikely 
that this apoM-independent fraction of HDL-induced S1P efflux is unspecific, for example, as 
the result of association with phospholipids. The nonsaturation of S1P efflux in the presence 
of HDLs from Apom
tg
 mice indicates that apoM, rather than phosphatidylcholine, acts as the 
slow determinant of S1P binding capacity. The saturable S1P efflux in the presence of HDLs 
from Apom
-/-
 mice points to the presence of an as yet unknown relatively fast inducer of S1P 
efflux. Because rHDL contains only apoA-I in addition to phospholipids, apoA-I is the prime 
candidate for this activity. In this respect, it is noteworthy that ABCA1 and ABCG1, and 
scavenger receptor B1, which are important cellular interaction partners for apoA-I or HDL-
induced efflux of cholesterol or phosphatidylcholine, have been suspected to promote or 
modulate cellular S1P efflux as well 
4, 8
. In fact, glyburide, a pharmacological inhibitor of 
ABC transporters including ABCA1, was previously found to inhibit S1P efflux from red 
blood cells. However, although present in erythrocytes, functional experiments excluded 
ABCA1 and ABCA7 as the mediators of S1P efflux from these cells 
7
. In agreement with the 
lack of involvement of ABCA1, we did not find any S1P efflux induced by lipid-free apoA-I, 
which, as the primary interaction partner of ABCA1, stimulates efflux of cholesterol and 
phosphatidylcholine from many cells. The roles of ABCG1 and scavenger receptor BI, which 
typically interact with  both native and artificially lipidated HDL 
29
, for S1P efflux, are as yet 
unknown.  
To address the second question, whether apoM may regulate S1P plasma 
concentrations beyond transport in plasma, we compared the urinary excretion of S1P of wt 
and Apom
-/-
 mice. Not unexpectedly, the urine of wt mice did not contain much S1P. 
However, quantifiable amounts of S1P were excreted with the urine by Apom
-/-
 mice. These 
data indicated that apoM plays some role for preventing urinary S1P excretion, but does not 
indicate whether the excreted S1P is of plasmatic or renal origin. On the one hand and next to 
hepatocytes, the epithelial cells lining the proximal tubules of the kidney are the only cells 
which express apoM 
31
. Hence, kidney-derived apoM may play an important role in handling 
S1P, for example for the interaction with S1P receptors. In fact, S1P and S1P receptors were 
reported to convey protection of the proximal tubule epithelium against oxidative stress 
induced by ischemia/ reperfusion injury 
32
. On the other hand, the plasma-derived 22 kDa 
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large murine apoM or 26 kDa large human apoM is ultrafiltrated through glomeruli and 
reabsorbed from the primary urine by the endocytic receptor megalin into the proximal tubule 
epithelial cells 
16
, so that the lack of apoM could interfere with the tubular recovery of S1P. 
To discriminate between these two explanations, we investigated the urinary excretion of 
apoM and S1P by mice which lack megalin, the chloride-proton exchanger ClC-5, or the 
lysosomal cystine transporter cystinosin, which all play important roles for the tubular 
reabsorption of carrier proteins and their cargo from the primary urine 
17, 19, 20
. We confirmed 
the previously observed urinary apoM excretion by megalin knockout mice 
16
. In addition, 
mice without ClC-5 or cystinosin showed a urinary loss of apoM. Like Apom
-/-
 mice, Lrp2
-/-
 
and Clcn5
-/-
 mice showed clearly increased urinary S1P excretion. This difference in urinary 
S1P excretion was much less prominent, if not absent, in Ctns
-/-
 mice. This may reflect the 
fact that the cystinosis model develops tubular dysfunction later in life 
33
. In our hands, even 
at the age of 30-38 weeks when tubular dysfunction is manifested, we did not see any increase 
in S1P excretion, although apoM was excreted with the urine. Nevertheless, the unusual 
urinary excretion of S1P in the urine of Apom
-/-
, Lrp2
-/-
, and Clcn5
-/-
 mice suggests that 
tubular reabsorption of apoM interferes with the urinary loss of S1P. However, in Lrp2
-/-
 and 
Clcn5
-/-
 mice, the urinary loss of apoM and S1P appears to be too low to substantially 
decrease the plasma concentrations of apoM and S1P. Therefore, it is also unlikely that the 
urinary loss contributes to the lower plasma and HDL-S1P levels observed in Apom
-/- 
mice 
12, 
13
. However, cubilin deficiency was previously reported to increase the turnover and decrease 
plasma albumin and apoA-I concentrations slightly, but significantly 
18
. Quantitative studies 
in larger numbers of mice may hence unravel subtle differences. 
In conclusion, our studies of mice differing by the expression of apoM or the activity 
of proteins involved in the tubular endocytosis of apoM indicate that binding of S1P by apoM 
plays at least two further roles in S1P metabolism beyond mediating S1P transport in HDL. 
First, HDL facilitates S1P efflux from erythrocytes by both apoM-dependent and apoM-
independent mechanisms. Second, apoM facilitates the reabsorption of S1P from the primary 
urine into tubular epithelial cells, however, with no impact on S1P plasma concentration. By 
the two newly identified activities, apoM may modulate the paracrine and autocrine 
interactions of S1P with vascular endothelial and renal tubular epithelial cells, respectively. In 
addition, we provide evidence for an additional HDL-associated factor which contributes to 
S1P efflux and transport by HDLs.  
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Abstract 
Purpose: Biochemical and genetic analyses established a contribution of lipid metabolism to 
age-related macular degeneration (AMD) pathology. Paraoxonase 1 (PON1) is an 
antioxidative protein involved in high density lipoprotein (HDL) function and was found to be 
associated with AMD. Here, we used Pon1
–/–
 mice to study the influence of PON1 on retinal 
physiology and to reveal the potential impact of PON1 on AMD aetiology.  
Methods: Laser capture microdissection served to isolate single retinal layers. Retinal 
function was assessed by ERG. Retinal and RPE morphology were monitored by fundus 
imaging, fluorescein angiography, light and transmission electron microscopy, and 
immunofluorescence microscopy. Levels of mRNA and composition of phospholipid species 
were determined by real-time PCR and LC-MS, respectively.  
Results: Adult (8 weeks old) Pon1
–/–
 mice displayed normal retinal function and morphology, 
but their retinas contained reduced amounts of lysophosphatidylcholines (LPCs) compared to 
controls. Aged (12 months old) Pon1
–/–
 animals did not show any morphologic or molecular 
signs of photoreceptor or RPE degeneration, or of accelerated aging. Photoreceptors of Pon1
–
/–
 and control mice were similarly susceptible to light damage.  
Conclusions: Results indicate that PON1 is not essential for normal development, function, 
ageing, and the defense against light damage of the mouse retina. Reduced levels of LPCs in 
eyes of Pon1
–/–
 mice may reflect a decreased activity of phospholipase A2 or altered 
antioxidative activity in aged eyes.  
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5.1. Introduction 
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness 
and visual disability in the elderly population of industrialized countries. Various 
environmental risk factors, such as advanced age, cigarette smoking, diet, obesity, 
atherosclerosis, hypertension, inflammatory disease, as well as genetic predisposition have 
been implicated in this complex disease
1-3
. The epidemiological risk factors point toward 
various molecular mechanisms that might be involved in the aetiology of AMD. Among 
those, cellular and extracellular oxidative stress, along with chronic inflammation are best-
known to have a role in disease development and/or progression
4-6
.  
Aging, the strongest risk factor for AMD, is associated with structural and functional 
changes in Bruch`s membrane and the retinal-pigment epithelium (RPE). Drusen, a hallmark 
of AMD
7, are formed between RPE and Bruch’s membrane, and contain polymorphous 
material. Major components of this material are lipid aggregates containing numerous 
lipoproteins and cholesterol
8, 9
. These results established a connection between lipid 
metabolism and AMD aetiology, which was confirmed further by genetic studies. Genome-
wide association scans identified several genes contributing to HDL metabolism to be 
associated with AMD, among them hepatic lipase (LIPC), cholesterylester transfer protein 
(CETP), lipoprotein lipase (LPL), and ATP-binding cassette, sub-family A1 (ABCA1) 
10, 11
. 
We and others also have found an association of paraoxonase 1 (PON1), a gene involved in 
HDL function, with advanced AMD in single populations
12-14
. 
Together with PON2 and PON3, PON1 forms a family of lactonases with antioxidant 
properties, which differ in sites of synthesis and mechanisms of action
15
. The PON1 gene is 
mainly expressed in liver
16
 and encodes a secreted enzyme with a broad spectrum of functions 
that favor the involvement of PON1 in AMD pathology. In particular, PON1 present in serum 
HDL inhibits low-density lipoprotein (LDL) oxidation, or “neutralizes” oxidized LDL by 
hydrolyzing lipid peroxides
17, 18
. Additionally, PON1 acts in an anti-inflammatory manner by 
reducing monocyte chemotaxis and adhesion to endothelial cells
19
, inhibiting monocyte-to-
macrophage differentiation
20
, and directly suppressing macrophage proinflammatory 
responses
21
. The antioxidant as well as the anti-inflammatory activities of PON1 suppress the 
formation of atherosclerotic plaques, pathologic lesions that share several properties with 
drusen
22, 23
. Whereas PON2 is an ubiquitous intracellular protein that can protect endoplasmic 
reticulum and mitochondria against reactive oxygen species (ROS)-mediated damage
24, 25
, 
PON3 acts similarly to PON1, as it is transported by HDL and protects HDL from 
oxidation
26
. 
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The genetic studies mentioned above, biochemical analyses reporting lower serum 
paraoxonase activity in patients with AMD
27
, and reports showing that smoking reduces 
PON1 activity in serum
28, 29
 are indications for a potential involvement of PON1 in the 
pathophysiology of AMD. Nevertheless, the role of PON1 in the eye has not been studied to 
our knowledge. We used Pon1
–/–
 mice to investigate the role of PON1 in the retina / RPE to 
elucidate its potential contribution to retinal lesions and eye pathology. 
 
5.2. Materials and methods 
5.2.1. Mice 
Animals were treated in accordance with the regulations of the Veterinary Authority of 
Zurich and with the statement of `The Association for Research in Vision and 
Ophthalmology` for the use of animals in research. Wild type (WT) 129S6/SvEvTac mice 
were purchased from Taconics (Eiby, Denmark). Pon1
–/–
 mice (B6.129X1-Pon1
tm1Lus
/J)
30
 
were purchased from Jackson Laboratory (Bar Harbor, ME, USA), and genotyped by PCR 
using the following primers: common forward primer 5`-CTT GTC CAT CCT CAG CTT 
GT-3`, WT reverse primer 5`-CCG ATG GTT CTT GTA AAG TGC-3`, mutant reverse 
primer 5`-CTT GGG TGG AGA GGC TAT TC-3`. Pon1
–/–
 mice were backcrossed for 10 
generations onto the 129S6/SvEvTac background prior to analyses. All mice were kept at the 
animal facility of the University Hospital Zurich in a dark-light cycle (12 h: 12 h) with 60 lux 
of light at cage level and a normal chow diet. 
 
5.2.2. Light exposure 
Six- to 8-week-old mice were dark adapted overnight (16 h). Pupils were dilated with 
1% cyclogyl (Alcon, Cham, Switzerland) and 5% phenylephrine (Ciba Vision, Niederwangen, 
Switzerland) 30 minutes before exposure to 17,000 lux of white light for 2 hours. After light 
exposure mice were kept in darkness until the next day before being returned to cyclic light. 
Mice were killed at different time points after light offset (N=3 for each group) and retinas, 
eyecups, or whole eyeballs were removed. Mice that were dark-adapted but not exposed to 
light served as controls. 
 
5.2.3. Laser capture microdissection 
Eyes of 8-week-old WT and Pon1
–/–
 mice were enucleated, immediately embedded in 
tissue freezing medium (Leica Microsystems Nussloch GmbH, Nussloch, Germany), and 
frozen in a 2-methylbutane bath cooled in liquid nitrogen. Retinal sections (20 µm) were 
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collected on Arcturus PEN Membrane Glass Slides (Applied Biosystems, Foster City, CA, 
USA), fixed (5 min acetone), air dried (5 min), and dehydrated (30 sec 100% ethanol, 5 min 
xylol). Retinal layers were isolated using an Arcturus XT Laser Capture Microdissection 
system (Bucher Biotec AG, Basel, Switzerland) and Arcturus CapSure Macro LCM Caps 
(Applied Biosystems). RNA was isolated using the Arcturus PicoPure RNA Isolation Kit 
(Applied Biosystems) according to the manufacturer’s directions, including a DNase 
treatment to remove residual genomic DNA. cDNA was synthesized using random hexamer 
primers (High-Capacity cDNA Reverse Transcription Kit; Applied Biosystems), and further 
analyzed by real-time PCR as described in section `RNA preparation and semi-quantitative 
real-time PCR`. 
 
5.2.4. Electroretinogram (ERG)  
Electroretinograms were recorded from both eyes simultaneously following published 
protocols
31, 32
. Briefly, mice were dark-adapted overnight and anesthetized the next day with 
ketamine (66.7 mg/kg; Ratiopharm GmbH, Ulm, Germany) and xylazine (11.7 mg/kg; Bayer 
HealthCare, Monheim, Germany). Pupils were dilated with 1% cyclogyl and 5% 
phenylephrine 30 min before performing single flash ERG recordings under dark-adapted 
(scotopic) and light adapted (photopic) conditions. Light adaptation was accomplished with 
low background illumination starting 5 min before photopic recordings. Single white-flash 
stimulus intensities ranged from –3.7 to 1.9 log cd*s/m2 under scotopic and from –0.6 to 2.9 
log cd*s/m
2
 under photopic conditions, divided into 12 and 8 steps, respectively. Ten 
responses per flash intensity were averaged with an interstimulus interval of either 4.95 sec or 
16.95 sec (for 1.4, 1.9, 2.4, and 2.9 log cd*s/m
2
). 
 
5.2.5. Fundus imaging and fluorescein angiography 
Pupils were dilated with 1% cyclogyl and 5% phenylephrine. After 30 min mice were 
anesthetized with ketamine (66.7 mg/kg) and xylazine (11.7 mg/kg) and corneas were 
moistened with 2% methocel (OmniVision, Puchheim, Germany). Fundi were monitored and 
photographed using a mouse imaging system (Micron III, Phoenix Research Laboratories, 
Pleasanton, CA, USA). Fluorescein solution (2% in PBS; AK-FLUOR; Lake Forest, IL, 
USA) was injected intraperitoneally and eyes were analyzed immediately.  
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5.2.6. Light and transmission electron microscopy  
Eyes were enucleated and fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer 
(pH 7.3) at 4˚C overnight. Cornea and lens were removed and eyecups cut dorso-ventrally 
through the optic nerve head. Trimmed tissue was washed in cacodylate buffer, incubated in 
osmium tetroxide for 1 hour at room temperature, dehydrated, and embedded in Epon 812. 
For light microscopy (Axioplan 2, Zeiss, Feldbach, Switzerland) semi-thin cross sections (500 
nm) were cut and counterstained with toluidine blue. For transmission electron microscopy 
(TEM), ultra-thin sections (50 nm) were stained with uranyl acetate and lead citrate, and 
analyzed using a Philips CM100 transmission electron microscope. 
 
5.2.7. RPE flat mount preparation and analysis 
Unless stated otherwise, all procedures were conducted at room temperature. Eyes 
were enucleated and incubated in 2% paraformaldehyde (PFA) in 0.1 M phosphate buffer pH 
7.4 (PB, 0.081M Na2HPO4, 0.019M NaH2PO4×H2O) for 5 min. Cornea and lens were 
removed and the remaining tissue was left in PB-salt (PB containing 140 mM NaCl and 2.7 
mM KCl) for 20 min to allow the retina to separate from the eyecup. The retina was gently 
removed and the eyecup containing the RPE cut into a “clover-leaf” shape and post-fixed in 
4% PFA in PB for 1 hour. Flatmounts were blocked with blocking solution (3% normal goat 
serum, 0.3% Triton X-100 in PBS) for 1 hour and incubated with the primary antibody anti-β-
catenin (1:300 in blocking solution; BD Biosciences, Allschwil, Switzerland) overnight at 
4°C. After washing 3 x 10 min in PBS, Cy3-conjugated anti-mouse secondary antibody 
(1:200 in blocking solution; Jackson ImmunoResearch, Suffolk, UK) and Alexa Fluor 488-
phalloidin (1.3 U/ml in blocking solution; Applied Biosystems) were applied for 2 hours. 
After washing, cell nuclei were stained with Hoechst (2 µg/ml in PBS; Sigma Aldrich, Buchs, 
Switzerland) for 30 min. Flatmounts were washed with PBS and mounted with anti-fade 
medium (10% Mowiol 4–88 (w/v); Calbiochem, San Diego, CA, USA; 25% glycerol (w/v); 
0.1% 1,4-diazabicyclo[2.2.2]octane in 100 mM Tris, pH 8.5). RPE sheets were examined 
using a digitalized fluorescence microscope and an ApoTome module (Axioplan 2, Zeiss, 
Switzerland).  
Morphometric measurements including eccentricity and form factor were performed 
with CellProfiler software
33
. Phalloidin-stained images (magnification: 20x) were 
illumination corrected and analyzed using the `Tissue Neighbours` pipeline with the 
background adaptive thresholding method. At least N=700 RPE cells per group were 
examined. RPE cells were counted in 4 quadrants of 176.8 x 235.3 µm (1040 x 1384 pixels), 
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approximately 800-900 µm temporal, dorsal, nasal and ventral of the optic nerve head. Three 
animals per genotype and condition were analyzed. 
 
5.2.8. RNA preparation and semi-quantitative real-time PCR 
Retinas were removed through a slit in the cornea and placed in an Eppendorf tube. 
The rest of the eye (eyecup without lens) was isolated separately. All samples were 
immediately frozen in liquid nitrogen and stored at -80°C. Total RNA from retina and 
eyecups was prepared using the High Pure RNA Isolation Kit (Roche Diagnostics, 
Mannheim, Germany) or the RNeasy kit (Qiagen, Hilden, Germany), respectively. RNA 
isolations included a DNase treatment to digest residual genomic DNA. Equal amounts of 
RNA were reverse transcribed using oligo(dT) primer and M-MLV reverse transcriptase 
(Promega, Madison, WI, USA). Real-time PCR with specific primer pairs (Table 1), a 
polymerase ready mix (LightCycler 480 SYBR Green I Master Mix; Roche Diagnostics, 
Basel, Switzerland), and a thermocycler (LightCycler, Roche Diagnostics) were used to study 
gene expression. Three animals per time point were analyzed in duplicates. Signals were 
normalized to β-actin and relative gene expression was calculated using the ∆∆Ct method. 
Table 1. Primers and conditions for real-time PCR 
 
 
5.2.9. Lipid extraction 
For most analyses, lipids were extracted from retinal and eyecup tissue together. We 
will refer to these samples as “retina/eyecup” samples from here on. In some instances retinas 
and eyecups were isolated separately and named accordingly. Isolated tissue samples were 
immediately frozen in liquid nitrogen and stored at -80°C. Retina/eyecup samples were 
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homogenized in lysis buffer (PBS, 0.2% Triton X-100 [v/v]) using a Precellys 24 tissue 
homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). The protein content 
was measured using the Bradford assay. Total lipids were extracted from aliquots of 
homogenized tissue containing 40 µg of protein. Extraction was conducted according to the 
procedure of Bligh and Dyer
34
 in the presence of 200 ng of the internal standards 
PG(17:0/17:0), LPG(17:1/0:0), PA(14:0/14:0), LPA(17:0/0:0), PE(14:0/14:0), LPE(17:1/0:0), 
PC(14:0/14:0), PC(24:0/24:0), LPC(17:0/0:0), SM (d18:1/12:0) and Cer(d18:1/17:0) (Avanti 
Polar Lipids, Alabaster, AL, USA). Samples were mixed with 375 µl of methanol/chloroform 
(2:1, v/v) and vortexed, followed by the addition of 100 µl water and 125 µl chloroform. The 
mixture was shaken for 15 minutes and centrifuged at 16,100×g for 5 minutes at 25°C. The 
lower phase was collected, 250 µl chloroform added, shaken for 15 minutes, and centrifuged 
at 16,100×g for 5 minutes at 25°C. All lower phases were combined and evaporated to 
dryness under a stream of nitrogen. Dried material was reconstituted in 200 µl of a mixture of 
mobile phases A (80%) and B (20%, see below). 10 µl was injected into the liquid 
chromatography-mass spectrometry (LC-MS) system for phospholipid analysis. 
 
5.2.10. Analysis of the retina/eyecup lipidome: LC-MS instrumentation and chromato-
graphic conditions  
Analyses of six different lipid classes: phosphatidylcholines (PC), sphingomyelins 
(SM), phosphatidylethanolamines (PE), phosphatidylglycerols (PG), phosphatidic acids (PA) 
and ceramides/hexosylceramides (Cer/HexCer) were performed by using LC-MS. Briefly, 
total lipid extracts were analyzed on a LC-MS system consisting of a Rheos 2200 pump (Flux 
Instruments, Reinach, Switzerland), an HTC PAL autosampler (CTC Analytics, Zwingen, 
Switzerland) and a TSQ Quantum Access triple quadrupole mass analyzer (Thermo Fisher 
Scientific, Waltham, MA, USA). Separation of lipid extracts was performed on a diol silica-
based column (QS Uptisphere 6 OH, 150 x 2.1 mm, 5 µm, Interchim, Montlucon, France). 
Mobile phase A was a mixture of hexane/isopropanol/water (70:30:2, v/v) with 15 mM 
ammonium formate. Mobile phase B was isopropanol/water (50:2, v/v) with 15 mM 
ammonium formate.  The solvent-gradient was 0 to 7 minutes A/B (%) 80/20, 8 to 10 minutes 
A/B (%) 60/40, 11 to 23 minutes A/B (%) 40/60 and 25 to 30 minutes A/B (%) 80/20 at a 
flow rate of 0.35 ml/min. The column was maintained at 30°C. Mass spectrometry was 
performed in positive ionization mode with the following parameters: 4500 V spray voltage, 
skimmer voltage 2 - 14 V (depending on the scan mode), 250°C capillary temperature, and 10 
and 6 (arbitrary units) sheath and auxiliary N2 gas, respectively. Molecular masses provided 
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by a neutral loss and precursor scan were used to selectively detect specific phospholipids. A 
neutral loss of masses m/z 115 and 189 from [M+NH4]
+ 
ions were used for analysis of PA and 
PG lipids, respectively. A precursor ion scan of m/z 184 specific for phosphocholine-
containing lipids was used for PC, SM and LPC. A neutral loss scan of m/z 141 was used for 
PE and a precursor scanning of m/z 264 was applied for screening of Cer. Acquired data were 
analyzed using Xcalibur (version 2.0.6, Thermo Fisher Scientific). The structure of the head 
groups were determined from the type of MS/MS scanning. Molecular species were identified 
by using LIMSA software
35
. All species were assigned to the lipid classes and species with a 
defined total numbers of carbon atoms and double bounds in acyl and/or alkyl chains. Data 
were corrected for isotopic overlap. Quantification was based on calibration curves for seven 
lipid standards including PC(16:0/18:2), SM(d18:1/16:0), LPC(16:0), PE(18:0/18:0), 
Cer(d18:1/14:0), PG(16:0/16:0), and PA(14:0/14:0). The calibration curves were constructed 
by plotting the PL/IS peak area ratios against the nominal concentration of the standards. The 
concentrations for the individual lipid species were calculated from linear regressions of the 
calibration curves. 
 
5.2.11. Statistical analysis 
Semiquantitative real-time PCR and morphometric analysis of the RPE flat mounts. 
Statistical analyses were performed using Prism4 software. All data are given as means ± SD 
of three animals per group. Statistical differences of means were calculated using 2-way 
ANOVA followed by a Bonferroni post hoc test. A p value of less than 0.05 was considered 
significant.  
Lipidomics analysis. Statistical analyses were performed using SPSS, version 19 
(SPSS Switzerland, Zurich, Switzerland). Normality of the data was determined by using the 
Kolmogorov-Smirnov test. Since not all lipid species had normally distributed values, the 
nonparametric Mann-Whitney U test was used. The Mann-Whitney U test was applied for 
comparison between Pon1
–/–
 and WT mice. Bonferroni correction was applied to adjust the p 
value for multiple comparisons (37 statistical tests). A p value of 0.001 or below was 
considered significant. Data are presented as median with lower and upper range values. 
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5.3. Results 
5.3.1. Paraoxonase 1 is highly expressed in the RPE 
To evaluate the expression pattern of paraoxonases in the retina we isolated the RPE, 
the outer nuclear layer (ONL), the inner nuclear layer (INL) and the ganglion cell layer (GCL) 
by laser capture microdissection, and analyzed levels of Pon1, Pon2 and Pon3 mRNA by 
semiquantitative real-time PCR (Fig. 1). Expression of monocarboxylate transporter, member 
3 (Mct3; RPE), guanine nucleotide binding protein, alpha transducing activity polypeptide 
(Gnat1; ONL), visual system homeobox 2 (Vsx2; INL), and melanopsin (Opn4; GCL) were 
used as layer-specific markers and showed that cross-contamination between collected layers 
was minimal. In WT mice, Pon1 was highest expressed in the RPE with 267-, 590-, and 651-
fold higher levels than in ONL, INL, and GCL, respectively. Similarly, Pon3 was most 
abundant in the RPE (45-, 43-, 72-fold higher levels than in ONL, INL, and GCL, 
respectively). Pon2 content was comparable in the RPE and the INL, approximately 25- and 
9-fold higher than in ONL and GCL, respectively. 
Even though Pon1
–/–
 mice have a neomycin cassette inserted into exon 1 of Pon1 and 
no paraoxonase activity
30
, the RNA transcript from the disrupted gene can still be detected by 
real-time PCR. Interestingly, we found differential effects of the neomycin insertion on Pon1 
expression in RPE and neuronal retina. Whereas expression of the disrupted Pon1 gene was 
33-fold decreased in the RPE, it was 15-fold increased in the INL and 6-fold in the GCL, 
indicating differential regulation of Pon1 expression in RPE and neuroretina. Levels of Pon2 
and Pon3 transcripts were not significantly affected by the lack of functional PON1. 
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Figure 1. Pon1 is highly expressed in the RPE. 
Retinal pigment epithelium (RPE), outer nuclear layer (ONL), inner nuclear layer (INL) and 
ganglion cell layer (GCL) were isolated from WT (grey bars) and Pon1
–/–
 mice (black bars) 
using laser capture microdissection. Relative gene expression was determined by semi-
quantitative real-time PCR in each individual layer. Values were normalized to -actin, and 
expressed relative to levels in the RPE of Pon1
–/–
 mice, which were set to 1. Shown are mean 
values ± SD of N=3. Expression of Mct3 (marker for RPE), Gnat1 (marker for ONL), Vsx2 
(marker for INL), and Opn4 (marker for GCL) was determined to monitor contamination 
between the isolated retinal layers. 
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5.3.2. Absence of PON1 does not compromise retinal function and architecture 
To evaluate whether PON1 is important for normal retinal development, ageing and 
function, we analyzed 8-week and 1-year old mice. Pon1
–/–
 mice showed regular retinal 
architecture and no signs of RPE or photoreceptor degeneration at either age (Fig. 2A). 
Similarly, funduscopy and fluorescein angiography revealed no retinal or vascular defects in 
Pon1
–/–
 mice (Fig. 2B). Normal scotopic and photopic ERGs with a- and b-wave amplitudes 
similar to WTs (Fig. 2C) supported the conclusion that Pon1
–/–
 mice developed a normal and 
functional retina. 
 
 
Figure 2. Lack of PON1 does not compromise retinal architecture and function 
Figure 2A: Retinal morphology of Pon1
–/–
 and control mice (WT) at 8 weeks and 1 year of 
age. Shown are representative sections of N=3. RPE, retinal pigment epithelium; POS, 
photoreceptor outer segments; PIS, photoreceptor inner segments; ONL, outer nuclear layer; 
INL, inner nuclear layer. Scale bar: 50 m. Figure 2B: Funduscopy (top panels) and 
 126 
fluorescein angiography (bottom panels) of WT and Pon1
–/–
 mice at 8 weeks of age. Shown 
are representative images of N=3. Figure 2C: Scotopic and photopic electroretinograms from 
WT and Pon1
–/–
 mice at 8 weeks of age. Top panels: representative traces from individual 
mice. Bottom panels: scotopic a- and b-wave amplitudes, as well as photopic b-wave 
amplitudes as a function of light intensity. N=3. 
 
5.3.3. Lack of PON1 does not affect RPE morphology 
Since we found high Pon1 expression in the RPE and PON1 was previously 
implicated in AMD
12-14, 27
, a disease strongly affecting RPE and Bruch`s membrane, we 
examined these structures in young and old mice. Transmission electron microscopy did not 
detect any obvious differences in the ultrastructure of RPE and Bruch`s membrane between 
Pon1
–/–
 and WT mice at any age (Fig. 3A). Also, RPE microvilli and basal infoldings 
appeared normal and no AMD-like features, such as Bruch`s membrane thickening or sub-
RPE deposits
36
, were present in any of the analyzed animals up to one year of age.  
To analyze RPE cell morphology on a larger scale, we prepared RPE flat mounts. The 
RPE monolayer is normally formed by a relatively uniform array of polygonal cells 
containing one to two centrally positioned nuclei. The regular shape is maintained by 
adherens and tight junctions, as well as by the actin-myosin cytoskeleton, whose components 
may serve as markers of epithelial integrity. We monitored the RPE cell boundaries by 
immunofluorescent staining for -catenin (adherens junctions) and phalloidin (F-actin), and 
did not observe any abnormalities in mice lacking PON1 up to one year of age (Fig. 3B). This 
was further supported by morphometric analyses, which were used to quantitatively assess 
RPE cell shape. The eccentricity (ECC) and form factor (FF) are two measures of distortion 
from a circular shape, whose values vary between 0 and 1, with ECC=0 and FF=1 for a 
perfect circle. These factors did not differ significantly between cells in the RPE of Pon1
–/–
 
and age-matched WT mice (Fig. 3C). 
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Figure 3. Lack of PON1 does not affect RPE morphology  
The RPE was analyzed in Pon1
–/–
 and control (WT) mice at 8 weeks (8w) and 1 year (1y) of 
age. Figure 3A: Transmission electron micrographs of the RPE and adjacent tissues. Shown 
are representative sections of N=3 for each panel. N, nucleus; BrM, Bruch`s membrane; BI, 
basal infoldings; MV, apical microvilli; M, melanosomes. Scale bar: 2 m. Figure 3B: RPE 
flat mounts immunostained for -catenin (red) and phalloidin (green). Nuclear staining 
(Hoechst) is visible in blue. Shown are representative microphotographs of N=3 for each 
panel. Scale bar: 50 m. Figure 3C: Morphometric analysis of RPE cells. Shown are mean 
values ± SD of at least N=700 RPE cells examined per group. Two-way ANOVA revealed 
no significant differences in RPE cell shape between WT and Pon1
–/–
 mice at 8w and 1y of 
age (p>0.05). 
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5.3.4. Gene expression in Pon1
–/–
 mice 
To reveal whether the lack of PON1 influences expression of related genes or of genes 
encoding known PON1 interaction partners, we analyzed gene expression in retina and 
eyecup at 8 weeks and 1 year of age. Similar to the LCM data (Fig. 1), expression of Pon1 
was lower in the neuronal retina compared to that in the eyecup (Fig. 4). Cross-contamination 
between RPE and neuronal retina was minimal as shown by the relative expression of Mct3 
(RPE) and Gnat1 (retina) in both isolated compartments (Table 2).  
In accordance with the LCM experiment, we found significant up-regulation of Pon1 
mRNA expression in the retina of 8 week old Pon1
–/–
 mice and down-regulation in the 
eyecup. Since lack of the antioxidative PON1 protein may influence the oxidative balance in a 
tissue, expression of other antioxidative genes may be affected. However, both other members 
of the paraoxonase family (Pon2 and Pon3), the two superoxide dismutases (Sod1 and Sod2), 
as well as heme oxygenase 1 (Hmox1) were similarly expressed in control and Pon1
–/–
 mice 
(Fig. 4). Remarkably, we detected an age-related moderate decrease in the expression of Sod1, 
Sod2, Pon3 (retina and eyecup), Pon2 (retina), Pon1 and Hmox1 (eyecup) independently of 
the Pon1 genotype (Fig. 4 and Table 2). 
Previous studies showed that the role of PON1 in HDL transport and function involves 
interaction with partner proteins, such as scavenger receptor class B (SCARB1, also known as 
SR-BI) and ATP-binding cassette transporter (ABCA1). Whereas SCARB1 facilitates 
acquisition of PON1 secreted from hepatocytes
37
, interaction between PON1 and ABCA1 
transporter enhances HDL-mediated cholesterol efflux from macrophages
38
. Both SCARB1 
and ABCA1 were shown previously to be involved in lipid efflux and reverse cholesterol 
transport in retina and RPE
39
, and this function might depend on interaction with PON1. 
Nevertheless, expression of Scarb1 was similar in control and Pon1
–/–
 mice at either age.  The 
expression of Abca1 was also similar in old control and knockout mice, whereas expression in 
young Pon1
–/–
 mice was variable in different sets of animals (see also Fig. 5), suggesting the 
influence of other, yet unknown factors. Further studies are required to investigate a potential 
functional connection between Pon1 and Abca1 in the retina. 
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Figure 4. Expression of PON1-related genes 
Expression of genes related to PON1 function was determined by semi-quantitative real-
time PCR in retinas (upper panels) and eyecups (lower panels) of WT (white bars) and 
Pon1
–/–
 mice (black bars) at 8 weeks (8w) and 1 year (1y) of age as indicated. Shown are 
mean values ± SD of N=3. Values were normalized to -actin, and levels in WT mice at 
8w were set to 1. Two-way ANOVA with Bonferroni post-hoc analysis was used to test 
statistical significance. A p-value of less than 0.05 was considered significant; **p<0.01; 
***p<0.001. Shown are statistics for the comparison of expression levels in WT and 
Pon1
–/–
 mice at 8w or 1y of age. See Table 2 for statistical analysis of age-dependent 
expression in WT and Pon1
–/–
 mice. 
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Table 2. Expression of PON1-related genes in retinas and eyecups of Pon1
–/–
 and WT mice at 8 weeks (8w) and one year (1y) of 
age. 
 
Expression of genes related to PON1 function was determined by semi-quantitative real-time PCR. Shown are mean values ± SD of 
N=3. Values were normalized to -actin and expressed relative to levels in the retina of WT mice at 8 weeks of age, which were set to 
1. Two-way ANOVA with Bonferroni post-hoc analysis was used to test the statistical significance. A p-value of less than 0.05 was 
considered significant; ns, not significant. Pon1, paraoxonase 1; Pon2, paraoxonase 2; Pon3, paraoxonase 3; Abca1, ATP-binding 
cassette, sub-family A (ABC1), member 1; Scarb1, scavenger receptor class B, member 1; Hmox1, heme oxygenase 1; Sod1, 
superoxide dismutase 1; Sod2, superoxide dismutase 2, Mct3, monocarboxylate transporter, member 3 (marker for RPE); Gnat1, 
guanine nucleotide binding protein, alpha transducing activity polypeptide (marker for the neuronal retina). 
 
 
Mean  ±  SD 
2-way ANOVA 
WT vs. Pon1
–/– 8w vs. 1y 
 Gene WT, 8w Pon1–/–, 8w WT, 1y Pon1–/–, 1y 8w 1y WT Pon1–/– 
R
E
T
IN
A
 
Pon1 1 ± 0.16 4.04 ± 1.57 0.71 ± 0.7 2.21 ± 0.24 p < 0.01 ns ns ns 
Pon2 1 ± 0.31 0.94 ± 0.23 0.62 ± 0.17 0.72 ± 0.18 ns ns ns ns 
Pon3 1 ± 0.18 1.06 ± 0.31 0.57 ± 0.36 0.48 ± 0.35 ns ns ns ns 
Hmox1 1 ± 0.50 1 ± 0.26 0.65 ± 0.50 1.02 ± 0.44 ns ns ns ns 
Sod1 1 ± 0.11 0.96 ± 0.16 0.62 ± 0.03 0.67 ± 0.09 ns ns p < 0.01 p < 0.05 
Sod2 1 ± 0.09 0.95 ± 0.40 0.45 ± 0.06 0.44 ± 0.1 ns ns p < 0.05 p < 0.05 
Scarb1 1 ± 0.19 1 ± 0.36 0.45 ± 0.05 0.44 ± 0.08 ns ns p < 0.05 p < 0.05 
Abca1 1 ± 0.18 0.4 ± 0.17 1.4 ± 0.13 1.39 ± 0.17 p < 0.01 ns ns p < 0.001 
Mct3 1 ± 0.75 5.1 ± 5.54 2.03 ± 2.12 0.38 ± 0.14 ns ns ns ns 
Gnat1 1 ± 0.53 0.87 ± 0.32 1.74 ± 0.30 1.67 ± 0.5 ns ns ns p < 0.05 
E
Y
E
 C
U
P
 
Pon1 4.58 ± 1.04 1.08 ± 0.06 1.61 ± 0.47 0.98 ± 0.28 p < 0.001 ns p < 0.001 ns 
Pon2 0.51 ± 0.05 0.55 ± 0.11 0.61 ± 0.07 0.59 ± 0.08 ns ns ns ns 
Pon3 7.59 ± 0.52 8.64 ± 1.26 3.57 ± 0.85 3.15 ± 0.74 ns ns p < 0.001 p < 0.001 
Hmox1 0.28 ± 0.04 0.33 ± 0.07 0.11 ± 0.02 0.1 ± 0.03 ns ns p < 0.01 p < 0.001 
Sod1 0.23 ± 0.01 0.19 ± 0.03 0.11 ± 0.02 0.1 ± 0.03 ns ns p < 0.001 p < 0.01 
Sod2 0.17 ± 0.01 0.17 ± 0.03 0.07 ± 0.01 0.07 ± 0.02 ns ns p < 0.001 p < 0.001 
Scarb1 0.05 ± 0.01 0.05 ± 0.02 0.02 ± 0.00 0.02 ± 0.00 ns ns ns p < 0.05 
Abca1 0.05 ± 0.01 0.13 ± 0.09 0.12 ± 0.03 0.09 ± 0.05 ns ns ns ns 
Mct3 48.63 ± 3.78 46.75 ± 11.48 27.28 ± 6.25 19.38 ± 12.22 ns ns p < 0.05 p < 0.01 
Gnat1 0.004 ± 0.01 0.01 ± 0.02 0.01 ± 0.01 0.001 ± 0.001 ns ns ns ns 
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Figure 5. PON1 does not protect against damage by acute light exposure. 
Figure 5A: Representative light micrographs of retinas of 8-week old control (WT) and Pon1
–/–
 
mice at 5 and 10 days after light exposure. Control mice (dark control, DC) were reared in 
normal cyclic light conditions (12 hours dark; 12 hours light) and not exposed to light. Arrows: 
pyknotic nuclei indicating photoreceptor cell death. Arrowheads: macrophages in the subretinal 
space. Shown are representative sections of N=3. Scale bar: 50 m. Figure 5B: Immunostaining 
of RPE flat mounts from 8-week old WT and Pon1
–/–
 dark control (DC) mice and at 10 days after 
light exposure (10 d). Red: -catenin; green: phalloidin; arrowheads: diffuse -catenin staining in 
RPE cells of light exposed mice. Scale bar: 50 m. Figure C5: Gene expression in retinas (upper 
panels) and eyecups (lower panels) of 8-week old WT (white bars) and Pon1
–/–
 (black bars) mice 
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at 12 hours after light exposure (12 h) or in dark controls (DC). Values were normalized to b-
actin and expressed relative to the levels in the retina of unexposed WT animals, which were set 
to 1. Shown are mean values ± SD of N=3. Two-way ANOVA with Bonferroni post-hoc analysis 
was used to test significance. A p-value of less than 0.05 was considered significant; *p<0.05; 
**p<0.01; ***p<0.001. Shown are significantly different expression levels between WT and 
Pon1
–/–
 mice in DC or light exposed mice. See Table 3 for statistical analysis of differences in 
gene expression between DC and light exposed WT and DC and light exposed Pon1
–/–
 mice. 
 
5.3.5. Alterations of phospholipid composition in retina/eyecup samples of Pon1
–/–
 mice 
The retina contains very high levels of polyunsaturated fatty acids (PUFAs). The majority 
of retinal PUFAs is esterified to phospholipids, which build up the membranous disks of 
photoreceptor outer segments
40
. Due to their molecular structure and constant exposure to a 
photo-oxidative environment
5, 6
, retinal phospholipids are particularly prone to oxidative 
modifications. Based on the fact that PON1 can reduce lipid peroxidation in LDL and cell 
membranes
17, 19
, we hypothesized that PON1 might have a similar effect on retinal phospholipids, 
and thus affect their composition. To test this assumption, we employed a combination of LC and 
MS for the identification and quantification of retina/eyecup phospholipids from WT and Pon1
–/–
 
mice.  
The overall phospholipid profile was similar in the retina/eyecup samples of WT and 
Pon1
–/–
 mice at the age of 8 weeks. The most abundant phospholipids were PCs and PEs (Table 
4). The most abundant PE species was PE 40:6, which possibly contained polyunsaturated C22:6n-3 
docosahexaenoic (DHA) fatty acid at the sn-1 or sn-2 position of the glycerol backbone. The PC 
40:6 was the third most abundant PC species after PC 32:0 and PC 34:1. Interestingly, highly 
unsaturated PC 44:12 and PE 44:12 species were identified in both mouse strains. They probably 
represent PC and PE lipids that were esterified with two molecules of DHA at the sn-1 and sn-2 
position of the glycerol backbone. The third abundant lipid class was SM. Among 
lysophosphatidylcholines (LPC), the most abundant species contained a DHA fatty acid (LPC 
22:6). Ceramides/hexosylceramides (Cer/HexCer), PGs and PAs were found at very low 
concentrations; therefore, we report only total concentrations of these three lipid classes. 
The major difference between 8-week old Pon1
–/–
 and WT mice was seen for total LPC 
(p=0.001) and in particular for LPC 22:6 species (p=0.001), which were detected at significantly 
reduced levels in Pon1
–/–
 mice (Table 4). These differences remained significant after Bonferroni 
correction for multiple testing. Analysis of phospholipids in WT retinas and eyecups, which were 
isolated separately, revealed that LPC 22:6 was the most abundant LPC species in the retina, 
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whereas it was almost absent in the eyecup (data not shown). Some polyunsaturated and 
monounsaturated PCs as well as polyunsaturated PEs were also decreased in Pon1
–/–
 mice 
(p<0.05). However, these differences missed significance after Bonferroni correction (Table 5). 
Other phospholipid species were not altered in Pon1
–/–
 compared to controls. When data for 
retinal phospholipids were calculated as mole percent, no significant differences between Pon1
–/–
 
and WT mice were detected (Table 6). Although the relative abundance of total LPC (p=0.0032) 
and LPC 22:6 (p=0.0015) lipids was markedly reduced the in retina/eyecup samples of Pon1
–/–
 
mice, these differences lost significance after correcting for multiple testing. 
Since aging is a major risk factor for the development of AMD, and lipid metabolism is 
known to be involved in the etiology of this disease, we characterized the phospholipid profiles 
of 1-year old WT and Pon1
–/–
 mice. In contrast to young adults at 8 weeks of age, levels of total 
LPC and LPC 22:6 species in 1 year old mice did not differ between the two mice strains (Table 
7). Interestingly, age-related changes in the phospholipid profiles showed different trends in WT 
and Pon1
–/–
 mice. While control animals showed a trend for decreased levels of total LPC and 
LPC 22:6 with age, Pon1
–/–
 mice revealed almost no age-related changes in the content of those 
phospholipids (Table 7).  
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Table 4. Phospholipids in the retina/eyecup samples from control (WT) and Pon1
–/–
 mice at 
8 weeks of age. 
 
PLs 
Content of PL in nmol per mg of retina and 
eyecup proteins 
Mann-Whitney Test, 
p values 
WT 8w  
vs Pon1
–/–
 8w 
WT 8w 
Median(min;max) 
Pon1
–/–
 8w 
Median(min;max) 
Total PC 143.5(92;170.5) 120.5(54.1;140.3) 0.023 
Total SM 20(7.2;26.8) 17(7.2;23.7) 0.174 
Total LPC 5.2(2.1;5.9) 2.5(1.2;4.1) 0.001 
Total PE 26.5(16.2;29.8) 21.9(11.4;24.6) 0.013 
Total Cer/HexCer 5.6(2.7;7.6) 6.1(2.6;9.4) 0.545 
Total PG 1.2(0.2;1.9) 0.9(0.3;1.5) 0.253 
Total PA 2.8(2.3;3.1) 2.9(2.5;3.2) 0.326 
PC 32:0 27.3(15.5;31.5) 23.3(10.9;27.7) 0.070 
PC 32:1 2.7(2.1;3.5) 2.1(1.1;2.6) 0.010 
PC 34:0 6.4(3.7;8) 5.9(3;7.6) 0.257 
PC 34:1 27.8(18.8;33.4) 23.4(10.9;28.9) 0.016 
PC 34:2 4.7(3;5.9) 4.2(1.7;4.6) 0.096 
PC 36:1 14.1(8;16.2) 11.1(5.3;13.3) 0.019 
PC 36:2 5.6(4.3;7.2) 4.7(2.2;5.8) 0.023 
PC 36:3 1.5(1;2) 1.3(0.4;1.7) 0.070 
PC 36:4 6.4(4.1;7.2) 5.4(2.6;6.3) 0.059 
PC 38:4 7.9(4.7;10.4) 6.6(2.8;8.3) 0.013 
PC 38:5 2.5(1.6;2.8) 2.4(0.9;2.9) 0.450 
PC 38:6 12.1(7.6;15.1) 9.5(4;12.3) 0.013 
PC 40:5 1.7(0.7;2.3) 1.3(0.8;1.9) 0.023 
PC 40:6 17.7(12.2;20.4) 13.7(5.7;15.6) 0.004 
PC 40:7 1.4(1.2;2.4) 1.1(0.5;1.5) 0.008 
PC 44:12 4.9(3.7;8.3) 3.9(1.4;5.7) 0.016 
SM34:1 5.8(2.3;7.6) 5.2(2.4;7.2) 0.174 
SM36:1 4.7(1.9;6.4) 3.9(1.9;5.5) 0.199 
SM38:1 2.4(0.8;3.3) 2.2(0.7;2.9) 0.199 
SM40:1 2.2(0.8;3.2) 2(0.8;2.9) 0.199 
SM42:1 2.1(0.6;2.7) 1.7(0.5;2.6) 0.131 
SM42:2 2.2(0.8;3.4) 1.8(0.7;2.7) 0.257 
SM42:3 0.4(0.1;0.5) 0.3(0.1;0.4) 0.059 
LPC 18:0 0.8(0.6;0.8) 0.7(0.4;0.9) 0.131 
LPC 18:1 1.7(0.6;2) 0.7(0.4;1.2) 0.002 
LPC 22:6 2.8(0.9;3.1) 1.2(0.4;2) 0.001 
PE 34:1 0.8(0.6;0.9) 0.7(0.4;0.9) 0.290 
PE 36:0 0.3(0.2;0.4) 0.3(0.2;0.4) 0.880 
PE 36:2 0.9(0.8;1.2) 0.9(0.7;1.1) 0.151 
PE 36:4 0.6(0.4;0.8) 0.6(0.4;0.8) 0.650 
PE 38:4 3.3(1.8;3.7) 2.6(1.5;3.1) 0.019 
PE 38:6 5(2.8;6.3) 4.2(2;5.1) 0.008 
PE 40:6 12.2(7.6;13.8) 10.3(5.1;11.4) 0.013 
PE 44:12 2.9(1.9;3.8) 2.3(1.1;2.7) 0.013 
 
The phospholipid (PL) analysis was performed by LC-MS. Content of PL classes and species is 
shown as nmol of PL per one mg of retina and eyecup proteins. Total phospholipids represent 
sum of molecular species of a given class and are presented for PC, SM, LPC, PE. Species 
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pattern is displayed for PCs, PEs, SMs and LPCs. Data values are displayed as median with 
range. N=10 for both genotypes. Statistical significance was determined by the Man-Whitney U 
test. After Bonferroni correction a p value of 0.001 corresponds to a significance level of 0.05. 
Statistically significant results are indicated in bold. An assignment of PL species includes 
numbers of carbon atoms and double bounds in both acyl chains (for example, PC 34:1 consist of 
34 carbon atoms and one double bond and can correspond to the following species PC(16:0/18:1) 
or PC(18:0/16:1), and so forth). SM assignment comprises the numbers of carbon atoms and 
double bonds in both sphingoid base and in N-linked fatty acid.  
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5.3.6. PON1 does not influence photoreceptor degeneration or RPE survival after light 
exposure 
To evaluate whether the lack of the antioxidative PON1 protein influences cell survival 
under oxidative stress conditions, we exposed WT and Pon1
–/–
 mice to high levels of white 
light
41
. At 5 days after exposure, many photoreceptors were lost and large numbers of pyknotic 
nuclei were detected in the ONL of WT and Pon1
–/–
 mice (Fig. 5A). We also observed similar 
levels of subretinal macrophages in Pon1
–/–
 and WT mice, although previous reports suggested 
inhibitory effects of PON1 on monocyte transmigration
30
. At 10 days after light exposure the 
photoreceptor layer was degenerated further, with only few pyknotic nuclei left in the ONL of 
both Pon1
–/–
 and WT mice. Additionally, some RPE cells displayed severe morphologic changes 
in both mouse lines (Fig. 5B). Enlarged RPE cells with increased cytoplasmic -catenin 
localization, as well as a global increase in cytoplasmic phalloidin (F-actin) staining were 
observed. The number of RPE cells before and after light exposure was comparable in WT and 
Pon1
–/–
 mice (data not shown). 
Acute LD not only induces retinal degeneration, but also activates survival pathways to 
protect retinal cells from cell death. Leukemia inhibitory factor (LIF) is a key cytokine regulating 
an endogenous rescue pathway that involves activation of the Janus kinase signal transducer and 
activator of transcription (Jak-STAT) signaling pathway, and expression of protective factors like 
endothelin-2 (Edn2) and fibroblast growth factor-2 (Fgf2)
42, 43
. In line with the comparable extent 
of tissue damage (Fig. 5A, 5B), light exposure caused a similar expression pattern of these genes 
in retinas of WT and Pon1
–/–
 mice, even though Edn2 and Fgf2 were significantly stronger 
induced in mice lacking PON1 (Fig. 5C). No differences between the two genotypes were 
detected in eyecups. Remarkably, upon exposure to the light Pon2, Sod1 and Sod2 expression 
was reduced in the retina, but not in the eyecup, while Hmox1 was upregulated in both tissues 
(Fig. 5C; Table 3). Additionally, expression of Socs3 was strongly upregulated in the eyecup, 
suggesting that JAK/STAT signaling was also induced in the RPE. Whether this was a 
consequence of LIF signaling or whether other factors led to such activation must be established. 
Untreated Pon1
–/–
 mice had decreased levels of total LPCs and in particular of LPC 22:6 
(see above). Since PON1 is an antioxidative enzyme, we tested whether its lack might impact the 
phospholipid composition under oxidative stress induced by light exposure. At 2 hours after light 
exposure, phospholipid profiles were comparable in WT and in Pon1
–/–
 retina/eyecups and 
showed increased levels of PE 34:1, PE 36:0 and PE 36:4 in both strains (Table 5). Furthermore, 
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light exposure increased the levels of total LPC and LPC 22:6 in Pon1
–/–
 but not in WT mice 
(Table 7). However, these differences did not remain statistically significant after correcting for 
multiple testing. In agreement with a lack of difference, concentrations of potentially DHA 
containing PC’s (PC38:6, PC 40:6, PC:40:7 and PC 44:12) did not differ between WT and PON1 
mice, neither before nor after light exposure. 
On the basis of mole percent, PE 36:0 levels increased in both strains upon light exposure, 
while PE 34:1, PE 36:4, PE 38:6, PE 40:6 species were more abundant in WT mice, but not in 
Pon1
–/–
 after the treatment. In contrary, PE 44:12 was relatively decreased in Pon1
-/-
, but not in 
WT mice. Relative increases of total LPC and LPC 22:6 were observed in Pon1
-/-
, but not in WT 
mice; however, without statistical significance after correction for multiple testing and without 
any concomitant changes in PC (Table 6).  
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Table 3. Gene expression in retinas and eyecups of Pon1
–/–
 and WT mice after light damage (LD). 
 
 
Mean ± SD 
2-way ANOVA 
WT vs. Pon1
–/– DC vs. LD 
Gene WT, DC Pon1
–/–
, DC WT, 12h Pon1
–/–
, 12h DC 12h after LD WT Pon1
–/–
 
R
E
T
IN
A
 
Lif 1 ± 0.47 1.73 ± 0.39 35.75 ± 10.41 44.29 ± 5.29 ns ns p < 0.001 p < 0.001 
Edn2 1 ± 0.23 3.18 ± 1.34 8.82 ± 1.39 32.3 ± 9.92 ns p < 0.001 ns p < 0.001 
Fgf2 1 ± 0.07 1.55 ± 0.09 1.85 ± 0.08 3.72 ± 1.85 ns p < 0.05 ns p < 0.05 
Stat3 1 ± 0.13 1.18 ± 0.14 4.02 ± 0.55 2.81 ± 0.29 ns p < 0.01 p < 0.001 p < 0.001 
Socs3 1 ± 0.39 1.64 ± 0.17 20.71 ± 16.94 18.91 ± 9.82 ns ns ns ns 
Hmox1 1 ± 0.29 0.6 ± 0.02 5.32 ± 0.22 4.83 ± 1.71 ns ns p < 0.001 p < 0.001 
Sod1 1 ± 0.12 0.76 ± 0.06 0.8 ± 0.20 0.53 ± 0.12 ns ns ns ns 
Sod2 1 ± 0.16 0.92 ± 0.05 0.65 ± 0.12 0.51 ± 0.06 ns ns p < 0.01 p < 0.01 
Scarb1 1 ± 0.59 1.56 ± 0.43 0.39 ± 0.23 1.03 ± 0.11 ns ns ns ns 
Abca1 1 ± 0.55 1.8 ± 0.79 1.42 ± 1.05 1.18 ± 0.24 ns ns ns ns 
Mct3 1 ± 0.35 0.64 ± 0.30 0.54 ± 0.24 1.79 ± 0.69 ns p < 0.01 ns p < 0.05 
Gnat1 1 ± 0.11 1.14 ± 0.28 0.2 ± 0.06 0.3 ± 0.05 ns ns p < 0.001 p < 0.001 
E
Y
E
 C
U
P
 
Lif 0.37 ± 0.13 0.72 ± 0.32 1.39 ± 1.12 2.07 ± 0.30 ns ns ns ns 
Edn2 0.01 ± 0.004 0.02 ± 0.01 0.04 ± 0.05 0.04 ± 0.02 ns ns ns ns 
Fgf2 0.02 ± 0.01 0.04 ± 0.02 0.06 ± 0.05 0.03 ± 0.004 ns ns ns ns 
Stat3 0.29 ± 0.04 0.32 ± 0.01 0.52 ± 0.15 0.46 ± 0.07 ns ns p < 0.05 ns 
Socs3 0.21 ± 0.06 0.15 ± 0.03 2.13 ± 0.50 1.52 ± 0.22 ns ns p < 0.001 p < 0.001 
Hmox1 0.21 ± 0.03 0.17 ± 0.04 0.56 ± 0.18 0.4 ± 0.01 ns ns p < 0.01 ns 
Sod1 0.16 ± 0.01 0.15 ± 0.01 0.17 ± 0.03 0.15 ± 0.04 ns ns ns ns 
Sod2 0.16 ± 0.02 0.15 ± 0.01 0.19 ± 0.01 0.14 ± 0.03 ns p < 0.05 ns ns 
Scarb1 0.01 ± 0.001 0.02 ± 0.01 0.02 ± 0.02 0.06 ± 0.02 ns p < 0.05 ns p < 0.05 
Abca1 0.02 ± 0.01 0.06 ± 0.03 0.12 ± 0.10 0.1 ± 0.04 ns ns ns ns 
Mct3 6 ± 3.22 8.15 ± 1.05 7.09 ± 3.38 1.5 ± 0.43 ns p < 0.05 ns p < 0.05 
Gnat1 < 0.001 < 0.001 0.003 ± 0.01 < 0.001 ns ns ns ns 
 
Gene expression was examined by semi-quantitative real-time PCR in retinas and eyecups of WT and Pon1
–/–
 mice, which either were 
(light damage, LD) or were not (dark control, DC) exposed to damaging light. Analysis was at 12 h after light exposure (12h). Values 
were normalized to -actin and expressed relative to levels in retinas of dark control WT mice, which were set to 1. Shown are mean 
values ± SD of N=3. Two-way ANOVA with Bonferroni post-hoc analysis was used to test the statistical significance. A p-value of less 
than 0.05 was considered significant. Lif, leukemia inhibitory factor; Edn2, endothelin 2; Fgf2, fibroblast growth factor 2; Stat3, signal 
transducer and activator of transcription 3; Socs3, suppressor of cytokine signaling 3; Hmox1, heme oxygenase 1; Sod1, superoxide 
dismutase 1; Sod2, superoxide dismutase 2; Abca1, ATP-binding cassette, sub-family A (ABC1), member 1; Scarb1, scavenger receptor 
class B, member 1; Mct3, monocarboxylate transporter, member 3 (marker for RPE); Gnat1, guanine nucleotide binding protein, alpha 
transducing activity polypeptide (marker for the neuronal retina). 
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Table 5. Phospholipid composition of the retina/eyecup samples from control (WT) and Pon1
–/–
 mice at 8 weeks and 1 year of age, 
and from 8 weeks of age mice exposed to the light. 
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The phospholipid (PL) analysis was performed by LC-MS. Content of PCs, PEs, SMs and LPCs, Cers/HexCers, PGs and PAs was 
calculated as nmol/ mg of retina and eyecup protein. Total PLs represent sum of molecular species of PC, PE, SM and LPC lipid classes. 
The median and ranges are given from N=10 for WT (8w), N=10 for Pon1
–/–
 (8w), N=5 for WT (1y), N=6 for Pon1
–/–
 (1y), N=10 for WT 
(LD), N=10 for Pon1
–/–
 (LD). Man-Whitney U test was applied since data were not normally distributed. After Bonferroni correction for 
37 tests a p value of 0.001 corresponds to a significance level of 0.05. Bold letters indicate statistically significant levels. An assignment of 
PL species includes numbers of carbon atoms and double bonds in both acyl chains (for example, PC 34:1 consist of 34 carbon atoms and 
one double bond and can correspond to the following species PC(16:0/18:1) or PC(18:0/16:1), and so forth). SM assignment comprises 
numbers of carbon atoms and double bonds in both sphingoid base and in N-linked fatty acid.  
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Table 6. Phospholipid composition of the retina/eyecup samples from control (WT) and Pon1
–/–
 mice at 8 weeks and 1 year of age, 
and from 8 weeks of age mice exposed to the light. 
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Content of PCs, PEs, SMs and LPCs, Cers/HexCers, PGs and PAs was calculated as mole % of total phospholipids. The median and 
ranges are given from N= 10 WT (8w), N=10 Pon1
-/-
 (8w), N = 5 WT (1y), N = 6 Pon1
–/–
 (1y), N = 10 WT (LD), N = 10 Pon1
-/-
 (LD). 
Man-Whitney U test was applied since data were not normally distributed. After Bonferroni correction for 37 tests a p-value of 0.001 
corresponds to a significance level of 0.05. Bold letters indicate statistically significant levels. 
  
 143 
Table 7. Levels of total LPCs and LPC 22:6 in the retina/eyecup samples from 8-week and 1-year old WT and Pon1
–/–
 mice, and 
from 8-week old mice exposed to the light. 
 
 
 
The total LPC and LPC22:6 are shown as nmol of lipid per one mg of retina and eyecup proteins. Displayed are median values with 
range. N=5 for WT (1y), N=6 for Pon1
–/–
 (1y), N=10 for WT (LD), N=10 for Pon1
–/–
 (LD). Statistical significance was determined by 
the Man-Whitney U test. After Bonferroni correction a p value of 0.001 corresponds to a significance level of 0.05. An assignment of 
LPCs includes numbers of carbon atoms and double bonds in acyl chain. Total LPC represents sum of all lysophosphatidylcholine 
species. 
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5.4. Discussion 
5.4.1. PON1 in the normal retina 
Since PON1 has been implicated in AMD
12-14, 27
, we assessed whether lack of PON1 
would alter retinal physiology in young and old Pon1
–/–
 mice. We showed that PON1 is not 
essential for development and maintenance of a normal retinal structure, vasculature, or 
function. Similarly, RPE cells were morphologically indistinguishable between WT and 
Pon1
–/–
 mice, even though the RPE has the highest level of Pon1 expression. Although PON1 
has antioxidative activity, no signs of oxidative damage were detected and no compensatory 
increase in the expression of other antioxidative enzymes was observed. Lack of PON1 also 
did not influence the susceptibility of retina and RPE to light damage.  
However, retina/eyecup samples of Pon1
–/–
 mice showed decreased levels of LPCs in 
general and of LPC 22:6 in particular. LPCs are molecular species produced by the hydrolysis 
of PCs through enzymes of the phospholipase A2 (PLA2) superfamily. Previous studies have 
shown that PON1 has a PLA2-like activity leading to the formation and release of LPCs from 
macrophages
38, 44
. Thus, in WT mice, PON1 may increase LPC production and modulate the 
content of phospholipids in the retina/RPE. In analogy to the stimulatory effect of PON1-
generated LPCs on cholesterol efflux from macrophages
44, 45
, LPCs might stimulate reverse 
lipid transport from RPE regulating lipid content in this cell layer
46
. 
Since PON1 is a secreted protein that retains its hydrophobic signal peptide
47
, it may 
remain in the membrane of PON1-producing cells, or may reach membranes of neighboring 
cells. Thus, PON1 synthesized in the RPE might affect photoreceptors as well. The 
immunohistochemical detection of PON1 in the region of photoreceptor inner segments (and 
other nonnucleated areas of the retina)
48
 and our observation that LPC 22:6, which was 
reduced in Pon1
–/–
 mice, was very abundant in the retina but almost absent from the eyecup 
(data not shown) supports a role for a PLA2-like activity of PON1 in the neuronal retina.  
We detected a general age-related decrease in the expression of antioxidative genes in 
retinas and especially eyecups of WT mice. Pon1 was among the affected genes and down-
regulated about 65%. Remarkably, also levels of total LPCs and of LPC 22:6 were decreased 
in 1-year old WT mice, by 63% and 75%, respectively (Table 7). This suggests a correlation 
between Pon1 expression and LPC levels, and indicates that reduced expression of Pon1 
resulted in reduced PON1-related PLA2 activity and, thus, in a diminished PON1-mediated 
hydrolysis of PCs. Furthermore, increased lipid peroxidation and glycation in the aged eyes 
might have additionally compromised PON1 activity as it has been observed in metabolic 
syndrome and type II diabetes in humans
49-51
.  
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5.4.2. PON1 in the light-exposed retina  
Even though PON1 has antioxidative and anti-inflammatory activities, Pon1
–/–
 and 
WT mice were similarly affected by light exposure: photoreceptors were equally susceptible 
to light induced degeneration; changes in RPE morphology after light exposure were 
comparable; expression of genes involved in antioxidative defense or the LIF-controlled cell 
survival pathway was similar; and content of PE 34:1, PE 36:0 and PE 36:4 in nmol/mg of 
proteins was increased to the same extent. However, levels of total LPC and LPC 22:6 
increased only in Pon1
–/–
, but not in WT mice after light exposure, suggesting that presence of 
PON1 prevents generation of LPC upon light exposure. Whether this is a direct effect of 
PON1 or whether a differential activation of phospholipases A2 in the two mouse strains 
influences LPC production remains to be explored. 
Several possible mechanisms may explain the lack of striking differences in response 
to light damage between Pon1
–/–
 and WT mice. Previous studies showed that PON1 may be 
inactivated by its own substrates, such as oxidized lipids
52
. Thus, generation of a large amount 
of oxidized molecules by light exposure may substantially reduce PON1 activity in WT mice. 
Alternatively, PON1 may “neutralize” only a subset of oxidized species produced in LD, such 
as oxidized PUFAs
53
. Other light-induced oxidation products may remain toxic and 
participate in the induction of cell death. It may also be of importance that PON1 is a secreted 
protein
47
 that may not be able to detoxify intracellular molecules that have been generated by 
light exposure and that are involved in the degenerative process.  
 
5.4.3. PON1 in AMD  
The condition of AMD is a complex, multifactorial disease. Most existing mouse 
models for AMD combine advanced age, which is the major risk factor to develop AMD, with 
genetic defects in key genes involved in AMD pathogenesis. Considering the complex nature 
of the disease, it may not be surprising that some models require the combination of more 
than two environmental or genetic risk factors to cause a pathological phenotype. An 
excellent example is a murine model that combines three known AMD risk factors: advanced 
age, high fat, and cholesterol-rich diet, and mutations in ApoE
54
. Importantly, neither age nor 
the diet alone was sufficient to elicit changes that mimic human AMD pathology in the 
transgenic ApoE4 mice.  
The absence of an AMD-like phenotype in eyes of aged Pon1
–/–
 mice suggests that 
even long-lasting absence of PON1 is not sufficient to cause detectable pathologic changes, 
like thickening of Bruch’s membrane or sub-RPE deposits typical for AMD. Noteworthy, 
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despite the well-established antiatherogenic properties of PON1, Pon1
–/–
 mice developed 
significantly larger atherosclerotic lesions than WT controls only when raised on a high-
fat/high-cholesterol, but not on a regular diet
30, 55
. This suggests that additional factors/stimuli 
may be needed to provoke phenotypes of complex diseases, like atherosclerosis or AMD in 
Pon1
–/–
 mice. This hypothesis is also supported by the observation that pathological processes 
in ApoE
–/–
 mice were slowed in the presence of a human PON1 transgene
56
, but accelerated 
by PON1 deficiency
55, 57
. 
These studies provide evidence that a coexisting chronic metabolic burden may be 
needed to reveal the role of PON1 in development and/or progression of a complex disease. A 
long-lasting exposure to low levels of light (in contrast to the short-term exposure to high 
light levels used in present study), a high-fat diet, or the inclusion of the ApoE-null genetic 
background might provide such an additional chronic stress to provoke AMD-like lesions in 
Pon1
–/–
 mice.  
We postulate that PON1 could be involved in AMD as a modulatory protein and that 
direct or indirect interactions with additional factors may influence its contribution to disease 
development and/or progression. Presence or absence of such factors may determine the 
association of PON1 with AMD in particular populations and may help to explain 
contradictory results regarding the implication of PON1 in AMD pathology. Nevertheless, the 
controversy on the role of PON1 in AMD still remains and there is a clear need for further 
studies to identify the precise function of PON1 in ocular tissues, such as RPE and neuronal 
retina. Knowledge of these functions seems a prerequisite to understand how the antioxidative 
and anti-inflammatory properties of PON1 may influence AMD. 
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6. DISCUSSION 
 
Atherosclerotic coronary artery disease (CAD) is a multifactorial disease, the 
progression of which is determined by many risk factors, including elevated total cholesterol 
and low-density lipoprotein cholesterol (LDL-C) as well as decreased high-density lipoprotein 
cholesterol (HDL-C) 
1, 2
. However, it is now becoming clear that the odd profile of serum 
cholesterol cannot explain all incidence of CAD. Indeed, some individuals with high HDL-C 
levels and normal LDL-C levels still develop CAD 
3
. In addition, our knowledge on the role 
of high-density lipoproteins (HDL) in the pathogenesis of atherosclerosis has changed, in the 
last decade. Besides their function in reverse cholesterol transport, HDL particles also exert 
beneficial atheroprotective effects on the cardiovascular system, which are directly linked to 
key bioactive protein and lipid components of HDL. Moreover, atheroprotective effects of 
HDL are significantly attenuated in CAD and acute coronary syndrome (ACS) patients 
4, 5
. 
All together these findings suggest that not only the quantity, i.e. plasma content of HDL-C, 
but also the quality of HDL, i.e. molecular composition, are important in the pathogenesis of 
CAD. Furthermore, besides cholesterol, other lipids, such as glycerophospholipids and 
sphingolipids, are emerging as important players in the pathogenesis of CAD. 
Glycerophospholipids and sphingolipids represent two primary categories of lipids 
with specific chemical structures and biochemical characteristics 
6, 7
. All 
glycerophospholipids and sphingomyelins (SMs) contain a phosphate group. Therefore, they 
are often summarized as phospholipids. Glycerophospholipids and sphingolipids function as 
structural components of cell membranes and the surface lipid monolayers of lipoproteins. In 
addition, some glycerophospholipids and sphingolipids, such as lysophosphatidic acids 
(LPAs), lysophosphatidylcholines (LPCs), ceramides (Cers) and sphingosine-1-phospate 
(S1P), are important intracellular and extracellular signaling molecules. Among them, S1P is 
probably the best characterized bioactive lipid as it plays an important role in immunity, 
inflammation and vascular function 
8, 9
. It has been suggested that HDL-bound S1P is 
responsible for many anti-inflammatory and cytoprotective effects of HDL 
10-12
. Enrichment 
of HDL with S1P is explained by the presence of apolipoprotein M (apoM), a specific S1P 
binding protein 
13
. Earlier studies showed the limiting effect of apoM on S1P transport and 
functions in plasma and HDL 
13
, but also found complex interactions between HDL, apoM 
and S1P in humans with monogenic disorders affecting HDL metabolism 
14
. 
The first part of this project included the development of an analytical method for 
quantification of individual lipid species of glycerophospholipids and sphingolipids. To 
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achieve the best results, we combined normal-phase liquid chromatography with a triple 
quadrupole mass spectrometer. Liquid chromatography was applied for separation of lipid 
classes, while mass spectrometry (MS) methods, such as parent ion and neutral loss scanning, 
were employed for accurate identification of lipid species. After that, we developed a method 
for analysis of S1P lipids. This method included the acylation of the primary amine and the 
secondary alcohol of S1Ps in order to overcome the “carry-over” problem caused by the 
zwitterionic nature of these lipids. MS analysis of S1Ps was performed by multiple reaction 
monitoring (MRM), which provided highly selective and very specific determination of S1P 
species. The robustness of both methods has been evaluated by intra- and inter-day validation 
studies, which confirmed the precision and accuracy of the measurements. 
In a case-control study, we investigated whether the plasma levels of 
glycerophospholipids and sphingolipids, as well as S1Ps and sphingoid bases, differ between 
healthy subjects and stable CAD or ACS patients. We observed statistically significant 
alterations in the number of lipid species in plasmas of CAD and ACS patients independent of 
statin therapy. Since plasma glycerophospholipids and sphingolipids are largely associated 
with HDL and LDL lipoproteins 
15, 16
, it is plausible that the massive alterations in the plasma 
lipidome of CAD and ACS patients are related to the changes in the structure and number of 
lipoprotein particles, which may affect the functionality of lipoproteins. 
In the same study, four odd-chain PC species – PC33:1, PC33:2, PC33:3 and PC35:3 
– indirectly identified as PC plasmalogens – were the most significantly altered in plasma of 
stable CAD and ACS patients. Moreover, we demonstrated that these species, similar to even-
chain PCs, were prominently but not exclusively associated with HDL. This is reflected by 
positive correlations of PC plasmalogens with HDL-C found both by us and other studies 
17
. 
Plasmalogens possess antioxidant properties and are able to attenuate the oxidation of cell 
membrane cholesterol, polyunsaturated fatty acids and LDL 
18-20
. Thus, low levels of PC33:1, 
PC33:2, PC33:3 and PC35:3 in plasma can be explained by increased oxidative stress in CAD 
and ACS, which accelerates the oxidative degradation of plasmalogens. 
In the same study, the analysis of plasma samples revealed the presence of different 
S1P species, with 18:1-S1P being the most abundant among them. Variations in the structure 
of S1Ps result from the promiscuous substrate use by serine:palmitoyltransferase (SPT), the 
enzyme responsible for the first step in the de novo synthesis of sphingolipids. In addition to 
the canonical substrates L-serine and C16:0-CoA, SPT can metabolize other acyl-CoAs, 
resulting in the formation of sphingoid bases with different numbers of carbon atoms in the 
alkyl chain 
21
. The d18:1 sphingoid base is by far the most abundant in sphingolipids, since it 
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represents the canonical product of SPT reaction. Thus, it is not surprising that 18:1-S1P was 
found to be the most abundant S1P species. Most reports in the literature about S1P actually 
refer to the 18:1-S1P.  
The plasma profile of S1P lipids was altered in CAD and ACS patients. Compared to 
healthy subjects, plasma levels of 18:1-S1P were lower in ACS patients, while plasma levels 
of 16:1-S1P were lower in CAD and ACS patients. Considering that more than half of plasma 
18:1-S1P is associated with HDL and that 18:1-S1P is responsible for some of 
atheroprotective effects of HDL, we can deduce that the reduced plasma content of 18:1-S1P 
and 16:1-S1P may contribute to the loss of the atheroprotective functions of HDL in CAD and 
ACS patients.  
We thereafter investigated the triangular relationship between HDL-associated 
phospholipids, anti-apoptotic activity of HDL and the presence of stable and acute CAD. The 
anti-apoptotic activity of HDL was evaluated by measuring endothelial cell (EC) apoptosis in 
the presence of HDL after cell death was induced by serum and growth factors deprivation. 
This case-control study showed the association of reduced HDL content of PC33:3 and 
PC35:2 (= PC plasmalogens) with CAD and ACS. This result is supported by previous studies 
that reported low levels of PE plasmalogens in acute-phase HDL, and a diminished content of 
some specific PC and/or PE plasmalogens in HDL of patients with low HDL-C 
22, 23
. In 
addition, we demonstrated a significant correlation of PC33:3 and PC35:2 with the anti-
apoptotic activity of HDL. Considering that a direct anti-apoptotic effect of plasmalogens has 
been demonstrated for the neuronal cells (line Neuro-2A) 
24
 and that disturbed formation of 
plasmalogens in the cells with peroxisomal dysfunction was found to be associated with 
increased apoptosis 
25
, the relationship between reduced content of PC plasmalogens and 
reduced anti-apoptotic activity of HDL may be an indication of a direct causal effect. 
However, it is also plausible that reduced levels of HDL-associated PC plasmalogens are the 
result of increased oxidative stress and, thus, elevated oxidative degradation of plasmalogens 
in CAD and ACS patients. At the same time, the action of pro-apoptotic derivatives of 
oxidased plasmalogens, such as α-chlorofatty aldehydes or acids generated by 
myeloperoxidase 
26
 may also play a role in the loss of the anti-apoptotic activity of HDL. 
In addition to the two plasmalogens, HDL-associated PC34:2 showed significant 
association with both CAD and ACS, and inverse correlation with EC apoptosis in the 
presence of HDL. PC34:2, which represents the most abundant PC species in HDL, was early 
identified as PC(16:0/18:2) 
23
. Experimental studies indicated that reconstituted HDL (rHDL) 
containing PC(16:0/18:2) were more effective than rHDL containing other saturated and 
 155 
monounsaturated PC lipids in inhibiting the endothelial expression of vascular cell adhesion 
molecule 1 
27, 28
 and inhibiting the activation of NADPH oxidase in neutrophils 
29
. Moreover, 
rHDL containing PC(16:0/18:2) but not PC(16:0/18:1) induced CETP-mediated release of 
prebeta1-HDL, a promoter of cholesterol efflux 
30
. In addition, NMR-based lipidomic analysis 
of HDL revealed significant associations of diminished contents of total PC with coronary 
heart disease in a case-control study 
31
. However, it remains unknown whether the association 
of PC34:2 with CAD and its correlation with the anti-apoptotic activity of HDL directly 
reflect anti-atherogenic properties of PC34:2 or whether low levels of PC34:2 in HDL may be 
an indicator of oxidative processes or enzyme activity affecting HDL functionality. 
We also found that HDL-associated 18:1-S1P and 18:2-S1P, but not 16:1-S1P, 
exhibited a significant correlation with the anti-apoptotic activity of HDL. However, none of 
the S1P species was associated with CAD or ACS. This may initially seem contrary to the 
previous reports on reduced amounts of HDL-bound S1P in CAD patients 
32
, however, 
variations in methodology of S1P quantification and HDL isolation may account for the 
different findings. First, that analysis of S1P was performed by HPLC coupled with a 
fluorescence detector, which did not provide information about the molecular structure of S1P 
and how many different S1P species were detected. Second, we as well as others showed that 
only 60% of plasma S1P is associated with HDL 
12-14, 33
, while Sattler and colleagues reported 
an almost 100% recovery of S1P in HDL of the healthy controls 
32
. 
In the next study, we investigated whether apoM can influence the plasma levels of the 
18:1-S1P, termed S1P hereafter. We showed that human HDL as well as HDL of wild type 
(wt) mice, induce time-dependent and saturable S1P efflux, which results in doubling the 
endogenous concentration of S1P. The fact that the doubled S1P concentration is still below 
the particle number of HDL may indicate the presence of a specific binding site that is not 
saturated after isolation of HDL from plasma, such as apoM. In agreement with this 
explanation, we found that HDL from Apom
tg
 mice overexpressing apoM significantly 
increase S1P efflux. However, compared to HDL from wt mice, S1P efflux was not 
diminished in the presence of HDL from Apom
-/-
 mice lacking apoM. This indicates the 
presence of additional apoM-independent mechanisms by which HDL facilitates S1P efflux 
from erythrocytes. Given that S1P efflux induced by HDL of Apom
-/-
 mice reaches a 
saturation point much below the number of HDL particles, it is unlikely that the apoM-
independent mechanism of S1P efflux is unspecific. Moreover, rHDL consisting only of 
apoA1 and PC(16:0/18:1) also induced S1P efflux, further confirming the existence of apoM-
independent mechanisms, with apoA1 as a possible inducer of S1P efflux. However, further 
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experiments indicated that delipidated apoA1 did not induce S1P efflux from erythrocytes, so 
it can be inferred that additional and yet unknown factors contribute to S1P efflux 
34
. 
In addition, we investigated whether apoM regulates the plasma content of S1P 
beyond mediating S1P transport in HDL. We showed that, in contrast to wt mice, the urine of 
Apom
-/-
 mice contained quantifiable amounts of S1P, indicating that apoM may play a role in 
preventing the urinary loss of S1P. Then we investigated the urinary excretion of apoM and 
S1P by mice with defective tubular endocytosis, including megalin knock-out mice (Lrp2
-/-
), 
mice lacking the chloride-proton exchanger CIC-5 (Clcn5
-/-
) or the lysosomal cystine 
transporter cystinosin (Ctns
-/-
). We detected apoM in the urine samples of Lrp2
-/-
, Clcn5
-/-
 and 
Ctns
-/-
 mice but not in their corresponding wt littermates. At the same time, increased urinary 
excretion of S1P was found in Lrp2
-/-
 and Clcn5
-/-
 mice, indicating that tubular reabsorption of 
apoM interferes with the urinary loss of S1P. However, the urinary loss of apoM and S1P in 
the mice with defective tubular endocytosis was too low to considerably decrease plasma 
levels of apoM and S1P 
34
. 
The anti-oxidant enzyme paraoxonase 1 (PON1), which is involved in the 
atheroprotective functions of HDL, was found to be associated with age-related macular 
degeneration (AMD). We investigated whether the lack of PON1 has any impact on the 
phospholipid profile of retina/eyecup tissues, indicating some role in AMD. Assessment of 
retinal physiology of Pon1
-/-
 mice revealed that PON1 is not essential for the development and 
maintenance of normal retinal structure or function. However, retina/eyecup samples of  
Pon1
-/-
 mice had decreased levels of LPCs in general, and of LPC22:6 in particular. 
Considering that PON1 has a phospholipase A2 (PLA2)-like activity leading to the formation 
of LPCs in macrophages 
35
, PON1 in wt mice may regulate the production of LPC lipids in 
the retina/eyecup. A large amount of LPC22:6 in the retina but not in the eyecup indicates that 
the PLA2-like activity of PON1 affects photoreceptors and neuronal retina. Furthermore, our 
study showed a decrease in the content of total LPCs and LPC22:6 in one year old wt mice, 
by 63% and 75%, respectively. This, and the fact that ageing decreases the expression of 
Pon1 gene, indicates that a reduced amount of PON1 resulted in a diminished content of 
LPCs. However, the absence of an AMD-like phenotype in the eyes of aged Pon1
-/-
 mice 
suggests that even a long-lasting absence of PON1 is not sufficient to cause detectable 
pathological changes, and indicates that additional factors or stimuli may be needed to 
provoke the phenotype of AMD in Pon1
-/-
 mice 
36
. 
Future research should focus on the development of LC-MS methods for the structural 
characterization and quantification of PC and PE plasmalogens. Our results of 
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glycerophospholipid and sphingolipid screening of the plasma and HDL samples from healthy 
subjects, CAD and ACS patients should be further verified in larger case-control and 
prospective studies. Moreover, further in vitro experiments with native HDL enriched with 
PC plasmalogens are required in order to directly evaluate the role of PC plasmalogens in the 
anti-apoptotic activity of HDL. Additional experiments are also needed for a better 
understanding of the apoM-independent mechanism by which HDL mediate S1P efflux from 
erythrocytes. Finally, there is a great need for the detailed characterization of PON1 functions 
in retinal tissue in order to clarify the so-far controversial role of PON1 in AMD.  
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